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PREFACE AND A CK NOWL EDGEM ENTS
There are a number of types of epileptic seizures and several 
different methods have been employed for their classification. In the 
present work seizures have been classified by the International Class­
ification of Epileptic Seizures described by Gastaut (1970). The use 
of anticonvulsant drugs in the therapeutic management of most forms 
of epilepsy is described in the introductory chapter. Subsequent 
chapters deal principally with absence (petit mal) and tonic-clonic 
(grand mal) types of seizures. These are two forms of generalised 
seizures for which drug therapy is most clearly defined. A range of 
anticonvulsant drugs has been included in the conformational analysis. 
Some clinically used drugs have been excluded however. Carbamazepine 
and sodium valproate are two recent anticonvulsants whose mechanisms 
of action may be unique, and whose relationships to other anti­
convulsants is not yet clear. They have been excluded from conform­
ational analysis to allow a more meaningful comparison between drugs 
vhose pharmacology is better understood. Carbonic anhydrase inhibitors 
have also been excluded from conformational analysis because their 
mechanism of action is relatively specific. Where convenient^ compounds 
have been referred to by their generic name (e.g. phenytoin). In the 
chapters on conformational analysis and electronic structure compounds 
have also been referred to by their chemical names (e.g. 5,5-diphenyl- 
hydantoin) in order to make structural comparisons easier.
A comparison of the major methods used in the theoretical 
application of chemistry to pharmacology has been given in Chapter 2.
The methods discussed range from empirical potential energy calculations 
to semi-empirical and ab initio molecular orbital techniques. The basis 
of each method is discussed, so that a comparison can be drawn between 
the methods used in the present work and other methods that are avail-
Vable . It has also been felt necessary to provide a systematic 
evaluation of the MINDO/3 method. This is reported in Chapter 3, 
giving an estimate of the reliability of the method in describing 
electronic structure.
Some of the computer programmes used have been written as a part 
of the present work. An outline of these programmes is given in 
Chapter 4. Other computer programmes were obtained from the following 
sources:
G.P. Jones (COMOL, ENMAP and PLUTO); P.R. Andrews (MOLMOD); Quantum 
Chemistry Programme Exchange, Indiana University (MINDO/3).
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C O N F O R M A T I O N A L  STUDIES OF CLI NICA LLY 
ACT IVE A N T I C O N V U L S A N T  DRUGS
J .AI DEF INA 
A B S TRAC T
The principal forms of epileptic seizures dealt with in this 
work are absence (petit mal) and tonic-clonic (grand mal) seizures.
A range of anticonvulsant drugs having experimental and clinical 
activity has been considered. The series comprises phenyl, ethyl 
and diphenyl derivatives of five- and six-membered heterocycles, 
benzodiazepines and partial structures, open-chain acetylureas, and 
also alkyl derivatives of several heterocycles. It has been suggested 
elsewhere that molecular conformation may be an important factor in 
determining anticonvulsant activity. The present work has been 
designed to investigate the influence of both stereochemistry and 
electronic structure on anticonvulsant action, with emphasis being 
placed on drugs showing activity against experimental electroshock 
seizures, and clinical use in the treatment of tonic-clonic epilepsy.
Empirical potential energy calculations using the COMOL method 
have been used to first determine the preferred conformations of drugs. 
Comparison is made with available experimental evidence on anti­
convulsant conformation. MINDO/3 molecular orbital calculations have 
subsequently been used to describe the electronic structure of drugs 
in their preferred conformations. Before applying the MINDO/3 method 
to anticonvulsants an evaluation has been carried out on its ability 
to account for the electronic structure of a series of model compounds. 
Comparison with published db initio calculations and experimental 
results shows that the method provides a good estimate of both ground- 
state properties and molecular electrostatic potentials. To carry 
out calculations on conformation and electronic structure, computer 
software has been obtained from several sources. In addition further 
computer programmes have been written for the presentation of results 
of conformational analysis and the estimation of chemical reactivity.
Conformational analysis shows that anticonvulsant drugs are able 
to adopt several low energy conformations, one of which is common to 
all drugs having activity against electroshock type seizures. This 
common conformation, which is likely to be responsible for anticonvulsant 
activity, has four main structural features: a phenyl substituent in
the appropriate orientation, a central electronegative region, an 
imide-type or equivalent nitrogen, and a secondary electronegative 
region. Studies on the benzodiazepines and partial structures indicate 
that the phenyl substituent and central electronegative region may be 
the most important of these structural features. Calculations on 
electronic structure show further similarities in the anticonvulsants. 
Most drugs have a similar potential for electrostatic and hydrogen 
bonding interactions with a drug receptor, through the electronegative 
and imide-type nitrogen system. Both cyclic and open-chain anticon­
vulsants are also shown to possess a common electrostatic potential 
field. The possibility of charge transfer between the anticonvulsant 
drug and the receptor is also discussed. MINDO/3 estimates of super- 
delocalizabilities indicate that phenyl substituents and carbonyl groups
viii
are the most likely regions of anticonvulsant drugs to be involved 
in charge transfer with a receptor. 13C-NMR spectroscopy has also 
been used to show a correlation between experimental chemical shifts 
and calculated values of electron densities.
The structure-activity relationship derived in the present 
work applies mainly to anticonvulsant activity against experimental 
electroshock seizures and associated clinical use in the treatment 
of tonic-clonic (grand mal) epilepsy. It appears that both stereo­
chemical and electronic factors play an important role in determining 
the activity of anticonvulsant drugs. Although some drugs probably 
act by more than one mechanism, it is likely that a common site of 
action is involved in bringing about a part of the activity of most 
drugs. Evaluation of the known pharmacology of anticonvulsants 
indicates that a common site of action is most likely to involve the 
neurotransmitters gamma-aminobutyric acid (GABA) and noradrenaline. 
The effects of anticonvulsant drugs on GABA and noradrenaline are 
discussed in this work, and possible common sites of action are 
outlined.
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NUMBER I NG OF F I V E -  AND S I X - M E M B E R E D  R I N G  
S Y S T E M S  IN  A N T I C O N V U L S A N T  D R U G S
S e v e r a l  f i v e -  and six -m em bered  r i n g  sy s te m s  o c c u r  in  a n t i ­
c o n v u ls a n t  d r u g s .  N um bering i s  g iv e n  f o r  th e  r i n g  sy s tem s 
s t u d i e d .  L e f t  hand colum n to p  to  b o tto m : b a r b i t u r i c  a c id ,
h y d a n to in  and o x a z o l i d in e - 2 ,4 - d i o n e .  R ig h t hand  co lum n: 
s u c c in im id e  and g l u ta r im id e .  N um bering o f  o th e r  h e t e r o ­
c y c l i c  sy s te m s  s tu d ie d  i s  g iv e n  in  th e  t e x t .
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CHAPTER 1
INTRODUCTION TO EPILEPSY AND ITS
THERAPEUTIC MANAGEMENT
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41-1 C L A S SIF ICATI ON AND E P I D E MI OLOGY
OF EPILEPSY
Epileptic seizures may be classifed according to clinical, 
electroencephalographic or causative features of the epilepsy. Complic­
ating factors are involved where some patients show signs which are 
characteristic of more than one type of epilepsy. Where only incomplete 
information is available the seizure type may remain unclassified.
Table 1-1 shows a classification scheme based on the International 
Classification of Epileptic Seizures of the Commission on Terminology 
of the International League Against Epilepsy (Gastaut, 1970; Woodbury 
and Fingl, 1975).
Epilepsy occurs in approximately one out of every 200 to 400 people. 
Epidemiologic studies have shown that as a whole, generalized seizures 
have a rate of incidence which does not vary much with age (Houser 
and Kurland, 1975). Seizures of the absence (petit mal) type are most 
common in young children. Partial seizures have the highest incidence 
of seizure types, and their incidence increases after the age of 50 
years. Table 1-2 shows the prevalence of epilepsy in populations of 
different countries (Hauser and Kurland, 1975; Linnett, 1976).
TABLE 1-2. Prevalence of epilepsy in.populations 
of different countries a**D
Country Prevalence
(per 1,000 of population)
Iceland
Japan
Great Britain 
Norway
Northern Israel 
Africa
United States of America
3.4
1.5
3.3
2.3
2.3 
1-15 
5.7
a Based on Hauser and Kurland (1975) and Linnett (1976).
b Prevalence of epilepsy may vary in different areas within the one 
country.
5TABLE 1-3. Prevalence and rate of incidence 
of epilepsy by seizure type
"L.
Seizure Type Prevalence^ Rate of Incidence^
(per 1,000 of (annual per 100,000
population) of population)
A. Partial Seizures
Total 4.0 30.4
B. Generalized Seizures
Absence 0.4 3.4
Tonic-Clonic 1.3 12.5
Total 2.1 22.0
C. Other Seizures
Total 0.2 4.5
a Derived from Hauser and Kurland (1975).
b Based on figures for 1st January, 1960, Rochester, Minnesota.
q Mean annual rate of incidence for years 1945-64, Rochester, Minnesota
TABLE 1-4. Prognosis of epilepsy. Percentage 
patients with remission by seizure
°f ,. a3btype 3
Percent Remission
Seizure Type All patients No anticonvulsant
medication42
A. Partial Seizures
Total 26 16
B. Generalized Seizures
Absence
Tonic-Clonic
Total
46 35
29 15
30 23
a Adapted from Hauser and Kurland (1975).
b Remission is defined as being seizure free for 5 or more years.
o Anticonvulsant medication discontinued prior to remission period.
6Although showing some variation, the prevalence of epilepsy is similar 
among different national populations. Table 1-3 shows the prevalence 
(total occurrence in the community) and rate of incidence (annual 
occurrence) of different types of epileptic seizures. Partial seizures 
and generalized seizures of the tonic-clonic and absence types account 
for significant occurrences of epilepsy.
Epileptic seizures can be controlled in many cases. The rate 
of remission from seizures does not vary much with age, although 
adolescents show a somewhat better prognosis than other age groups.
The remission rate is independent of sex. The prognosis of seizures 
is improved by the administration of anticonvulsant medication, as 
shown in Table 1-4. The highest remission from seizures is observed 
with absence epilepsy. The Table also shows that a significant 
proportion of patients remains seizure-free after anticonvulsant 
medication is stopped. The number of patients attaining remission 
of seizures increases with time after the initial diagnosis of 
epilepsy. An overall remission rate of 50 per cent of patients 
being seizure-free for 5 or more years is obtained at 20 years after 
initial diagnosis.
1 -2  NEUROPATHOLOGY OF E P IL E P T IC  SEIZURES
In some cases the cause of an epileptic seizure may be known. 
However in a large proportion of cases the reason why a seizure occurs 
is not clear. Meldrum (1976) has outlined the biochemical and 
pathological factors which may influence the occurrence of seizures. 
Some of the important factors are summarized in the following dis­
cussion.
7WATER AND ELECTROLYTE DISTURBANCES
Overhydration leads to a dilution of the plasma Na"*" concentration. 
The resulting hyponatraemia (reduced Na+ level) can lead to seizures, 
the prognosis of which is poor with anticonvulsant drugs. Administration 
of sodium chloride along with the water can prevent the seizures. De­
hydration is associated with hypernatraemia (increased Na+ level) and 
this may also be the cause of seizures. Changes in other electrolytes 
may also be associated with epileptic activity. Changes in K+ levels 
do not increase susceptibility to seizures, but hypocalcaemia (reduced
I I I I
Ca level) and hypomagnesaemia (reduced Mg level) may be responsible 
for seizures. In these cases there is a good response to the admin­
istration of calcium gluconate or magnesium sulphate.
BLOOD GASES
Cerebral hypoxia (reduced O2 level) resulting from causes 
such as cardiac arrest, cerebral air embolism, vascular obstruction, 
head injury and atmospheric decompression, can lead to seizures. 
Similarly a reduction in the level of CO2» as in hyperventilation, 
may lead to seizures. This property of hyperventilation can be used 
to advantage in conducting electroencephalographic tests.
HORMONAL EFFECTS
Adrenal hormones can have an effect on seizure susceptibility. 
Mineralocorticoid adrenal hormones have an anticonvulsant action, which 
may be related to the anaesthetic—like action of desoxycorticosterone. 
Glucocorticoids increase susceptibility to electroshock seizures.
Sex hormones have also been shown to affect seizures. The 
female sex hormone oestrogen is convulsant, while another important 
female sex hormone, progesterone, has an anticonvulsant action. These 
hormonal effects influence seizure susceptibility during the menstrual
8cycle. It has been shown that in the luteal phase of the cycle, when 
progesterone levels are high, there is a reduced frequency of seizures 
in epileptic women. The male sex hormone testosterone has also been 
shown to have an anticonvulsant action.
Hypoglycaemia (reduced blood glucose level) may also lead to 
seizures, particularly in the case of absence (petit mal) seizures. 
Seizures are most severe when the patient is undergoing the transition 
to hypoglycaemic coma and when coma is present. Insulin-induced 
hypoglycaemia may also be a cause of seizures.
TUMOUR
A high proportion of patients with brain tumours develops 
seizures. Epilepsy is commonly the presenting symptom of the disease. 
Frontal tumours are most commonly associated with generalized seizures, 
centroparietal tumours with focal motor seizures and temporal lobe 
tumours with psychomotor seizures. Neurosurgical removal of the tumour 
overcomes epileptic seizures in more than half the cases.
TRAUMA AND BRAIN DAMAGE
Head injury leads to epileptic seizures in a significant number 
of cases. The incidence of seizures is higher for penetrating injuries 
than for blunt injuries. The highest incidence is in the first few hours 
after the injury has occurred. In patients with post-traumatic 
epilepsy, seizures occur in half the cases one or more years after 
the injury has been received. Post-traumatic seizures are commonly 
generalized, although focal seizures occur in a significant number of 
cases which involve penetrating head injuries.
Perinatal brain damage may also be the cause of epilepsy. Anoxic 
or asphyxial damage during the later months of pregnancy or in relation 
to birth, as well as intracerebral haemorrhage at birth, may result
9in the occurrence of seizures. Seizures in these cases may occur in 
the first week of life of the infant, or may develop later in childhood.
CEREBRAL INFECTION AND DISEASE
A wide range of infective agents can give rise to seizures, which 
may occur during the acute phase of the infection, or at a later stage 
when the infection itself has passed. The incidence of seizures in the 
acute phase of viral infections depends on the age of the patient and 
the type and extent of the infection. Among bacterial infections 
tuberculous meningitis has a relatively high risk of later epilepsy. 
Parasites can also be the cause of seizures. In some tropical areas 
cerebral malaria is a common cause of seizures in children.
Congenital vascular malformations may be associated with 
seizures. Other cerebrovascular causes include subdural haematomata, 
which result in a high incidence of seizures in infants. In heart 
disease a Cerebral embolism is a potential cause of focal or generalized 
seizures. Cerebrovascular disease is the most common cause of seizures 
after the age of 50 years.
1-3 THE RAPE UTIC M A N A G E M E N T  OF EPILEPSY
In the middle of the 19th century drug treatment for epilepsy was 
introduced with the administration of bromides. However toxicity was a 
major problem with this type of therapy (Krall, Penry, Kupferberg and 
Swinyard, 1978). In 1912 phenobarbitone was shown to have improved 
efficacy and reduced toxicity in the therapeutic management of epilepsy, 
and in 1938 phenytoin was introduced as another valuable anticonvulsant 
drug. A few years later in 1945 trimethadione was found to be of use 
for absence seizures, which were not controlled by phenytoin or phen­
obarbitone. In the period up to 1960 several other anticonvulsant drugs
10
were developed. At this time the range of anticonvulsants covered a 
variety of chemical types, including barbiturates, hydantoins, 
oxazolidinediones, succinimides and acetylureas. Jenney and Pfeiffer 
(1956) also demonstrated that the maximal electroshock (MES) and 
pentylenetetrazol tests were useful for predicting clinical activity 
in controlling tonic-clonic and absence seizures respectively. In 
recent years only a few anticonvulsant drugs have come into clinical 
use, including the benzodiazepines, carbamazepine and sodium valproate. 
Table 1-5 shows the structures of anticonvulsants which are used 
clinically in the treatment of epilepsy. An important part of the drug 
treatment of seizures is to select which of the available anticonvulsants 
is most likely to give the best management of epilepsy in a particular 
patient.
Several reviews and papers are available on various aspects 
of the drug treatment of epilepsy. Krall, Penny, Kupferberg and 
Swinyard (1978) and Krall, Penny, White, Kupferberg and Swinyard (1978) 
provide a good account of the historical development of drug screening 
and anticonvulsant therapy. Individual anticonvulsant drugs, their 
dosage and toxicity, and the selection of anticonvulsants for treating 
the different forms of epilepsy have also been reviewed by several 
authors (Eadie, 1979; Ziegler, 1980; Kutt and McDowell, 1980; Richens, 
1976; Woodbury and Fingl, 1975). The following discussion summarizes 
the main classes of anticonvulsant drugs and their use in the management 
of different seizure types.
ANTICONVULSANT DRUGS 
HYDANTOINS AND BARBITURATES
The preferred therapy for major forms of epilepsy is either 
phenytoin or phenobarbitone. Two important factors which influence 
the decision of which drug to use are efficacy and toxicity. Both
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phenytoin and phenobarbitone are effective in treating the major forms 
of epilepsy, although phenobarbitone is of limited value in treating 
psychomotor seizures. However their toxicity differs. Phenytoin has 
more numerous adverse effects, including altered cerebellar function, 
behavioural changes, gastrointestinal and endocrine effects, as well 
as an increase in the frequency of seizures in some cases when toxic 
levels are reached. If the toxic effects of phenytoin which are observed 
are not too serious, they may be preferred to the greater sedation 
produced by phenobarbitone. The pharmacokinetics of phenytoin are also 
well understood, which means that its therapeutic levels can be more 
effectively monitored. Because of its lower toxicity phenobarbitone is 
often preferred in the treatment of epileptic children. Primidone is 
structurally related to phenobarbitone, and may also be used in treating 
the major forms of epilepsy. Phenytoin, phenobarbitone and primidone 
are not effective in treating absence seizures.
BENZODIAZEPINES
Benzodiazepines can also be used in the management of epilepsy. 
Diazepam is a useful drug for the intravenous treatment of status 
epilepticus. It is not suitable for long-term oral treatment as its 
effect is small and diminishes with time, possibly due to tolerance 
which may develop with the drug. Sedation is also an unwanted effect 
of diazepam. Clonazepam is a newer benzodiazepine which has some use 
in treating tonic-clonic and psychomotor types of major seizures.
Several benzodiazepines have also been used in the treatment of absence 
seizures. However their use is again limited by tolerance. Increasing 
the dosage can help with this problem, but then sedation and other un­
wanted effects may become troublesome.
14
CARBAMAZEPINE
Carbamazepine is also an effective anticonvulsant drug for 
tonic-clonic, focal and psychomotor seizures. It appears to be of 
particular use in treating psychomotor seizures. Absence seizures are 
not affected. Carbamazepine appears to exert an independent action, 
and cannot replace previously administered drugs in multiple drug 
therapy. Where carbamazepine is used blood counts and liver function 
should be monitored.
SODIUM VALPROATE
Sodium valproate is of use in most types of seizures, including 
absence seizures, and may be beneficial in patients whose epilepsy is 
not controlled by other drugs. Plasma levels of phenobarbitone can be 
increased in multiple drug therapy with sodium valproate, resulting in 
the potential for phenobarbitone-induced sedation. Where this occurs 
the dose of phenobarbitone may have to be reduced. When sodium valproate 
is used it is necessary to monitor platelet and liver function.
ACETYLUREAS
Phenacemide and pheneturide are two open-chain acetylurea 
analogues of the hydantoins. These drugs may be of benefit in treating 
psychomotor seizures which are not otherwise controlled. However their 
use is limited by toxicity. When administering these drugs it is 
necessary to monitor liver, kidney and bone-marrow function.
CARBONIC ANHYDRASE INHIBITORS
Sulthiame is a carbonic anhydrase inhibitor which has some benefit 
in the control of seizures. It has little anticonvulsant effect of its 
own, but when added to existing therapy will increase plasma levels 
of phenytoin, phenobarbitone and primidone. However the toxicity of
15
sulthiame is significant, and if increased plasma levels of primary 
anticonvulsants are desired, it may be better to adjust the dosage of 
the original drugs. Acetazolamide is another carbonic anhydrase 
inhibitor which can also be used in the management of epilepsy.
SUCCINIMIDES
Ethosuximide is the most widely used of the succinimides for 
the treatment of absence seizures. It is not effective in treating other 
types of epilepsy. Seizure control with ethosuximide is usually good. 
When using this drug it is necessary to monitor blood count. Phen- 
suximide and methsuximide may also be used for absence seizures.
OXA ZOLIDINEDIONES
Trimethadione can also be given for treating absence seizures, 
although oxazolidinediones do not give as good results as the succin-
I
imides. Trimethadione may also exacerbate tonic-clonic seizures 
where these are present in addition to the absence seizures. Because 
of high toxicity close medical supervision should be given during 
the use of trimethadione.
TREATMENT OF SEIZURES
TONIC-CLONIC SEIZURES
Phenytoin is usually the drug of first choice because it is 
relatively safe and produces little sedation. When plasma phenytoin 
concentrations reach 20yg/ml small dose increases will avoid toxicity 
if the liver metabolism of phenytoin becomes saturated. If seizures are 
not controlled by the administration of phenytoin alone, then pheno- 
barbitone or primidone can be added to the therapeutic regimen. If 
these latter drugs are used their dose should be increased gradually 
to avoid sedation. Carbamazepine can be added as a third drug if
16
required. In cases where seizures remain uncontrolled, mephenytoin, 
sulthiame or benzodiazepines can be used.
PSYCHOMOTOR SEIZURES
Phenytoin and primidone have been the usual drugs employed in 
the treatment of psychomotor seizures. Carbamazepine is now a popular 
drug for this seizure type. The prognosis is not as good for psycho­
motor seizures as it is with other forms of epilepsy. In cases which 
are resistant to control by the standard drugs, mephenytoin, phen- 
suximide, benzodiazepines and sodium valproate can be used.
ABSENCE SEIZURES
Ethosuximide is often the drug of first choice for absence 
seizures. Sodium valproate is a useful alternative or additional drug. 
Sodium valproate causes gastric irritation, and so its dose should be 
increased slowly. Trimethadione is not used much due to its high 
toxicity. In difficult cases benzodiazepines and acetazolamide can be 
used. With absence epilepsy there is often a further development of 
major seizures of the tonic-clonic type. Therefore drugs for major 
seizure control may have to be given as well, even though these drugs 
may exacerbate currently existing absence seizures.
MYOCLONIC AND AKINETIC SEIZURES AND 
INFANTILE SPASMS
These seizure types are difficult to control. With infantile 
spasms pyridoxine, ACTH (adrenal corticotrophic hormone), prednisone, 
and sometimes benzodiazepines can be used. For myoclonic and akinetic 
seizures the benzodiazepines, diazepam, nitrazepam and clonazepam can 
be used. Clonazepam may be effective in relatively low dosage. Even 
so its starting dose should be lower than the complete dose required, 
in order to avoid sedation at the beginning of therapy. The useful
17
effects of benzodiazepines do not last with time. In the control of 
myoclonic seizures sodium valproate can also be used.
STATUS EPILEPTICUS
Generalized tonic-clonic status epilepticus is a medical emergency. 
The therapeutic approach required is to first of all secure adequate 
respiration, then to stop seizures, and subsequently to identify and 
treat the cause of the seizures. Diazepam can be given as an intra­
venous injection to provide an initial and rapid suppression of seizures. 
Clonazepam can also be used, but respiratory depression and sedation 
may be more pronounced than with diazepam. Phenytoin is then given 
as a slower intravenous infusion to extend control of the seizures 
over a longer time. Where seizures are not controlled,ether, a short 
acting barbiturate anaesthetic, or chlormethiazole can be used. With 
absence or partial status epilepticus drug therapy involves the use of 
intravenous barbiturates. In partial status epilepticus phenytoin or 
phenobarbitone may have to be used as well.
PLASMA LEVEL MONITORING OF ANTICONVULSANTS
The degree of drug action is dependent on the concentration of 
drug in the vicinity of the biological receptor with which interaction 
takes place. For anticonvulsants the receptor concentration will 
depend on the concentration of the drug in the central nervous system. 
The CNS level in turn depends on the level of anticonvulsant drug which 
is achieved in the plasma during drug therapy. Because of individual 
variation among patients, standard dosage regimens do not produce 
consistent levels of drugs in the plasma. Therefore measurements of 
plasma drug concentration, rather than drug dosage,offer a better guide 
to the successful control and therapeutic management of seizures 
(Eadie, 1976; Leal and Troupin, 1977; Richens and Warrington, 1979).
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Most usually plasma level determination of anticonvulsant drugs 
is undertaken during long-term therapy of epilepsy, although in some 
cases plasma levels may be required where only short-term therapy is 
being given. Most anticonvulsant drugs are eliminated slowly and 
accumulate during long-term administration. This type of pharmaco­
kinetic behaviour allows relatively stable plasma levels to be achieved 
and monitored. Because of the relationship between anticonvulsant plasma 
drug level and clinical effects, the monitoring of anticonvulsant levels 
allows the physician to decide if the given dosage produces a plasma 
level which is in the usual effective therapeutic range, or which is 
in the higher potentially toxic range. Dosages and desired therapeutic 
plasma concentrations of commonly used anticonvulsant drugs are listed 
in Table 1-6.
1-4 M E C H A N I S M  OF ACT ION OF A N T I C O N V U L S A N T  DRUGS
This section reviews a number of different mechanisms of action 
which have been proposed for anticonvulsant drugs. Emphasis is placed 
on drugs which have activity against experimental electroshock seizures 
or which are used clinically in the treatment of tonic-clonic (grand 
mal) epilepsy. Various mechanisms are discussed, including biochemical 
effects on enzymes and metal ions, as well as effects on cyclic nucleo­
tides and neurotransmitters within the central nervous system. It is 
possible that anticonvulsant drugs have more than one type of action. 
There is also the possibility that different drugs share a common site 
of action in bringing about a part of their anticonvulsant activity.
The available evidence suggests that possible common sites of action 
are most likely to be found in synapses for the neurotransmitters 
gamma-aminobutyric acid (GABA) and noradrenaline.
20
FOLIC ACID
Some of the major anticonvulsants, phenytoin, phenobarbitone 
and primidone, have antifolate properties. Long-term administration 
of these drugs is associated with a reduction in folic acid levels in 
the cerebrospinal fluid (Reynolds, 1978). Folic acid itself has 
neuroexcitant properties, and the effects of formyl tetrahydrofolate 
on peripheral nerves are blocked by phenytoin (Spector,
1972). Possible modes of action of anticonvulsant drugs on folic acid 
include the following (Reynolds, 1978):
1. Decreased absorption of folic acid.
2. Increased utilization of folic acid in metabolism.
3. Interaction of drugs with folic acid coenzymes.
It has been suggested that folic acid may be involved in synaptic 
events and monoamine metabolism, although the significance of folic 
acid in neural function is yet to be clearly established.
ALDEHYDE REDUCTASE
The enzyme aldehyde reductase is an important enzyme in the 
degradative metabolism of biogenic amines. The amines are first 
oxidized to their corresponding aldehydes r which are then metabolized 
by aldehyde reductase. Several anticonvulsants including phenytoin, 
phenobarbitone and glutethimide, have been shown to inhibit the activity 
of aldehyde reductase (Erwin and Deitrich, 1973; Ris, Deitrich and von 
Wartburg, 1975). Anticonvulsants having the unsubstituted cyclic imide 
-C0-NH-C0- system were found to be good inhibitors of the human 
isoenzyme H 4.3 of aldehyde reductase. Diazepam was found not to 
inhibit the enzyme.
Drugs which inhibit aldehyde reductase have the potential to
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increase the levels of biogenic amines and aldehydes. Biogenic 
aldehydes, which are direct substrates of the enzyme, have been shown
+ + I Ito inhibit both Na , K - ATPase and Mg - ATPase, as well as mito­
chondrial cytochrome c oxidase (Ris, Deitrich and von Wartburg, 1975) .
CARBONIC ANHYDRASE
Carbonic anhydrase is the enzyme which catalyzes the conversion 
of water and carbon dioxide to bicarbonate ion. Inhibitors of carbonic 
anhydrase, including methazolamide, acetazolamide and sulthiame, have 
anticonvulsant activity. The mechanism of action of these drugs is 
unknown, although it is possibly related to a decrease in Na+ transport 
across neuronal membranes (Spinks and Waring, 1963).
MONOVALENT AND DIVALENT METAL IONS
Phenytoin has been shown to inhibit the transport of Na+ ions 
into neurones (Pincus and others, 1970). It has also been shown that 
phenytoin inhibits sodium conductance in squid axons (Lipicky, Gilbert
I Iand Stillman, 1972). An effect of anticonvulsants on Ca transport
has also been observed. Sohn and Ferrendelli (1976) have shown that
++phenytoin and phenobarbitone inhibit the transport of Ca ions into 
brain synaptosomes. These authors suggest that anticonvulsants may
I Iinhibit Ca influx by a membrane stabilizing effect, and that reduced
I Iintracellular Ca might result in decreased neurotransmitter release.
I IReduced intracellular Ca could alternatively result from the effect
I Iof drugs on Ca -ATPase. Willow and Johnston (1979) have shown that
I Ianaesthetic barbiturates are able to stimulate the activity of Ca 
ATPase in brain synaptosomes, therefore having the potential to increase
I I I Iactive efflux of Ca from neurones, and result in a decrease of Ca 
mediated release of neurotransmitters.
22
CYCLIC NUCLEOTIDES
Maximal electroshock seizures induce an elevation in brain cyclic 
nucleotide levels (Lust and others, 1978). In the 100 second interval 
after electroshock the levels of both cyclic AMP and cyclic GMP are 
raised. Cyclic AMP reaches a maximum of 130pmole/mg protein in the 
cerebral cortex and 30pmole/mg protein in the cerebellum. Phenytoin 
has no effect on resting levels of cyclic AMP, but does inhibit the 
induced rise in cyclic AMP, with most effect in the cerebellum, where 
the rise is inhibited by up to 40 percent. The level of cyclic GMP 
in the cerebellum is raised by electroshock from about 4 to 14pmole/mg 
protein. Phenytoin inhibits the rise in cerebellar cyclic GMP by more 
than 50 percent, as well as depressing the resting level of cyclic GMP 
in the cerebellum. Other anticonvulsants, including phenobarbitone, 
diazepam and procyclidine, also depress the levels of cyclic GMP in the 
cerebellum (Lust and others, 1978; Mao, Guidotti and Costa, 1975). It
+ I Ihas been suggested that altered transport of Na and Ca ions may be 
responsible for the reduction of cyclic GMP levels by phenytoin 
(Ferrendelli and Kinscherf, 1977).
It is not established how changes in cyclic nucleotide levels 
relate to neurotransmitter function and cerebellar activity. However 
the above evidence does suggest that the cerebellum may be an important 
area for anticonvulsant activity.
ACETYLCHOLINE
Acetylcholine is a neuroexcitatory transmitter within the central 
nervous system. In the non-epileptic state diazepam reduces the release 
of acetylcholine from nerve terminals, but phenytoin has no effect on 
acetylcholine release (Bianchi, Beani and Bertelli, 1975) . Acetylcholine 
does not appear to play a major role in the action of anticonvulsant drugs 
in general, although it is involved in acetylcholine-related seizures
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(Spinks and Waring, 1963; Maynert, Marczynski and Browning, 1975). 
Inhibitors of the degradative enzyme cholinesterase cause an elevation 
of acetylcholine levels, and result in tremors and convulsions. Some 
cholinergic drugs may also give rise to convulsions. Anticholinergic 
drugs can be used to suppress seizures induced by an acetylcholine 
mechanism, and are therefore useful in treating anticholinesterase 
insecticidal poisoning, but are not useful in suppressing other types 
of seizures.
GAMMA-AMINOBUTYRIC ACID (GABA)
GABA is a neuroinhibitory transmitter within the central nervous 
system. Drugs may exert pharmacological effects at various sites within 
the GABA synapse, including effects on storage and release, on uptake 
and metabolism, as well as the receptor site itself (Andrews and Johnston, 
1979a; Johnston, 1978). It appears that anticonvulsant action maybe 
mediated in part by an effect on GABA neurotransmission.
GABA STORAGE ARB RELEASE
I IDiazepam and barbiturates decrease both electrically and Ca - 
stimulated GABA release in brain preparations, while K+ - stimulated 
release of GABA is enhanced by diazepam (Meldrum, 1978)“»--
GABA UPTAKE
(-)-Nipecotic acid and (+)-2,4-diaminobutyric acid are two 
inhibitors of the neuronal uptake of GABA (Johnston and Twitchin, 1977; 
Johnston and others, 1976), while 8-alanine blocks the uptake of GABA 
into glial cells (Saelens and Vinick, 1978). The intracerebral injection 
of (-)-nipecotic acid provides protection against audiogenic seizures, 
(+)-2,4-diaminobutyric acid is both convulsant and anticonvulsant, but
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ß-alanine affords no protection against seizures (Meldrum, 1978).
Both phenytoin and phenobarbitone have been shown not to block GABA 
uptake (Harris, Hopkin and Neal, 1973), while elsewhere phenobarbitone 
has been shown to enhance uptake (Weinberger, Nicklas and Berl, 1976).
GABA METABOLISM
The biosynthetic and degradative metabolism of GABA is outlined 
in Figure 1-1 (Roberts, 1974). Phenytoin and phenobarbitone have been 
shown to increase GABA levels in cerebral hemispheres, particularly 
when GABA has been partially depleted with isoniazid.
Glutamine
I
TGlutamate
1 Glutamic acid decarboxylase (GAD)
GABA
1 GABA transaminase (GABA-T)
Succinic semialdehyde
Succinic semialdehyde dehydrogenase
TSuccinate *
(SSAD)
Figure 1-1 Biosynthetic and degradative metabolism of GABA (Roberts, 
1974). Glutamate is converted into GABA by the enzyme 
glutamic acid decarboxylase (GAD). GABA is metabolized 
by GABA transaminase (GABA-T) to succinic semialdehyde, 
and subsequently by succinic semialdehyde dehydrogenase 
(SSAD) to succinate, which enters the tricarboxylic acid 
cycle.
Primidone is only effective in elevating GABA levels in isoniazid- 
treated animals (Saad, El Masry and Scott, 1972) . Diazepam also 
increases GABA levels, and is again more effective in isoniazid- 
treated animals (Saad, 1972). The effect of diazepam in isoniazid- 
treated animals is not due to an action on the GABA-synthesizing 
enzyme glutamic acid decarboxylase (GAD), as Tong and Edmonds (1976) 
have shown that diazepam does not increase the activity of this enzyme.
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Other metabolic or indirect actions may be responsible for the increased 
GABA level.
Sodium valproate (di-n-propylacetate) is a clinically used anti­
convulsant whose action may be mediated in part by an effect on GABA 
neurotransmission. Administration of high doses of sodium valproate 
to animals results in an increase in brain levels of GABA (Anlezark 
and others, 1976). At these high doses sodium valproate inhibits both 
of the metabolic enzymes GABA transaminase (GABA-T) and succinic 
semialdehyde dehydrogenase (SSAD). At high doses sodium valproate 
and two other inhibitors of GABA-T, y-acetylenic GABA and y-vinyl GABA, 
suppress intermittent photic seizures (Meldrum, 1978). At more therapeutic 
doses sodium valproate does not inhibit GABA-T or increase GABA levels, 
yet still retains an anticonvulsant action against audiogenic seizures 
(Anlezark and others, 1976). At low doses of sodium valproate there 
is still inhibition of SSAD, but the clinical significance of this 
inhibition is not known.
GABA RECEPTOR
At the GABA receptor there are several potential sites at which 
anticonvulsants may act. Apart from direct interaction of GABA 
agonists with the receptor site itself, it has been suggested that 
some drugs may interact at neighbouring ionophore and modulator sites 
in the receptor complex.
GABA agonists
Muscimol is a GABA agonist with some anticonvulsant properties.
It has activity against audiogenic seizures (Anlezark, Collins and 
Meldrum, 1978), but is not effective in suppressing intermittent 
photic seizures in baboons, and in fact can produce effects similar 
to epileptic seizures (Meldrum, 1978). It might be that administration
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of a GABA agonist to the whole brain causes a seizure effect by 
inducing widespread inhibition. In this case there could be interference 
with necessary neuronal activity for the suppression of seizures.
Another complicating factor is that there may be more than one type 
of GABA receptor. GABA and muscimol have different relative activities 
in different areas of the central nervous system, suggesting that 
muscimol interacts more strongly with a certain proportion of GABA 
receptors (Curtis, Duggan, Felix and Johnston, 1971; Curtis, Duggan,
Felix, Johnston and McLennan, 1971). Phenytoin, phenobarbitone and 
diazepam, on the basis of tissue binding studies, have been shown not 
to interact at the GABA receptor (Olsen and others, 1978).
Chloride ionophore^ and a-dihydropicrotoxinin 
binding site
The GABA receptor appears to be linked to a chloride ionophore, 
as the administration of GABA leads to an increase in membrane perm­
eability to Cl ions (Gerschenfeld, 1973). Picrotoxin blocks the 
GABA-mediated increase in Cl permeability. The site of picrotixin 
blockade is unknown, but is possibly near the chloride channel itself 
as a part of the overall ionophore structure. Binding studies have 
been carried out using GABA and a-dihydropicrotoxinin (a-DHP), a close 
analogue of picrotoxinin, the active constituent of picrotoxin (Olsen, 
Ticku, and Miller, 1978; Olsen and others, 1978; Ticku, Ban and Olsen, 
1978; Ticku and Olsen, 1978). Table 1-7 shows that the relative 
proportions of the GABA and a-DHP binding sites are similar for different 
regions of the brain.
GABA and muscimol do not inhibit a-DHP binding at doses up to lOOyM. 
Bicuculline is a GABA antagonist with an IC50 value of 4yM against GABA 
receptor binding, but a significantly higher IC50 value of lOOyM against 
a-DHP binding (Ticku, Ban and Olsen, 1978). Conversely picrotoxinin
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TABLE 1-7. Regional distribution of GABA and
a-dihydropicrotoxinin (a-DHP) binding
sites in rat braina
Brain Region
Binding (dpm/mg protein)
GABA a-DHP RatioGABA: a-DHP
Cerebral cortex 7 760 4 300 1.80
Cerebellum 11 230 5 140 2.18
Brain stem 2 500 2 380 1.05
a Data taken from Ticku, Ban and Olsen (1978).
does not inhibit the binding of GABA to the GABA receptor (Olsen and 
others, 1978). These observations indicate that the GABA receptor and 
a-DHP binding site are distinct.
Several anticonvulsants, including phenytoin, phenobarbitone and 
primidone, have been shown to inhibit a-DHP binding at therapeutic 
concentrations (Ticku, Ban and-Olsen, 1978; Ticku and Olsen, 1978).
Diazepam was found not to inhibit a-DHP binding. In addition to anti­
convulsants, there are convulsant drugs, including picrotoxin analogues, 
barbiturates, benzylpenicillin, bicuculline and strychnine, which also 
inhibit a-DHP binding. It has been suggested that convulsants acting at 
the a-DHP site might bind in the same way as a-DHP itself, whereas 
anticonvulsants might bind to the same site in a different way, and 
have the opposite pharmacological effect (Olsen and others, 1978;
Ticku and Olsen, 1978). These authors have suggested that GABA and 
neurodepressant drugs acting at the a-DHP site (hypnotics and anti­
convulsants) might favour the activated state of the ionophore, which 
would increase Cl permeability, whereas convulsant drugs might favour 
the resting state of the ionophore. Experiments on cultured mammalian 
neurones indicate that different effects on GABA-mediated neurotransmission 
are observed for convulsant and anticonvulsant drugs (Macdonald and
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GABA
B a r k e r ,  1 9 7 9 ) .
N atural m odulator o f  GABA rec e p to r  b ind ing
I t  h a s  b e e n  p r o p o s e d  t h a t  GABA b i n d i n g  a t  t h e  p o s t s y n a p t i c  
r e c e p t o r  may b e  r e g u l a t e d  b y  a  n a t u r a l  i n h i b i t o r y  m o d u l a t o r  ( G u i d o t t i  
an d  o t h e r s ,  1 9 7 8 ) .  R e c o n s t r u c t i o n  o f  p u r i f i e d  m em branes w i t h  a n  i s o l a t e d  
p r o t e i n  m o d u l a t o r  s i g n i f i c a n t l y  i m p a i r s  GABA r e c e p t o r  b i n d i n g ,  w i t h  
k i n e t i c s  b e i n g  s i m i l a r  t o  t h o s e  o b t a i n e d  u s i n g  f r e s h l y  p r e p a r e d ,  n o n -  
p u r i f i e d  m em b ra n es .  D iaz ep am  and  o t h e r  b e n z o d i a z e p i n e s  a p p e a r  t o  
co m p e te  w i t h  t h e  m o d u l a t o r  f o r  b i n d i n g  s i t e s  i n  t h e  GABA r e c e p t o r  c o m p le x .  
D iazep am  i n c r e a s e s  GABA b i n d i n g  i n  f r e s h  m em b ra n es ,  an d  i t  h a s  b e e n  
s u g g e s t e d  t h a t  h e r e  d i a z e p a m  i s  p r e v e n t i n g  t h e  n o rm a l  i n h i b i t o r y  e f f e c t  
o f  t h e  m o d u l a t o r  on  GABA b i n d i n g .  I n  s u p p o r t  o f  t h i s  s u g g e s t i o n  i t  
h a s  a l s o  b e e n  o b s e r v e d  t h a t  d ia z e p a m  p r e v e n t s  a n  i n h i b i t o r y  e f f e c t  when 
i s o l a t e d  m o d u l a t o r  i s  ad d e d  t o  p u r i f i e d  m em b ra n es .  The a b o v e  a u t h o r s
C l
m o d u l a t o r
b e n z o ­
d i a z e p i n e s
J c h l o r i d e
m o d u l a t o r
s i t e
r e c e p t o r i o n o p h o r e c h a n n e ls i t e
F i g u r e  1 -2  S u p r a m o l e c u l a r  s t r u c t u r e  o f  t h e  GABA r e c e p t o r ,  d raw n
fro m  t h e  d e s c r i p t i o n  g i v e n  i n  A ndrew s an d  J o h n s t o n  (1 9 7 9 a )  
and  G u i d o t t i  and o t h e r s  ( 1 9 7 8 ) .  The r e c e p t o r  c o m p le x  
c o m p r i s e s  t h e  GABA r e c e p t o r  s i t e ,  a  b i n d i n g  s i t e  f o r  
one  o r  m ore  n a t u r a l  i n h i b i t o r y  m o d u l a t o r s  o f  GABA 
b i n d i n g ,  and  an  i o n o p h o r e  f o r  Cl t r a n s p o r t .  B en zo ­
d i a z e p i n e s  a r e  s u g g e s t e d  t o  f a c i l i t a t e  GABA b i n d i n g  
b y  i n t e r a c t i n g  a t  a  p r o t e i n  m o d u l a t o r  s i t e ,  a n d  b l o c k i n g  
t h e  i n h i b i t o r y  a c t i o n  o f  t h e  n a t u r a l  p r o t e i n  m o d u l a t o r .
h a v e  s u g g e s t e d  t h e r e  may b e  a  s u p r a m o l e c u l a r  s t r u c t u r e  o f  t h e  GABA 
r e c e p t o r ,  c o m p r i s i n g  t h e  GABA r e c e p t o r  i t s e l f ,  a s  w e l l  a s  a n  i o n o p h o r e  
and  a  p r o t e i n  m o d u l a t o r  s i t e .  T h i s  schem e i s  r e p r e s e n t e d  i n  F i g u r e  1 - 2 .
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Johnston and Kennedy Cl978) have also suggested that a phospholipid, 
possibly phosphatidylethanolamine, may act as a natural modulator of 
GABA binding.
Although the above in vitro studies show a clear facilitatory 
effect of diazepam on GABA receptor binding, chronic in vivo administration 
of diazepam has the opposite effect. After treatment with diazepam or 
phenobarbitone for 30 days, and subsequent decapitation and analysis, rats 
show a reduction in GABA binding (Möhler, Okada and Enna, 1978). This 
indicates there may be a reduction in the number of receptor sites for 
GABA after chronic diazepam administration, or that the receptors lose 
some of their affinity for GABA.
MONOAMINES: SEROTONIN, DOPAMINE AND NORADRENALINE
The monoamines serotonin, dopamine and noradrenaline all occur 
within the central nervous system. Although their brain function is 
still to be clearly defined, there is evidence that their neurodepressant 
activity, particularly that of noradrenaline, may be related to the 
inhibition of seizures and the action of anticonvulsant drugs. At 
monoamine synapses drugs can potentially affect storage and release, 
uptake and metabolism, as well as the receptor site itself. The storage 
and uptake of noradrenaline is of particular interest in relation to 
anticonvulsant action.
STORAGE AND RELEASE
Reserpine is a monoamine depleting agent, causing the depletion 
of all three monoamines, serotonin, dopamine and noradrenaline. 
Administration of reserpine increases susceptibility to electroshock 
seizures, and antagonizes the anticonvulsant action of phenytoin and 
phenobarbitone, as well as the carbonic anhydrase inhibitor methazolamide. 
The anticonvulsant effect of methazolamide is not restored after repletion
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of serotonin with the amino acid biosynthetic precursor D,L-tryptophan, 
but is restored after repletion of dopamine and noradrenaline with D,L- 
dopa (Gray and Rauh, 1967). Selective depletion of forebrain stores of 
noradrenaline, and separately of dopamine, with the catecholaminergic 
neorotoxin 6-hydroxydopamine (6-OHDA) suggests that noradrenaline is 
more important in suppressing electroshock seizures (Mason and Corcoran, 
1979).
Amphetamine causes the presynaptic release of catecholamines 
(Boakes, Bradley and Candy, 1972) and is responsible for anticonvulsant 
action. Amphetamine itself decreases susceptibility to electroshock 
seizures, and also potentiates the effects of phenytoin, phenobarbitone 
and acetazolamide (Rudzik and Johnson, 1970) .
UPTAKE
The uptake of released noradrenaline at neuronal synapses is 
characterized by three processes. Noradrenaline can be taken up by 
postsynaptic or other neuronal tissue in extraneuronal uptake (uptake 2), 
or it can be taken back up into the presynaptic nerve terminal in 
neuronal uptake (uptake 1). Once inside the presynaptic terminal 
noradrenaline is further taken up into storage vesicles in the process 
of vesicular uptake.
Phenytoin has been shown to affect the neuronal uptake of 
catecholamines (Hadfield, 1972). In anoxic synaptosomes phenytoin 
stimulates the uptake of noradrenaline, whereas in more physiologic 
oxygenated synaptosomes the uptake is inhibited by 46 percent at a 
phenytoin concentration of 10 4M. The uptake of dopamine is facilitated 
by phenytoin in the the hypothalamus, but is inhibited by 77 percent in 
the caudate-putamen at a phenytoin concentration of 10 4M. The inhibition 
of dopamine uptake is near maximal at 10 6M phenytoin concentration. 
Azzaro, Gutrecht and Smith (1973) have similarly shown that phenytoin
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inhibits noradrenaline uptake at a concentration of 10 3M. These 
authors have also shown that with 10 5-10 4M concentrations of phenytoin, 
uptake is less affected, but oxidative metabolism of noradrenaline is 
significantly inhibited. Pletscher (1977) has shown that phenobarbitone 
is a poor inhibitor of noradrenaline uptake into adrenal chromaffin 
granules, whereas diazepam inhibits the uptake into chromaffin granules 
by 50 percent at a concentration of 7 x 10 5M.
Noradrenaline uptake is inhibited by a number of other drugs which 
possess experimental activity against electroshock seizures or which have 
been used in clinical trials for the treatment of epilepsy. Procyclidine 
and trihexyphenidyl are two substituted benzyl alcohols possessing anti­
convulsant activity which have been studied in a clinical trial (Millichap, 
Pitchford and Millichap, 1968), and which have also been shown to inhibit 
noradrenaline uptake (Horn, Coyle and Snyder, 1971) . Imipramine is a 
tricyclic dibenzoazepine which is used clinically for the treatment of 
depression. Imipramine also possesses anticonvulsant activity (Lange, 
Julien and Fowler, 1976) and inhibits noradrenaline uptake (Horn, Coyle 
and Snyder, 1971). The clinical usefulness of imipramine in epilepsy 
is limited by its biphasic action. At low doses imipramine is anti­
convulsant, but at higher doses it is proconvulsant and exacerbates 
currently existing epilepsy. Other drugs which both possess anticonvulsant 
activity and inhibit the uptake of noradrenaline are methylphenidate and 
several ß-blocking agents, including propanolol (Gray and Rauh, 1967; 
Jaeger, Esplin and Capek, 1979; Madan and Barar, 1974; Maxwell and 
others, 1970; Mylecharane and Raper, 1970).
Because of the association between anticonvulsant activity against 
experimental electroshock seizures and clinical use in the treatment of 
tonic-clonic epilepsy, it is interesting to note that electroconvulsive 
shock itself has an effect on noradrenaline uptake. Electroconvulsive 
shock treatment of mice, involving induced tonic-clonic seizures, leads
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to a sustained decrease in the affinity of the uptake site for 
noradrenaline (Hendley and Welch, 1975). It is yet to be established 
if the observed decrease in noradrenaline uptake is a part of the 
seizure mechanism itself, or is a consequence of the treatment. If 
decreased uptake is a consequence of electroconvulsive shock treatment, 
then the effect of anticonvulsant drugs in inhibiting noradrenaline 
uptake may be to mimick a natural protective mechanism against seizure 
induction.
The biochemical mechanism by which phenytoin inhibits uptake of 
noradrenaline has also been studied. Hadfield and Weber (1975) have 
shown that phenytoin inhibition is of the non-competitive type, which 
suggests that phenytoin may not interact at the uptake site for nor­
adrenaline itself, but may interfere with some other biochemical 
component involved in transporting noradrenaline across the neuronal
membrane. White (1976) has proposed a scheme in which the uptake process
4* -J- 4*is dependent on the activity of Na , K -ATPase through a Na gradient 
across the membrane, which is generated by the ATPase and which is 
responsible for noradrenaline transport. Phenytoin and diazepam have 
been shown to inhibit the activity of Na+ , K^-ATPase in brain synaptosomes 
(Gilbert and Wyllie, 1976). In the scheme proposed by White this 
inhibition of Na+ , K+-ATPase activity would reduce the Na+ gradient, 
and consequently reduce the driving force for transport of noradrenaline 
across the neuronal membrane.
After having been transported across the presynaptic membrane in 
neuronal uptake, noradrenaline is then subject to degradative metabolism 
by MAO or to vesicular uptake into presynaptic storage vesicles. Figure 
1-3 illustrates the noradrenaline synapse and outlines events occurring 
within the presynaptic nerve terminal. The process of vesicular uptake
I Iis dependent on Mg -ATPase, and in view of this requirement it is 
interesting to note that phenytoin, phenobarbitone, diazepam and other
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Figure 1-3 Neurochemical events at the noradrenaline (NOR) synapse.
After release NOR interacts at the postsynaptic receptor 
site (R). NOR is then subject to several processes. It 
can be distributed to the circulation or taken back up 
into nearby tissue. It can undergo neuronal uptake, or 
uptake 1 (Ui) into the presynaptic terminal, followed by 
metabolism by monoamine oxidase, or further uptake into 
storage vesicles. Alternatively NOR can undergo extra­
neuronal uptake or uptake 2 (U2), after which it is 
again metabolized.
anticonvulsants have been shown to inhibit Mg -ATPase activity in 
the vesicle fraction of brain homogenates (Gilbert and Wyllie, 1976).
METABOLISM
The biosynthesis of serotonin and catecholamines is shown in 
Figure 1-4. Compounds interfering with various stages of monoamine 
metabolism have effects on seizure susceptibility and anticonvulsant 
action.
a-Methyltyrosine competes with naturally occurring tyrosine for 
the enzyme tyrosine hydroxylase, which normally converts tyrosine into 
dopa. The administration of a-methyltyrosine leads to a reduction in 
the levels of both dopamine and noradrenaline, as well as increasing 
susceptibility to electroshock seizures and antagonizing the anticon-
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v u l s a n t  a c t i o n  o f  p h e n y to in  and p h e n o b a r b i to n e  ( K i l i a n  and F r e y ,  1973; 
Meyer and F r e y ,  1973) .  D i s u l f i r a m  and FLA-63 a r e  two i n h i b i t o r s  o f  
dopamine 3 - h y d r o x y la s e ,  w hich  c o n v e r t s  dopamine i n t o  n o r a d r e n a l i n e .  
A d m i n i s t r a t i o n  o f  t h e s e  d ru g s  lo w e rs  n o r a d r e n a l i n e  l e v e l s ,  w h i l e  dopamine 
l e v e l s  a r e  no rm a l  o r  e l e v a t e d .  Both  d i s u l f i r a m  and FLA-63 i n c r e a s e  
s u s c e p t i b i l i t y  to  e l e c t r o s h o c k  s e i z u r e s  ( K i l i a n  and F r e y ,  197 3 ) .
T y r o s in e
V
T ry p to p h a n  Dopa
Dopa
v d e c a r b o x y la s e
5 - H y d ro x y try p to p h a n  Dopamine
Dopamine
v >r 3 ~ h y d ro x y la s e
S e r o to n i n  N o r a d r e n a l in e
( 5 -h y d r o x y t r y p ta m in e )
F i g u r e  1-4 B i o s y n t h e s i s  o f  s e r o t o n i n  and t h e  c a te c h o la m in e s
dopam ine and n o r a d r e n a l i n e  (Hagen and Cohen, 1966;
Von E u l e r ,  1972).
D i s u l f i r a m  h as  a l s o  b e e n  shown to  p o t e n t i a t e  t h e  e f f e c t  o f  r e s e r p i n e  
i n  i n c r e a s i n g  s u s c e p t i b i l i t y  to  s e i z u r e s  (Wenger, S t i t z e l  and C r a ig ,
1973) and to  a n t a g o n i z e  t h e  a n t i c o n v u l s a n t  a c t i o n  o f  p h e n y to in  (Meyer 
and F r e y ,  1973) .  FLA-63 h a s  been  shown to  a n t a g o n i z e  t h e  a n t i c o n v u l s a n t  
a c t i o n  o f  t h e  b i o s y n t h e t i c  p r e c u r s o r  L -d o p a ,  by p r e v e n t i n g  t h e  f u r t h e r  
m e ta b o l is m  o f  L -dopa  to  n o r a d r e n a l i n e  (McKenzie and S o roko , 1973).
The s e r o t o n i n  p r e c u r s o r  5 - h y d ro x y t r y p to p h a n  a l s o  d e c r e a s e s  
s u s c e p t i b i l i t y  to  e l e c t r o s h o c k  s e i z u r e s  and p o t e n t i a t e s  t h e  a c t i o n  o f  
p h e n o b a r b i to n e ,  b u t  n o t  o f  p h e n y to in  ( K i l i a n  and F r e y ,  1973; Meyer 
and F r e y ,  1973) .  p - C h l o r o p h e n y l a l a n i n e  i s  an i n h i b i t o r  o f  t h e  enzyme 
t r y p t o p h a n  h y d r o x y la s e ,  w h ich  c o n v e r t s  t r y p to p h a n  i n t o  5 - h y d r o x y t r y p t o ­
phan . The a d m i n i s t r a t i o n  o f  p - c h l o r o p h e n y l a l a n i n e  i n c r e a s e s
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susceptibility to seizures and antagonizes the effect of phenytoin and 
phenobarbitone (Kilian and Frey, 1973; Meyer and Frey, 1973). 5-
Hydroxytryptophan overcomes the inhibitory effect of p-chlorophenyl- 
alanine on the anticonvulsant action of phenobarbitone. These 
effects on metabolism indicate that serotonin may be involved to some 
extent in the action of anticonvulsant drugs.
MAO is an important enzyme in the degradative metabolism of 
catecholamines and serotonin. Inhibitors of MAO possess anticonvulsant 
activity (Prockop, Shore and Brodie, 1959) as well as influencing the 
action of other drugs. Iproniazid is a MAO inhibitor which has been 
shown to restore the levels of both noradrenaline and serotonin in 
reserpine-treated mice. It also reverses the effect of reserpine on 
the anticonvulsant action of methazolamide (Gray and Rauh, 1967) and 
potentiates the action of phenobarbitone and phenacemide (Yen 
and others, 1962). Tranylcypromine is another MAO inhibitor 
which has been shown to potentiate the anticonvulsant action of the 
catecholamine precursor dopa, but not of the serotonin precursor 
5-hydroxytryptophan (Rudzik and Johnson, 1970) . Phenytoin has also 
been shown to inhibit MAO activity (Azzaro, Gutrecht and Smith, 1973), 
however the significance of MAO inhibition in the therapeutic action of 
anticonvulsant drugs is yet to be established, since anticonvulsant 
therapy in patients suffering from tonic-clonic epilepsy is not associated 
with a decrease in the levels of oxidative metabolites of serotonin and 
dopamine (Chadwick, Jenner and Reynolds, 1975).
MONOAMINE RECEPTORS
Specific receptors exist for the monamines serotonin, dopamine 
and noradrenaline. The adrenergic receptors for noradrenaline are 
further classified into a, 3i and $2 types. The administration of 
monoamine agonists and antagonists provides additional evidence for the
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participation of monoamines in the action of anticonvulsant drugs.
Clonidine is a sympathomimetic (noradrenaline-like) amine with 
actions in the central nervous system. It binds to agonist sites at 
a-adrenergic receptors, and is displaced by noradrenaline and phenyl- 
ethylamines with potency and stereoselectivity corresponding to activity 
at a-receptors (U’Prichard, Greenberg and Snyder, 1977). Administration 
of clonidine causes synchronization of the EEG and a reduction in sus­
ceptibility to audio and photic arousal. These central effects of 
clonidine are blocked by the a-antagonist phentolamine (Florio, Bianchi 
and Longo, 1975). Phentolamine also increases susceptibility to electro­
shock seizures, and antagonizes the anticonvulsant action of phenobarb- 
itone (Kilian and Frey, 1973; Meyer and Frey, 1973). The dopamine 
agonist apomorphine has been shown to have anticonvulsant activity in 
the rat, but not in the mouse (McKenzie and Soroko, 1972). Also in the 
mouse the dopamine antagonist haloperidol has no effect on susceptibility 
to seizures or the anticonvulsant action of phenobarbitone (Kilian and 
Frey, 1973 ; Meyer and Frey, 1973). The serotonin antagonist 
cyproheptadine has been found by the same authors to increase suscept­
ibility to seizures and antagonize the action of phenobarbitone, but 
not of phenytoin.
1 -5  RELATIONSHIP BETWEEN CHEMICAL 
STRUCTURE AND ANTICONVULSANT ACTION
Anticonvulsant drugs have been derived from a range of chemical 
structures, including barbiturates, hydantoins, oxazolidinediones, 
succinimides, glutarimides, benzodiazepines and open-chain acetylureas.
In spite of this apparent diversity there are important structural 
similarities. With the exception of some specific pharmacological 
classes (eg. carbonic anhydrase inhibitors) most anticonvulsants possess
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a nitrogen heteroatomic system, usually a cyclic imide, and contain 
at least one carbonyl group (Spinks and Waring, 1963). For activity 
against experimental electroshock seizures, and associated use in the 
treatment of tonic-clonic (grand mal) epilepsy, the presence of a phenyl 
group and one other substituent attached to the heteroatomic system 
appears to be important (Close and Spielman, 1961; Spinks and. Waring, 
1963).
Several physico-chemical properties have also been investigated 
in relation to anticonvulsant action, including the octanol-water 
partition coefficient and the dipole moment. An increase in the 
partition coefficient, and therefore in lipophilicity, or a decrease 
in the dipole moment, may enhance anticonvulsant activity (Lapsewicz 
and others, 1978; Lien, 1970; Lien, Liao and Shinouda, 1979). 
Hydrogen-bonding has also been studied. Andrews (1969) has applied 
the extended Hückel theory (EHT) and CNDO/2 molecular orbital methods 
to a series of alkyl and arylsubstituted anticonvulsants. Infra-red 
(IR) and nuclear magnetic resonance (NMR) experimental spectroscopic 
methods have also been applied to anticonvulsants (Andrews and Buchanan, 
1971; Patrick and Bresee, 1976). Both theoretical and experimental 
approaches indicate that hydrogen-bonding may be necessary for binding 
to a biological receptor, but that other structural features are likely 
to determine the type and extent of activity.
Studies on molecular conformation have also led to structure- 
activity postulates. Aldrich and Kier (1974) have applied CNDO/2 and 
ARCANA (extended Hückel type) calculations to determine the preferred 
conformations of open-chain carboxamide acid metabolites of barbiturate, 
hydantoin, oxazolidinedione and succinimide anticonvulsants. These 
authors suggest that anticonvulsants may first undergo a ring-opening 
reaction and then interact with either GABA receptors or the metabolic 
enzyme GABA-transaminase. However this suggestion is not well supported
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by experimental evidence. The metabolites concerned are only minor 
ones, and have not been shown to have anticonvulsant activity. In a 
series of papers Camerman and Camerman have advanced another postulate 
based on X-ray crystallographic studies on a series of anticonvulsants 
(Camerman and Camerman, 1970, 1971a, 1971b, 1972a, 1972b, 1974, 1975, 
1977; Fawcett, Camerman and Camerman, 1977). It has been suggested 
that observed similarities in molecular conformation of anticonvulsants 
are responsible for therapeutic activity. In the Camermans ’ theory 
emphasis is placed on the orientation of the two hydrocarbon rings, 
and of two additional electronegative groups, in a series of compounds 
bearing phenyl and cyclohexyl substituents.
Although the Camermans’ approach is promising it is restricted 
by the limitations of the crystallographic method in determining 
alternative low energy conformations. Several criticisms have also 
been directed at the theory, and these are discussed as follows.
(1) Jones and Kennard (1978) have pointed out that two hydrocarbon 
rings are not always present in anticonvulsants. This criticism 
is valid, only one phenyl substituent being necessary for activity.
(2) The Camermans' published crystal data does not produce a 
consistent orientation of hydrocarbon rings in different 
compounds (Jones and Kennard, 1978). This suggestion is not 
correct. The Camermans1 crystal structures are consistent 
provided that corresponding absolute configurations are compared 
throughout their series of structures.
(3) The distances between the two electronegative groups are shorter 
in some compounds, particularly in procyclidine and trihexy­
phenidyl (Jones and Kennard, 1978). This criticism is valid.
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In both proeyelidine and trihexyphenidyl ammonium type nitrogens 
are described by Camerman and Camerman as being electronegative 
groups. However at physiological pH of 7.4 these nitrogens 
will exist predominantly in the cationic form.
(4) Some benzodiazepines with similar conformations have quite
different anticonvulsant activities (Gilli and others, 1978;
Sternbach, Sancilio and Blount, 1974). This criticism is 
based on activity shown against chemically induced seizures, 
which is related to absence Cpetil mal) epilepsy, whereas the 
Camermans' theory applies to activity against electroshock 
seizures, which is associated with clinical use in the treatment 
of tonic-clonic (grand mal) epilepsy. Variation of substituents 
in the benzodiazepine nucleus has significantly less effect on 
activity shown against electroshock seizures.
In spite of the limitations and criticisms of the crystallographic 
approach taken by Camerman and Camerman, their work shows fundamental 
similarities in the conformations of anticonvulsant drugs. The possible 
role of molecular conformation in anticonvulsant action is an important 
basis for further work on the structure-activity relationships of anti­
convulsant drugs. The present work has been designed to consider both 
the stereochemistry and electronic structure of anticonvulsant drugs. 
Emphasis is placed on drugs active against experimental electroshock 
seizures, and used clinically in the treatment of tonic-clonic epilepsy. 
Empirical potential energy calculations used in this work allow for a 
comprehensive analysis of drug conformation to be carried out. Alternative 
low energy conformations are estimated for each drug. Subsequent com­
parison between drugs then allows for potential bioactive conformations 
to be determined. Calculations on electronic structure are also used
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to suggest the likely interactions which take place between anti­
convulsant drugs and their biological receptors.
CHAPTER 2
THEORETICAL METHODS FOR THE CALCULATION 
OF CONFORMATION AND ELECTRONIC STRUCTURE
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2-1 CLASSICAL METHODS OF CALCULATION
Classical or empirical potential energy methods partition the 
total energy of a molecule into individual physical components. These 
methods and their applications to macromolecules have been reviewed in 
a monograph by Hopfinger (1973). The total energy is given by the 
expression
, „tor , „ei , „dis + E + E + E
E represents the potential energy due to non-bonded interactions in 
the molecule, commonly referred to as steric repulsion energy. Et0r 
is the torsional potential energy component arising from the interaction 
of atomic orbitals across bonds in the molecule. Where electron delocal­
ization occurs across a bond the torsional energy varies with the degree
elof rotation. The component E is due to electrostatic interactions
d isbetween polar or charged centres in the molecule. E represents the 
energy due to distortion of bond angles and bond lengths.
The non-bonded potential energy is given by the equation
The pairwise non-bonded interaction between atomic centres A and B in 
the molecule can be described by a Lennard-Jones 6-12 potential function:
The coefficient XiT> in the attractive term can be estimated from the AB
Slater-Kirkwood equation (Slater and Kirkwood, 1931) in a modified form 
as suggested by Scott and Scheraga (1966):
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B
where e is the electron charge, m is the mass of an electron, h is
Planck’s constant, is the atomic polarizability of atomic centre A, 
ef fand N a is the effective number of valence electrons. The coefficient A
k^b in the repulsive term is given by the equation:
KAB i Aab AB (min)
where R1tW . N is the sum of the Van der Waal’s radii of atoms A and B. AB (mm)
Alternatively the pairwise interaction may be described by a 
Buckingham type potential function:
kab exp (-uAB V - r!TAB
where |_i is in the range 4.35 to 4.70.AJj
The torsional potential energy is usually of the form
. E°
E °r = Z — TT“ (1 ± cosnO.)i 2 l
where 9 is the torsion angle of bond i about which rotation is occurring, 
and n depends on the symmetry of the molecule. E° is the energy barrier 
to rotation. The sum is taken over all bonds i about which rotation 
can take place. In practice only bonds being considered for rotation 
in conformational analysis need be taken into account.
The electrostatic potential energy is given by the equation
Z
A>B
kV B
£ R..
where k is a constant, is the net charge of-atomic centre A and £ 
is the dielectric constant of the environment surrounding the molecule.
It should be noted that empirical potential energy calculations do not 
provide information on the electronic structure of molecules. The electron
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distribution within a molecule must be characterized by more extensive 
quantum mechanical methods of calculation.
The distortion potential energy is given by the expression
Tb
.dis I Ei=l 0?
1 N I Zi=l
3. uwhere there are N bond angles and N bond lengths in the molecule.
3 bThe values and k_^  represent force constants, and 0_^  and are the 
distortions in bond angles and bond lengths.
The principal use of empirical potential energy methods is their 
application in conformational analysis. The total energy given by 
these calculations is a relative energy, which can be used to indicate 
the stability of one conformation of a molecule relative to another 
conformation which the molecule may adopt. The COMOL programme (con­
formational energy of organic molecules) is a useful empirical potential 
energy method for studying molecular conformation (Koch, 1973). In this 
method the non-bonded potential function is given by the generalized 
form:
ka b  exp (-m a b  V
When M, =0 and =12 the potential function is of the Lennard-Jones AB AB
6-12 type. When M. = y and M'' = 0 the function is of the BuckinghamAB AB AB
type. In the COMOL programme the empirical parameters for non-bonded 
potentials are those given by Giglio (1969). Potential functions of 
this type have been successfully used in conformational analysis and 
crystal structure determination for a number of molecules. They have 
been applied to both hydrocarbon (Giglio and Liquori, 1967) and hetero- 
atomic compounds, including dimethylglyoxime (Giglio, 1969), N,N^- 
dicyclohexylurea (Coiro, Giacomello and Giglio, 1971) and diketopiperazine
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(Giacomello and Giglio, 1970). They have also been successfully 
applied to polypeptide chains (De Santis and others, 1965), the 
androgen steroid 5a-androstan-3,17-dione (Damiani and others, 1967), 
as well as several neuroleptic drugs (Koch, 1974). The COMOL programme 
can also incorporate torsional and electrostatic components of the 
energy. The programme does not contain geometry optimization routines 
and therefore does not include a distortion energy component.
2 -2  QUANTUM MECHANICAL METHODS 
OF CALCULATION
Quantum mechanical methods of calculation are based on the 
application of molecular orbital theory. The eigenstate equation in 
this theory relates the Hamiltonian operator to the energy and the 
wavefunction which describes the molecular system:
fW = ET
A general introduction to molecular orbital theory can be found in 
several texts and monographs, including George (1972), Murrell, Kettle 
and Tedder (1970), Pilar (1968) and Zimmerman (1975). Borden (1975) 
and Pople (1970) also discuss molecular orbital theory, and show how 
different methods of calculation may be applied to organic molecules.
Most theoretical methods are based on the Hartree-Fock approach to 
determining molecular wavefunctions, as this is the approach most 
usually adopted in non-relativistic calculations in quantum chemistry.
There are two broad types of molecular orbital calculations. The 
most rigorous are db initio methods. In these calculations all electrons 
are taken into account and all integrals arising from giving the 
Hamiltonian operator an explicit definition are evaluated. The second 
broad type of calculation employs semi-empirical methods. Here only the
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simpler molecular integrals are retained by approximating the form of 
the Hamiltonian operator. Semi-empirical calculations generally do not 
directly account for inner-shell (non-valence) electrons. The methods 
of this type may be classed as either 7T-electron or all-valence calcul­
ations. 7T-Electron methods assume a fixed core of nucleii and a-electrons, 
whereas all-valence calculations treat both a- and tt- electrons in the 
valence-shell. In performing molecular orbital calculations there is 
the need to consider integrals over both atomic and molecular orbitals. 
Table 2-1 lists the most important integrals which are encountered. It 
is also useful to be able to convert from atomic to other units. Table 
2-2 lists the important conversion factors for this purpose.
Table 2—1. List of atomic and molecular integrals
Integral type
Overlap integral 
One-electron core integral 
Two-electron coulomb integral 
Two-electron exchange integral
Symbol
Molecular Atomic
integral integral
S . . Srs
H. H
pq
J. . Jij pqrs
K. . Kpqrs
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Table 2-2. Conversion table for units of distance 
and energy^2-»^
Distance bohr X
1 bohr 1 0.52917
o1 A 1.88975 1
Energy hartree eV kcal mol 1
1 hartree 1 27.21 627.5
1 eV 3.675xl0~2 1 23.06
1 kcal mol 1 1.594xl0“3 4.336xl0~2 1
a Based on Taylor, Parker & Langenberg (1969). 
b Atomic units are the bohr and hartree.
HARTREE-FOCK FORMALISM
The Hartree-Fock (H-F) approximation to molecular wavefunction 
behaviour was initially developed without an exchange operator as the . 
Hartree method. Inclusion of the exchange operator gives the Hartree- 
Fock formalism. The original development of the theory can be found 
in Hartree(1928a, 1928b), Fock (1930) and Slater (1930a). The 
Hamiltonian operator of a molecular system is written as the three 
component sum.
2n
Z
2n
+ Z 1 + VNNy=l y>v yv
for a system of 2n electrons and N nucleii. The first term is the core 
Hamiltonian, the second term represents repulsion between electrons 
y and V which are separated by distance v , and the third term 
represents nuclear repulsion. The individual core Hamiltonian H
acting on electron y in the field of N nucleii is given by the equation
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N
72 . O
a=l rya
- ( ^  +  E
where V2 is defined as
7.2 62 + + ü
6x2 6y2 6z2
The nuclear repulsion term is defined as
N Z Z v g PNN a>p rap
The Hartree method employs the independent-particle approximation, 
which gives the total wavefunction f as a product of molecular spin- 
orbitals,
2n
¥ (1,2,___2n) n iMi)
i=l
which are computationally satisfactory to use. However, ¥ here is not 
antisymmetric, and so does not satisfy the Pauli principle. The H-F 
approach introduces antisymmetry by the use of a Slater determinantal 
wavefunction (Slater, 1929). Combining the above expression for the 
Hamiltonian with a Slater determinant (SD) for ¥, and substituting in 
the eigenstate equation
E = f 'V* H V! dT OF* is complex conjugate of ¥)
the energy is found to be given by
2n 2n 2n
E = Z H + Z J - Z K + V T. y . yv . , yv NNy=l y>v H y>v
where H is a core integral, J is a coulomb integral, K is any 6 * yv 6 * yv
exchange integral, and is the nuclear repulsion term.
The orbital energies are given by the eigenvalue representation 
of the H-F equations.
{EM = / 't'u F ^  dT ; y - 1,2....2n}
F is the mono electronic Fock-operator, which is defined as follows
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2n
F =  HC +  L (J -  K ). v v v=l
The coulomb o p e r a t o r  J ^ ,  and th e  ex ch an g e  o p e r a t o r  K^, a r e  g iv e n  by 
th e  two e q u a t i o n s
U , ) . t -  /  /  (1) Hx CD (2) H\.(2) d T ( l ) d T ( 2 )V a t  a t  r  12 V V
( K ) .  “ f  K  U ) <I',.U) r 1-'!'* (2) < P A 2 )  d x (1)dT(2)v a t  a  v r  12 v t
They r e p r e s e n t  t h e  b e h a v io u r  o f  an e l e c t r o n  i n  t h e  f i e l d  o f  a l l  the  
o th er  e le c tr o n s .  The coulomb and exchange  i n t e g r a l s  can  th e n  be  d e f i n e d  
i n  te rm s  o f  th e  e l e c t r o n  o p e r a t o r s .
Jyv “^V y y
-  /  K>* (1) f,, ( D  f -  f  (2) 4 .  ( 2 ) d x ( l ) d x ( 2 )y u ^12 v v
= (yy|vv)
J  c o r r e s p o n d s  to  th e  e l e c t r o n  r e p u l s i o n  b e tw een  e l e c t r o n s  1 and 2 , 
w hich  have  th e  p r o b a b i l i t y  d i s t r i b u t i o n s  (1) ip (1) and ip  ^ (2) ip^(2 ) ,  
r e s p e c t i v e l y .
/  (1) iOv ( l )  (2) ^  ( 2 ) d x ( l ) d x (2)
(yv|vy)
K ^ h a s  no c l a s s i c a l  i n t e r p r e t a t i o n .  I t  a r i s e s  due to  t h e  a n t i s y m m e try
p r i n c i p l e .  K i s  z e ro  i f  ip and ip have  d i f f e r e n t  s p i n  f u n c t i o n s .r yv ry yv r
For many m o le c u le s ,  and i n  p a r t i c u l a r  f o r  a p p l i c a t i o n s  i n  pharm­
a c o lo g y ,  c l o s e d - s h e l l  m o le c u la r  o r b i t a l  t h e o r y  i s  u s e f u l .  C l o s e d - s h e l l  
m o le c u le s  a r e  th o s e  c o n t a i n i n g  an even number o f  e l e c t r o n s ,  and in  t h e s e  
c a s e s  i t  i s  c o n v e n ie n t  t o  u se  t h e  n o t a t i o n  ( a b j c d )  f o r  t h e  e x p r e s s io n
I  <t>* (1) <t>b ( l )  (2) 4>d <2) d v ( l ) d v ( 2 )
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Here the space element dv is used for the space-orbitals <j). This 
element can be related to the spin-space element dx, which includes the 
spin co-ordinate da, and which is appropriate to spin orbitals if;, 
dx = dvda 
and dv = dxdydz
Integrals over molecular orbitals are now defined as follows.
H. = / 4>* CD 4>. Cl) dvCD
Jy = (ü|jj)
K.j = Clj I jl)
The total energy of the system is now expressed as
n n
E = 2 Z H. + Z (2J. . - K. .) + V.
(2.1)
(2 .2)
It is important to realise that the total energy is not just the sum of 
the orbital energies plus a nuclear repulsion term. Each orbital energy 
is of the form
e. = / <f>. F <|>. dv = H. + Z (2J. . - K. .)l i i i j = 1 ij ij
It is often useful to write as £°, the orbital energy associated 
with the core. £_^ can then be represented as
£ . = £ . +  Z (2J.. - K..) 
1 1 j-i
Summing over all occupied orbitals gives
n
2 Z £ 
i=l ‘
2 Z £. + 2 Z (2J. . - K. .)
i-1 1 i,j = l 13 13
However, the total energy is given by the equation
2 Z £ + Z C2J - K ) + V
i=l i,j = l 3 3
The electron repulsion term has therefore been included twice in the sum 
of the orbital energies. The total energy can then be written as
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E
n
2 £  
i=l£i '
n
£
i, 3 = 1
C2J , . - K..) + V ij ij NN (2.3)
The operator which gives the electronic energy from the individual 
molecular orbitals can be constructed quite easily.
It is convenient to write
n
F = HC + G ; where G = £ (2J . - K.)j = l J J
The operator giving the electronic energy, donated here by the letter 
(2., is then expressed by the equation
£ f 4) 0 (j) dv
i=l
where Q. takes the form
d = 2F - G = 2HC + G = F + Hc
In equation 2.3 it is apparent that the form 2F - G has been used for 0. 
The total energy is given by
Et (or E) Ee + VNN
ROOTHAAN'S EQUATIONS AND THE LCAO APPROXIMATION
Roothaan (1951a)developed the Hartree-Fock formalism so that it 
could be applied to molecular systems in terms of the linear combination 
of atomic orbitals (LCAO) approximation. For closed-shell molecules 
this approximation is expressed by the equation.
h = Z, Cpi Xp (2-4)P=1
The conceptual basis of LCAO-MO theory rests with the expectation 
that an electron near a particular nucleus will interact more with that 
nucleus than with other nucleii, and hence the molecular orbital (j). in 
that region should be similar to the isolated atomic orbital occurring
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there, y • Contributions from the m atomic orbitals, centred on the N P
nucleii, are expressed by the coefficients C . There are n equations 
of the type 2.4 to describe occupied orbitals in the ground-state.
Similarly to the integrals over molecular orbitals (equation 2.1), 
integrals over atomic orbitals are now defined.
f Xp CD Xq CD dv(l)
/ Xp (1) Hi Xq Cl) dv(l)
(2.5)
J -  (pq ! rs)pqrs
K = (psIrq)pqrs 1
Substitution of equations 2.4 and 2.5 into equation 2.1 results in the 
following definitions of integrals over molecular* orbitals in terms of 
the atomic orbital basis set.
i 2 c .i pip,q=i
m
£
H
pq
*
c .
c . 
qi
c . J
*
C . C .
ij P , q , r , s = l pi qi pqrs rj sj
’ . =
m
£
*
c . C . K
*
C . C .
ij p , q , r ,s=l pi si pqrs rj qj
Using the definition of bond order
2 £ C . C . 
i=i pi qi
it can be shown that the Fock-matrix elements F are given by the
pq
equation
F = H + £ P (J - J*K )pq pq r>s=1 rs pqrs pqrs
m
£ P (J - ) can also be written as
r ,s=i r s  P^ r s  Pqr s
where
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l ■ P {CpqIrs) - h(vsIrq)} 
r,s=l rS
and is often represented by the symbol G . In this formulation equation 
2.2 leads to the following expression for the energy.
m m
E = Z P H + ^ Z P P ( J  - J$K s n pq pq pq rs pqrs pqrs)p,q-l p,q,r,S-l
Using alternative notation this can also be expressed as
m m
E P H + %  Z P P  {(pqIrs) - ^(ps|rq)}
p>q=i
Hpq pq p,q,r,s=l pq rs
Roothaan applied the variation theorem and obtained the matrix equation
(F - eS)C = 0
which has a non-trivial solution when 
det(F-eS) = 0
ühThis determinantal equation is of the m degree, giving n doubly 
occupied space-orbitals, and m-n virtual (unoccupied, or excited) 
orbitals, in the 2n-electron closed-shell molecule. Generally, the 
number of valence atomic orbitals, m, is made to exceed the number of 
occupied orbitals in the ground-state, n, giving m-n > 0 virtual orbitals.
Roothaan’s formulation defines a Fock-operator which depends 
implicitly on the atomic orbital basis set (just as the Hartree-Fock 
method gives implicit dependence on the molecular orbitals). Therefore 
the solution to the above determinantal equation must necessarily be solved 
by an iterative process. Iteration is usually continued until the 
orbitals which are generated reproduce the potential field preceding 
them. This is known as the self-consistent field (SCF) method. In 
estimating the eigenvalues (orbital energies) and eigenvectors (wavefunction 
coefficients) in the SCF method there are two alternatives for establishing 
a convergence criterion. The eigenvectors themselves can be used to 
determine self- consistency. Because of the large number of eigenvectors, 
a smaller set of parameters which depends on the eigenvectors, for example
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initial parameters 
(calculated and empirical)
initial Fock-matrix
improved --
►trial Fock- 
matrix diagonalization
trial one-electron wavefunction 
(with associated orbital energies)
density matrix 
(charges, bond orders)
electron density 
convergence method?
Yes No
density convergence 
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—  No
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electronic energy
convergence achieved? Yes-
Figure 2-1 Flow-chart of the general SCF 
procedure used in solving Roothaan's 
equations.
total energy
tother
parameters
STOP
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electron densities, is usually chosen. The other possibility is to 
use the electronic energy, which is calculated from the eigenvectors 
and also represents a test for convergence. The overall SCF procedure 
outlined here is illustrated in Figure 2-1.
A number of different molecular orbital methods have been developed 
using Roothaan's application of the LCAO approximation. The following 
discussion outlines the theory of the commonly used methods, and indicates 
for which type of molecular system each method is most suited.
HÜCKEL METHOD
The Hückel molecular orbital (HMO) method is used to carry out 
ir-electron calculations within the approximation of q-tt separation 
(Hückel, 1931, 1932). The 7T-electronic Hamiltonian is of the form
2nZv-l + zy>v r]iV
for a system having 2n electrons in m orbitals of TT-symmetry. 
electronic energy of a TT-system can then be expressed as
The
ETT
The Hamiltonian HTT
Hamiltonians.
/ V * H YdxTT
is replaced by a sum of monoelectronic effective
Hef fy
0f fThe effective Hamiltonian H deals with a TT-electron moving in a field 
due to the nucleii, inner-shell electrons, cr-valence electrons and the 
other n-electrons. The effective Hamiltonian is not evaluated explicitly 
in Hückel theory, nor is interelectronic repulsion dealt with directly.
The electronic 
n
E =TT Zi=l
energy of the TT-system can be expressed 
/ TT^  d TTi dv
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where Q. is the operator giving the electronic energy. Writing this 
operator in the alternative form
Q. = 2  F - G
the TT-electronic energy is now given by
Z / 7T. (2F - G)7T.dv 
i=l 1 1
Using the expression for orbital energies
£ .  =  /  TT. F TT. dvi i i-
the electronic energy is described by the equation
E = 2 S £ . -  Z / it. G tt. dv
* i-1 1 i-1 1
Writing the sum of integrals in this expression as
n ^
G = - Z / TT. Gir.dv. , i ii=l
the electronic energy is given by the equation
n
E = 2 Z £. + G 
w i - i 1
The quantity G which deals with interelectronic repulsion is not 
evaluated in Hiickel molecular orbital theory.
The LCAO approximation is used:
m 
Z C 
r=l ri ^r
so that the determinantal equation of the Fock matrix takes the form
det(F - £S) = 0
Various approximations are now made in the solution of this equation:
1. Orthonormality of the basis set of TT atomic orbitals ^  assumed,
so that S = 0  for r ^ s and S = 1  for r = s. rs rs
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All non-neighbour Fock matrix elements are zero. The matrix 
consists only of the diagonal elements
F - esrr rr
and the non-diagonal elements corresponding to orbitals on
adjacent atoms
F - eS rs rs
The elements of the Fock matrix are estimated by empirical 
parameters:
(3 = Frs rs
where is a coulomb integral and ß is a resonance integral,
which are a measure of the electron-attracting power of the atom
r and the bond r-s respectively. The formulae for a and ß arer rs
given by 
a a_ + 6 ß _C r CC
3 = n ß__rs rs CC
where a and ß are the coulomb and resonance integrals for a
L*
carbon atom, and the values of 6^ and Tl are derived empirically,
As the electronic energy is given by the sum of the orbital 
energies:
n
E = 2 E e.7T . . 11=1
where each orbital energy is of the form 
£i = aC + ki6CC
the electronic energy can be expressed by the equation
2nac + ( 2 U ) 6 CC 
1=1
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n
The individual k. and the sum 2 E k. are the important terms for giving 
1 i=l 1
the orbital energies and the TT-electronic energy.
The total energy of the 7T-system is given by
+ VNN
n
= 2 E
i=l
e. +i G + V.NN
Both G and are ignored, and the total energy is given by the 
estimate of the electronic energy as the sum of the orbital energies. 
For this reason Hückel molecular orbital theory should not be used to 
give a reliable estimate of the total energy. This is particularly 
important for polar and ionized molecules, where the terms G and V 
do not cancel each other out. For other molecules where the errors are 
somewhat constant, the method can be used to give relative energies.
EXTENDED HÜCKEL THEORY
Extended Hückel theory (EHT) is an all-valence method which applies 
the Hückel molecular orbital approach to both a- and TT-electrons (Hoffmann, 
1963). In EHT the nearest-neighbour approximation is not used, so that 
Fock matrix elements corresponding to non-adjacent atoms are included.
The diagonal and non-diagonal elements are evaluated according to the 
equations
- I
F = - h K (I + I ) S rs r s rs
where I is the ionization potential of the basis orbital r and K is 
a constant, usually given the value of 1.75. The overlap integrals S
are also included in the calculations.
Total energy is expressed by the equation 
n
E = 2 E £. + G + V. , i NNi=l
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As in Hückel theory the interelectronic term G and the internuclear term 
are n0t eva^uate< »^ so t i^at the total energy is given by the sume of 
the orbital energies
n
E = 2 E e.
i-i1
The total energy in the EHT method can be used for conformational 
analysis. As the total energy is only dependent on the orbital energies, 
conformational behaviour may be fairly easily related to bonding char­
acteristics within the molecule. However steric repulsion may be over­
estimated and energy barriers to rotation may be inaccurate (Hoffmann,
1963). The relative spacing of energy levels appears reasonable (Kaufman 
and others, 1973), but the charge distribution is exaggerated. The EHT 
method is more suited to non-polar molecules than it is to molecules 
where heteroatoms cause a significant degree of polarity (Hoyland, 1970).
A disadvantage of EHT is that the diagonal elements F in the Fock 
matrix do not vary for an individual atom type in different molecular 
environments. Iterative extended Hückel theory (IEHT) gives an improve­
ment in this respect, by allowing the diagonal element F to depend on 
the electron density of atom r (Rein, Clarke and Harris, 1970).
NEGLECT OF DIFFERENTIAL OVERLAP METHODS:
CNDO, INDO AND MINDO
The CNDO method (complete neglect of differential overlap) is a 
semi-empirical SCF molecular orbital technique (Pople, Santry and Segal, 
1965; Pople and Segal, 1965, 1966; Santry and Segal, 1967). Of the two 
versions, CNDO/1 and CNDO/2, only the latter improved version is usually 
used in CNDO-type calculations. The fundamental approximation of the 
method is the assumption of zero differential overlap (ZDO). At this 
level of approximation only certain integrals are retained. The Kronecker 
delta is applied to give the following reduced sets of integrals:
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(1) {S } rs {S 5 }rs rs (S }rr
(2) {(pqIrs)} = ((pqIrs)6 6 }pq r s
(and since r,s may equal p,q)
= { (pp Irr)} plus { (pp I pp)}
In order to preserve space invariance the further approximation of 
averaged coulomb repulsion is made. The following notation is used:
Yrs= (rrIss)
so that this additional approximation is expressed as
^r*A, s<*A yaa
^raA, s^B yab
(sAsA lsAsA)
A A B B s s I s s
where r^A means that orbital r is centred on atom A, and s is a 
spherically symmetrical Slater-type s-orbital. The coulomb repulsion 
integrals ythen depend only 'on the types of atoms to which orbitals 
belong. Thus theymatrix is of dimension N x N for N nucleii.
The Fock matrix elements are of the usual type
F = H + G rs rs rs (2.6)
The core term, H , is given by the set of equations
H . . = U - Z VAT,r « A, r A rr AB
r « A, s « A (2.7)
Hr = i, S . B  = 6rs = hK + ßB)Srs
Using ionization potential, I, and electron affinity, A, the 
potential term U is approximated by either of the semi-empirical 
equations
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CD D.
(2) U
- X r  - »I -  ^ A A
-Ar - ZAYAA
where Z' is the core charge (equal to the number of valence electrons) 
of atom A. Condition Cl) represents electron removal and condition (2) 
represents electron aquisition. As the theory should be able to describe 
both of these electron movements, an average is taken, resulting in the 
equation
Urr ■ + V  ' * *^AA (2‘8)
The other potential term is approximated by
V = Z'y AB ByAB
the electron repulsion term is written within the ZDO approximation
Grs = Ppp(rs|pP)5rs ' *Prs(rr|ss)
Separating this expression into diagonal and off-diagonal elements 
results in the following two equations
m
G = % P y  + £ P Yrr rr rr , ss rsstr
G = %P Y rs rs rs
Using average coulomb repulsion and summing bond orders over atomic centres 
these equations become
CPAA - * r r » A A  + & V aB
g = -kP y AT,rs rs AB
(2.9)
Substituting equations 2.7, 2.8 and 2.9 into equation 2.6, it can be 
shown that the Fock-matrix elements are now given by the equations
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-JsCl + A ) + [(PAA - Z') - i*(P - 1)]Y; r r LVAA A rr JIi
* ^ ^
F = 3  - Y*u • where 3 = ^(3° + 3°)Srs rs rs AB rs A B rs
(for r oc A and s « B)
In the CNDO/2 approximation the total energy can be conveniently 
written as a sum of one-centre and two-centre terms.
z ea + £ eabA=1 B>A
The one-centre energy terms are described by the equation
!A ■ * Prr + V  - (ZI -rccA
+ A (PrrPss “ * r s )YAA
while the two-centre terms are given by
EAB Z (2Prs^AB ^PrsYAB^r^A, socB
+ ZB - CPAAZB + PBBZA " W bB ^  
can be approximated by Y^ -g* this becoming more valid as the distance 
increases. Using this approximation, the second term in the expression 
for can be simplified to
1 (PAA ZA)(PBB V YAB
As -(P - Z^) is the net charge Q about the atomic centre A this termAA ^ A
can be further simplified:
[.........  ^ = QAQBYAB
This last equation shows that the method takes into account the interaction 
between charged centres in a molecule. Alternatively the total energy
can be calculated by adding the internuclear term V>TlT to the electronicNN
energy. This procedure is usually followed as it conveniently partitions
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the total energy into electronic and nuclear components.
The CNDO/2 method gives reasonable estimates of orbital energies 
(Kaufman and others, 1973). Also the off-diagonal elements F^g of the 
Fock matrix are dependent on the charge distribution within a molecule. 
Therefore heteronuclear regions and polarity are taken into account. As 
a result the method produces good estimates of dipole moments (Hoyland, 
1970). However steric repulsion is underestimated and eclipsed and 
gauche conformations are calculated to be too stable relative to staggered 
and trans conformations (Hoyland, 1970).
The INDO method (intermediate neglect of differential overlap) 
is an improvement on the CNDO procedure as it includes more of the two- 
electron integrals (Pople, Beveridge and Dobosh, 1967). The two-electron, 
two-centre integrals are still approximated as in the CNDO method:
YAB = Cpp Irr) (p A, roc B)
But one-centre integrals are evaluated in a more advanced way, and 
integrals of the type (pq|pq) are no longer ignored. The formulae used 
to evaluate one—centre integrals in the INDO method are as follows.
s = Is or 2s
P»P" = 2PX> 2p or 2p y z
s,p,p" A
(ss|ss) 
(ss|pp) 
(sp|sp)
= F°
Cp p Ip p ) ■ F° + 21 F
(p p Ip 'p ") = F° - —  F 25
(p p ' I p p ") = —  F2 25
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where F° = y and G1 and F2 are empirical parameters depending on atom
rixV
type. The core potential term U is also evaluated differently in the 
INDO method.
Urr =  -h(Xr + Ar) + + ^(G1) + (ja (F2)
where the functions jji, 2^ and $3 depend on atom type. For closed-shell 
molecules both the CNDO/2 and INDO methods give similar results (Hoyland, 
1970; Kaufman and others, 1973; Pople, Beveridge and Dobosh, 1967). In 
open-shell molecules where there are unpaired electrons the INDO method 
results in a significant improvement (Pople, Beveridge and Dobosh, 1967) .
The MINDO (modified INDO) method has been developed on a parameter­
ized basis within the INDO framework in order to reproduce experimental 
heats of formation and other molecular properties. The method has been 
progressively revised to give the improved version MINDO/3 (Bingham,
Dewar and Lo, 1975a, 1975b, 1975c, 1975d; Dewar, Lo and Ramsden, 1975).
In the MINDO/3 method the two-electron, two-centre integrals are evaluated 
by the expression
YAB = (Pplrr) (P 00 A, r p* B)
This average coulomb repulsion approximation is the same as that employed 
in the CNDO/2 and INDO methods, except that in MINDO/3 the repulsion 
integrals are now evaluated by the empirical equation
YAB = e*tRlB + * (PA + PB)2}_l5
where depends on the average of one-centre coulomb integrals of atom 
A. The one-centre integrals of the form (ss|ss), (ss|pp), (sp|sp), 
Cp p Ip p), Cp p Ip 'p O  and Cpp"|pp") are evaluated by a method based on 
Oleari’s scheme for using a least squares fit to the total valence state 
atomic energies (Dewar and Lo, 1972). The core potential term U is 
calculated from valence state ionization potentials.
In the MINDO/3 method core-electron attractions are underestimated.
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This is counteracted by modifying the internuclear repulsion term V^. 
The usual form of the internuclear term
VNN
N
Z
A>B
would lead to a net overestimation of the coulomb repulsion between 
atoms in the molecule. Consequently the internuclear term is modified 
to give the more appropriate expression
VNN
N
E CR 
A>B AB
where the individual core-repulsion term CR^ is given by the equation
CRAB = ZAZB Y^AB + " YA B ^  ^ AB^ *AB
where d is a function of the internuclear distance R._,. u AB
The MINDO/3 method provides good estimates of ground-state
molecular properties, including heats of formation, molecular geometries,
dipole moments and ionization potentials (Bingham, Dewar and Lo, 1975a,
1975b, 1975c, 1975d; Dewar, Lo and Ramsden, 1975). The method is also
available as a computer programme (Dewar and others, 1976) which includes
an efficient geometry optimization routine. Although the electronic
structure of isolated molecules is estimated satisfactorily by the method,
hydrogen-bonding between molecules is not adequately described (Zielinski,
Breen and Rein, 1978; Klopman and others, 1978).
PCILO METHOD
The PCILO method employs configuration interaction (Cl), which is 
the mixing of ground-state and excited-state electronic configurations 
(Diner, Malrieu and Claverie, 1969; Malrieu, Claverie and Diner, 1969; 
Diner and others, 1969; Jordan and others, 1969; Diner and others, 1970). 
Excited states are developed by the promotion of electrons from occupied 
to unoccupied or virtual orbitals. Configuration interaction is therefore 
a multi-configurational approach to the solution of the eigenstate.
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The total Cl wavefunction ia a linear combination of single configuration
determinantal wavefunctions .k
0 = E C. f,k k
Variational procedures may be used to minimise the energy with respect 
to the coefficients C^. However the large number of virtual orbitals 
makes the Cl matrix so big, that predetermined truncation of orbital 
mixing (dimensioning of the Cl matrix) must be imposed. PCILO 
calculations involve a combination of perturbative configuration inter­
action (PCI) and localized orbitals (LOTs). Perturbation is a convenient 
technique to arrive at closer approximations to the exact wavefunction. 
Energy corrections can be defined at varying levels of refinement. After 
successively higher order corrections the energy approaches the limit 
imposed by the approximations used in the basic method itself. As con­
figuration interaction improves electron correlation, the PCILO method 
should provide a closer estimate of the exact Hartree-Fock energy than 
a comparable method which does not use configuration interaction. In 
PCILO calculations each localized or bond orbital is constructed from 
atomic orbitals on adjacent atoms, and corresponds to a chemical bond 
description of the electron distribution between the two bonding centres. 
This zeroth-order description is then improved by the perturbative 
technique. In order to keep the calculations at a moderate level of 
complexity the ZDO approximation is applied to bond orbitals. This is 
an improvement on the ZDO approximation when used in the SCF formalism, 
because in PCILO calculations overlap is neglected not between bonding 
centres, but between bonds. Integrals are evaluated according to the 
scheme adopted in the CNDO/2 method.
The zeroth-order energy is that given by a Slater determinant 
constructed from the bonding orbitals. By definition the first-order 
energy correction is zero. Although the initial energy value is a good 
starting point for the perturbation series, second-order and third-order
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corrections are responsible for a significant improvement in the zeroth- 
order value. In arriving at the higher-order energies only mono-excited 
and di-excited configurations are used, where localized antibonding orbitals 
are employed to construct the excited-state configurations. In defining 
the energy corrections the following notation is used for electronic 
configurations.
0 = ground-state zeroth-order configuration
I,J = excited configurations (mono-excited and di-excited)
The second-order energy correction is then given by the equation
g(2) _ £  ^ / 0 H I dv ^
The third-order correction to the energy is similarly defined
(3) 2 Z 
K Jtfo)
/ 0 H I dv / i H j d v  / J H 0 dv 
(E0 - Et) (E0 - K )
The PCILO method avoids an SCF procedure. As a result the cal­
culations are relatively rapid and therefore suited to conformational 
analysis. However the method has several disadvantages. Since the 
localized orbital approach is used the calculations do not provide 
information on the energies of molecular orbitals. The method also fails 
to account properly for lone-pair electrons in a molecule (Kaufman, 1974). 
In addition PCILO calculations have difficulty in compromising in cases 
where a molecular region cannot be adequately represented by one canonical 
structure. Here the PCILO method is restricted to single calculations of 
each reasonable canonical form. The most useful canonical structure should 
be chosen for the molecule as a whole and for the particular application 
in question.
AB INITIO METHODS
Ab in'itio molecular orbital methods treat all electrons in the 
molecule, taking into account both inner-shell and valence-shell electrons.
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Calculations of this type are then limited mainly by the Hartree-Fock 
formalism and by the size of the basis set of orbitals used in the 
calculations. Several reviews are available describing the different 
approaches which have been taken in performing ab initio calculations 
(Dolgushin, Kruglyak and Pinchuk, 1979; Duke, 1975; Golebiewski and 
Parczewski, 1974; Hinze, 1974; Pople, 1970). In ab initio calculations 
the Fock matrix elements are completely evaluated according to their 
definition
m
F = H + Z P {(pq I rs) -^(ps|rq)} pq pq TtS=1 rs 1
where all the integrals (pq|rs) are calculated numerically. Because of 
the large number of integrals to be calculated ab initio calculations 
require a considerable amount of computer time.
An important aspect of ab initio calculations is the choice of the 
basis set. Several different types of basis functions can be employed. 
These are summarized as follows.
(1) Slater-type orbitals (STO's):
*p = RCn Cr) Yl,m (0>«
where p represents the set of constants {£,n,l,m} which contains the
exponent 4» the principal quantum number n, and the azimuthal and magnetic
quantum numbers 1 and m. Y. (0,(j)) is a normalized spherical harmonic.1 ,m
The exponent £ is related to Slater's effective nuclear charge Z by the 
equation
The function R (r) is given by the expression
R (r) = ----  J*5 rn_1 exp(-Sr)
C (2n)!
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(2) Gaussian-type orbitals (GTO’s):
Xp = Np x y z exp (-£r )
where N is a normalization constant and x, y, z are local Cartesian P
co-ordinates.
(3) Gaussian-lobe orbitals (GLO's):
Xp = Np exp (-£r2)
Although a Slater-type orbital can more satisfactorily account for an 
atomic orbital in the basis set, the calculation of the resulting integrals 
is slow. It is common to represent each Slater-type orbital by several 
Gaussian orbitals. Such methods are called STO-NG methods, where N is 
the number of Gaussian orbitals representing each Slater-type orbital. 
Calculations employing ST0-3G and ST0-4G basis sets are common types.
Other selections of the basis set have also been made. An improvement 
is to add an extra Gaussian function to describe the outer part of the 
atomic orbital. One scheme using this principle represents an inner-shell 
atomic orbital by a 4G combination, and a valence-shell atomic orbital by 
an inner 3G and outer 1G combination. This is known as the STO-(4-31G) 
method. Another approach is to vary N Gaussian functions to that the 
calculated energy of an atom is minimized. The resulting atomic orbitals 
are called least-energy minimal atomic orbitals (LEMAO's) and the ab initio 
method is referred to as LEMAO-NG. On the other hand more approximate 
methods have also been developed. One of these approaches is to use a 
subminimal basis set in which floating spherical Gaussian orbitals 
(FSGO's) are used to represent a pair of electrons (Frost, Prentice and 
Rouse, 1967). In this method the spherical orbitals are of the Gaussian- 
lobe type. Another of the more approximate methods combines the results 
of accurate calculations on small molecular fragments to describe 
larger molecules (Newton., Boer and Lipscomb, 1966).
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Christoffersen (1972) has also applied the molecular fragment approach 
to an FSGO method of calculation.
Ab initio calculations provide good estimates of molecular 
geometries, dipole moments and ionization potentials. They can also be 
successfully applied to conformational analysis, although computational 
time becomes limiting in this case. The FSGO method does not give a 
good total energy, but if the FSGO’s are carefully optimized in bond 
regions, then the method may also provide a good estimate of conformational 
behaviour.
2-3 APP LICA TION OF T H E O R E T I C A L  CHEMISTRY 
TO PHARMACOLOGY
Molecular orbital calculations provide useful information on the 
electronic structure and chemical reactivity of drug molecules. Some of 
the most important parameters to be used for this purpose include q^, the 
total electron density on atom A, and the net atomic charge defined by
The highest-occupied and lowest-unoccupied (lowest-empty) molecular 
orbitals (HOMO and LEMO) are important for describing frontier-controlled 
interactions between molecules, where the electrons in the most reactive 
orbitals are involved. Parameters relating to the HOMO and LEMO are the 
orbital energies E^ and E^ , and also the frontier orbital density, 
which is the electron density contributed by the HOMO at a particular 
atomic centre, and is expressed by the equation
f^  = 2C2A A,HOMO
where the superscript E denotes frontier orbital density for atom A 
reacting with an electrophilic agent, and is given by the ex­
pression
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°A,HOMO ^ Cr,HOMO
for orbitals r centred on atom A. Similarly a nucleophilic frontier 
Norbital density f^ can be defined using the LEMO. Another related 
parameter is the superdelocalizability, which can be defined for 
electrophilic, nucleophilic or radical interactions with another 
molecule:
S
S
S
E
A
N
A
R
A
n
2 £ 
i=l
m
2 £ 
i=n+l
+ s “)
for a molecule with 2n electrons and m atomic orbitals in the basis set. 
The coefficient term C2 . is given by the expression
Z
r«A
A further useful parameter is the electrostatic potential V , which 
represents the energy of interaction of the molecule as a whole with 
an approaching positive charge at point P. The theoretical procedure 
used for calculating is discussed in Chapter 3.
Table 2-3 lists selected molecular orbital studies on the electronic 
structure of drugs. The Hiickel molecular orbital method has been used in 
some studies, particularly those prior to 1970. Since the availability 
of semiempirical methods, studies employing EHT,CND0/2 and INDO calculations 
have become more common. The CNDO/2 and INDO methods are the most used of 
the semiempirical techniques. PCILO calculations have been used to study 
electronic structure to a lesser extent. Recently ab initio calculations 
have been applied to a number of drug molecules.
The total energy E^ is commonly used to determine the preferred
conformations of drug molecules. Theoretical calculations can also be
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used to study non-preferred conformations, and the energy barriers which 
are involved during conformational changes. As the Hückel molecular 
orbital method does not depend on the three-dimensional structure of a 
molecule, it cannot be used in conformational analysis. However most 
other methods have been used to study conformational behaviour. Pullman 
and Courriere (1973) have reviewed the success of the PCILO method for 
studying the conformational behaviour of drugs. Compared with experimental 
results from X-ray crystallography and NMR spectroscopy, PCILO calculations 
correctly determine the preferred conformations of a range of drug classes, 
including phenylethylamines and catecholamines, cholinergics, barbiturates, 
antipsychotics and other classes. In acetylcholine the PCILO method 
predicts the gauche conformation to be 2-3 kcal mol 1 more stable than 
the tvans conformation (Pullman, Courriere and Coubeils, 1971), which 
is in agreement with results from X-ray crystallography (Canepa, Pauling 
and Sörum, 1966; Herdklotz and Sass, 1970) and NMR spectroscopy (Partington, 
Feeney and Burgen, 1972), both experimental methods showing that the 
gauche form of acetylcholine is present. Ab initio calculations (Port 
and Pullman, 1973) also show that the gauche form is preferred. In the 
gauche conformation there is a stabilizing electrostatic interaction 
between the electronegative oxygen region and the quaternary ammonium region 
of the molecule. In other neurotransmitters where there is a weaker 
stabilization of gauche conformations in solution, NMR analysis of the 
cationic forms of histamine (Casy, Ison and Ham, 1970; Ganellin and 
others, 1973; Ham, Casy and Ison, 1973) and serotonin (Ison,
Partington and Roberts, 1972) shows that approximately equal proportions 
of gauche and tvans conformations exist. PCILO calculations of histamine 
(Pullman and Port, 1974) and serotonin (Pullman, Courriere and Berthod,
1974) show that in the isolated-state both neurotransmitters prefer the 
gauche conformation, but when solvent effects are taken into account 
gauche and tvans forms are found to be at almost equal energy, in agree­
ment with the experimental results. Ab initio calculations of histamine
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(Pullman and Port, 1974) and serotonin (Port and Pullman, 1974) also 
show that in the isolated-state both molecules prefer a gauche con­
formation. In histamine the imidazole ring is approximately planar 
with the C-C bond in the side-chain, whereas in serotonin the indole 
ring is perpendicular to the side-chain.
Other semi-empirical methods (EHT, CNDO/2, INDO) do not produce 
as good results in conformational analysis. For acetylcholine the EHT 
method does predict a preferred gauche conformation, but it also suggests 
that rotation about the ester bond is quite flexible (Kier, 1967). This 
is in contradiction to PCILO calculations, which predict the expected 
planar arrangement for an ester group. Both CNDO/2 (Ajo and others,
1973) and INDO (Beveridge and Radna, 1971) calculations on acetylcholine 
underestimate non-bonded repulsions and lead to the prediction of con­
formations where short steric distances are involved. With histamine 
EHT calculations (Kier, 1968a) show that the trans form is slightly more 
stable than the gauche form. CNDO/2 calculations on histamine (Ganellin 
and others, 1973) do show that in the isolated-state the gauche conform­
ation is favoured. However in contrast to the PCILO and ab initio 
calculations the CNDO/2 method predicts a less planar arrangement of 
the imidazole ring with respect to the side-chain. With serotonin EHT 
calculations (Kier, 1968b) indicate that the trans form is favoured, in 
disagreement with PCILO and ab initio calculations. The INDO method 
(Kang and Cho, 1971) predicts a fully eclipsed conformation of serotonin 
to be significantly more stable than either gauche or trans forms.
Empirical potential energy calculations have also been applied to 
a number of biomolecules and drugs, including polypeptides (Hopfinger, 
1973), peptide hormones (Momany, 1976), neuroleptics (Koch, 1974) and 
prostaglandins (Murakami and Akahori, 1977), as well as several neuro­
transmitters. Empirical calculations and NMR analysis on dopamine
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(Bustard and Egan, 1971) indicate that the trans conformation is only 
slightly more stable than the gauche form. These calculations which 
do not take electrostatic energy into account are in agreement with 
PCILO calculations on dopamine (Pullman and others, 1972), which 
estimate that the trans and gauche forms are of equal energy. Calcul­
ations which exclude the electrostatic contribution to the energy have 
also been applied to histamine (Kumbar, 1975). The trans and gauche 
conformations are suggested to be of similar energy, with the trans form 
being preferred. This is in disagreement with PCILO and ah initio 
calculations (Pullman and Port, 1974), which show that in the isolated- 
state histamine prefers the gauche conformation. The reason for the dis­
crepancy is that in histamine there is a stabilizing interaction between 
the imidazole ring and the protonated aminoethyl side-chain. This 
interaction will not be taken into account unless an electrostatic con­
tribution to the energy is included. Acetylcholine is also a polar 
molecule and therefore requires an electrostatic component in the energy. 
Empirical calculations by Ajo and others (1972) show that where the 
electrostatic component is excluded the trans form is favoured, but when 
electrostatic energy is included the stability of the gauche form is 
increased relative to the trans form. Also calculations on serotonin 
which take electrostatic energy into account (Johnson, Kang and Green, 
1973) correctly predict that the gauche form is favoured, in agreement 
with PCILO (Pullman, Courriere and Berthod, 1974) and ab initio (Port 
and Pullman, 1974) calculations.
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2-4 RATIONALE FOR THE COMBINED USE OF 
COMOL AND MINDO/3 METHODS
The present work is designed to study the conformational behaviour 
and electronic structure of a series of anticonvulsant drugs. To carry 
out the work a combination of classical COMOL and quantum mechanical 
MINDO/3 methods has been used. COMOL calculations have been used to 
determine preferred conformations for the range of anticonvulsants, with 
MINDO/3 calculations being subsequently applied to describe the electronic 
structure of anticonvulsants in their preferred conformations. Similar 
combinations of methods to study conformation and electronic structure 
have also been used in other investigations. In a study of narcotic drugs 
Loew and others (.1974) have used PCILO calculations to determine preferred 
conformations, and then INDO calculations to provide electrostatic pot­
entials for individual conformations. A combination of PCILO and 
CNDO/2 methods has also been used in a study of histamine analogues 
(Defina and Vaughan, 1977).
In the anticonvulsants studied here conformational energy is largely 
determined by the rotation of hydrocarbon substituents attached to hetero- 
atomic molecular systems. Consequently variations in this energy are 
mostly determined by non-bonded or steric interactions. Classical 
calculations employing empirical potential energy functions are suitable 
for carrying out conformational analysis of this type. Empirical cal­
culations are rapid compared to other methods and allow a thorough 
investigation of the conformational energy surface within a reasonable 
amount of computer time. In the compounds studied there will only be a 
small degree of polarity in the hydrocarbon substituents undergoing 
rotation, and therefore electrostatic contributions to the energy have 
not been included. As torsional potentials are only of the order of 1 
kcal mol 1 a torsional potential function has also been excluded from
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the energy expression, as suggested in a study on the rotation of 
hydrocarbon substituents in peptide units (Koloskar, Sasisekharan and 
Sarathy, 1975).
Quantum mechanical methods of calculation which neglect differential 
overlap have been found useful in the past for investigating the electronic 
structure of heteroatomic systems. Both CNDO/2 and INDO methods give 
reasonable estimates of charges and the energies of higher occupied orb­
itals in pyrrole and pyrazole (Kaufman and others, 1973). INDO calculations 
also provide a good correlation of higher occupied orbital energies with 
experimentally observed spectral transitions in nitrogen heterocycles, 
including pyrrole and pyridine (Ridley and Zerner, 1973). Andrews (1969) 
has shown that CNDO/2 calculations satisfactorily account for observed 
dipole moments in anticonvulsant drugs. The CNDO/2 method also gives an 
accurate estimation of nitrogen electron density in aminoalkyl groups 
of narcotic drugs, as confirmed by X-ray photoelectron spectroscopy 
(Saethre and others, 1975). In the present work the MINDO/3 method has 
been used because of its improved ability to estimate the ground-state 
properties of molecules. It can also be used to provide an estimate of 
the electron distribution for calculations of the molecular electrostatic 
potential. Although shown to give useful results, the MINDO/3 method has 
not previously been evaluated for describing the detailed electronic 
structure of drug-related molecules. In order to more adequately determine 
the value of MINDO/3 calculations, an evaluation has been performed on a 
series of model compounds, and is reported in Chapter 3.
13C-NMR spectroscopy is also used in the present work to provide 
information on the electronic structure of carbonyl groups in anti­
convulsants. This experimental technique has been applied elsewhere 
to compounds containing carbonyl groups, including steroids (Butler,
1976), amides (McClelland and Reynolds, 1974), penicillins and cephalo­
sporins (Mondelli and Ventura, 1977), barbiturates (Fratiello, Mardirossian
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and Chavez, 1973; Long and Goldstein, 1974; Okada and Esaki, 1974) 
and hydantoins (Colebrook, Icli and Hund, 1975; Long and Goldstein, 
1974). 13C chemical shifts have also been correlated with electron 
densities of carbonyl groups in neuroleptic drugs (Riga and others, 
1977). 13C-NMR spectroscopy is used in the present study to provide
a further assessment of the results obtained from MINDO/3 calculations, 
by correlating observed chemical shifts in anticonvulsants with theor­
etically determined electron densities.
CHAPTER 3
EVALUATION OF MLNDO/3 CALCULATIONS 
ON MODEL DRUG SYSTEMS
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This chapter reports the results of a systematic evaluation of 
the MINDO/3 method (Bingham, Dewar and Lo, 1975a, 1975b, 1975c, 1975d; 
Dewar, Lo and Ramsden, 1975). The evaluation has been carried out for 
the calculation of several ground-state properties and molecular 
electrostatic potentials in model compounds. The compounds chosen for 
calculation have structural characteristics in common with several 
important biological systems, and are useful model structures to rep­
resent the type of electron delocalization found in heteroatomic systems 
of anticonvulsant drugs. They therefore provide a good basis for an 
evaluation of MINDO/3 calculations in simple molecular systems of this 
type. The results of MINDO/3 calculations in several other chemical 
systems are also reviewed, in order to provide a wider perspective of 
the use of the MINDO/3 method in biological applications.
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3-1 GR O U N D - S T A T E  PROPERTIES
THEORETICAL PROCEDURE
This section evaluates calculations on several ground-state 
properties: molecular geometry, ionization potential, charge distrib­
ution and dipole moment. Calculations have been carried out using a 
verson of MINDO/3 (Dewar and others, 1976) adapted for use on the 
UNIVAC 1100/42 computer at the Australian National University. Con­
vergence parameters were set at the values recommended in the programme 
documentation. Two series of model compounds have been studied in 
this section. All model compounds in each series have been studied 
previously by both ab initio and experimental methods. The first 
series of five-membered heterocycles consists of pyrrole, furan and 
thiophene. Initial geometries for the molecules were taken from 
experimental results of microwave spectroscopy (Bak and others, 1961,
1962; Nygaard and others, 1969). For this series of heterocycles C 
symmetry was imposed with otherwise full optimization of bond lengths 
and bond angles. Applying the symmetry condition makes each heterocycle 
a planar molecule, with a vertical plane of symmetry perpendicular to 
the molecular plane, and passing through the heteroatom. The second 
series of compounds consists of formamide and urea as well as several 
methylated derivatives of these molecules. Initial geometries were 
based on results of gas-phase electron diffraction of amides (Kitano 
and Kuchitsu, 1973, 1974a, 1974b) and the crystal structure of urea 
(Caron atid Donohue, 1969). For the amides and ureas no symmetry conditions 
were imposed. All bond lengths, bond angles and torsion angles were 
optimized for these molecules.
To avoid interference from crystal packing forces and hydrogen­
bonding, calculated geometries and dipole moments are compared with 
experimental gas-phase data. MINDO/3 orbital energies are directly
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compared with vertical ionization potentials from photoelectron 
spectroscopy on the basis of orbital symmetry. Symmetry labels of 
orbitals correspond to standard nomenclature (Jaffe and Orchin, 1967). 
Atomic charges are compared with ab in'Lt'Lo values.
RESULTS AND DISCUSSION FOR HETEROCYCLE SERIES
The heterocycle series illustrated in Figure 3-1 serves as a 
useful model for lone-pair delocalization into an adjacent carbon TT-system. 
Numbering of ring positions and the convention adopted for the orient­
ation of a positive dipole moment are illustrated in Figure 3-2.
Table 3-1 shows that MINDO/3 predicts geometries of the heterocycles 
in good agreement with experimental results from microwave spectroscopy 
(Bak and others, 1961, 1962; Nygaard and others, 1969). Throughout
Othe series bond lengths are estimated to within 0.04 A, and bond angles 
to within 3° of experimental values. Important trends throughout the 
series are also accounted for by MINDO/3. The X1-C2 bond lengths are 
correctly predicted to be in the order: thiophene > pyrrole > furan.
It is also informative to compare the lengths of the C2-C3 ’double’ 
bond and the C3-C4 'single' bond of the heterocycles. MINDO/3 predicts 
pyrrole to have the longest C2-C3 length and the shortest C3-C4 length. 
This trend is confirmed by the experimental geometries, and it suggests 
that pyrrole has a relatively high degree of aromaticity. The degree 
of aromaticity in pyrrole is usually considered greater than that in 
furan (Politzer and Weinstein, 1975). The aromaticity of thiophene 
on the other hand, appears to be slightly underestimated by the cal­
culations. The predicted trend in the internal bond angle C2-X1-C5 is: 
pyrrole > furan > thiophene, which is also confirmed by experiment.
Tables 3-2 and 3-3 show the calculated dipole moments and atomic 
charges, together with experimental (Buckingham, Harris and Le Fevre,
1953; Harris, Le Fevre and Sullivan, 1953) and ab 'tn'it'to (von Niessen,
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Cederbaum and Diercksen, 1976; von Niessen, Kraemer and Cederbaum, 1976) 
results. MINDO/3 calculated dipole moments for pyrrole and furan are 
reasonable, but with thiophene a large polarization term results in an 
over-estimation of the total dipole moment. Inclusion of 3d-orbitals 
in the basis set might give some improvement in the dipole moment for 
thiophene, but the participation of 3d-orbitals in sulphur bonding is 
not yet clearly established (Baker and others, 1970; Clark, 1968a;
Clark, Gleiter and Heilbronner, 1973; Gelius, Roos and Siegbahn, 1972; 
Johnstone and Mellon, 1973; Kwart and King, 1977) .
Figure 3—1 Chemical structures of the heterocycle series.
From left to right: pyrrole, furan and thiophene.
Figure 3-2 Numbering of heterocycles and convention adopted 
for orientation of a positive dipole moment.
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The charge distributions given by MINDO/3 are in reasonable 
agreement with ab initio calculations, although MINDO/3 apparently 
underestimates the ability of nitrogen to attract electronic charge.
This is reflected in the lower polarity predicted by the method for 
bonds to hydrogen atoms. However, the actual polarity of carbon- 
hydrogen and nitrogen-hydrogen bonds remains to be established. It 
has been suggested elsewhere that ab initio calculations may exaggerate 
charge polarization in pyrrole (Clark, 1968b).
Tables 3-4 to 3-6 list the energy levels for the present series 
of heterocycles. MINDO/3 compares better with experimental ionization 
potentials (Derrick and others, 1971a, 1971b, 1971c) than Hartree-Fock 
ab initio calculations (von Niessen, Cederbaum and Diercksen, 1976; 
von Niessen, Kraemer and Cederbaum, 1976), and is comparable to the 
more rigorous many-body approach, where allowance for electron 
correlation and reorganization provides a better estimate of ionization 
potentials. Although MINDO/3 does underestimate the binding energy 
of upper level a-orbitals, other ionization potentials are generally 
predicted to within 0.5 eV of both many-body and experimental values. 
Often this accuracy is to within 0.1-0.2 eV. Figure 3-3 presents 
energy level diagrams for the series of heterocycles. I€ can be seen 
that the sequencing of orbitals and the energy level differences are 
in good agreement with experiment. The second and third highest 
TT-orbitals, 2b^ (7r) and lb^ (7r), are sensitive to the electronegativity 
of the heteroatom, each having considerable electron density at the 
heteronuclear position. The 2b^ (7r) orbital is essentially a non-bonding 
orbital centered at ring positions XI, C3 and C4. The lb^Tr) orbital 
is a bonding orbital delocalized around the entire ring. Ionization 
potentials of these two orbitals increase in going from pyrrole to 
furan. This is primarily due to increasing heteroatom electronegativity, 
which causes an increase in the binding energy of the orbitals. The
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uppermost orbital is the la^ C'n') orbital, centered on the carbon atoms 
of the ring, and consequently less sensitive to heteroatom electro­
negativity.
TABLE 3-4. Comparison of MINDO/3 ionization potentials 
(eV) with ab initio and experimental values 
for pyrrole
Orbital MINDO/3
ab initio2 
Hartree-Fock Many-body Experimental^
lal 37.49 34.95 • • • • • • • •
2al 26.78 28.30 .. • • • •
19.45 21.38 19.64 18.8
S 17.18 20.08 18.17 17.5
12.29 16.22 14.86 14.8
631 11.19 14.44 12.98 12.6
lb2 26.97 26.65 • • • • • • • •
* 2 18.64 20.84 18.96 18.1
* 2 11.95 15.83 14.37 14.3
4„2 11.44 15.01 13.39 13.0
lb x (it) 13.77 15.44 13.70 13.7
2b j (it) 8.77 9.54 8.92 9.20
la2Cir) 8.20 8.31 8.17 8.21
a von Niessen, Cederbaum and Diercksen (1976) 
b Derrick and others (1971c)
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TABLE 3 -5 .  Com parison  o f  MINDO/3 i o n i z a t i o n  p o t e n t i a l s  
(eV) w i t h  ab i n i t i o  and e x p e r i m e n t a l  v a lu e s  
f o r  f u r a n
O r b i t a l MINDO/3
7 • • , • aab vrvit'io
H a r t r e e - F o c k Many-body E x p e r im e n ta l^
l a i 38 .31 3 9 .79 • • • • • • • •
2 a i 2 8 .4 3 2 9 .8 3 • • • • • • • •
3 a i 19 .89 2 1 .27 19 .25 19 .0
4 a i 16 .74 2 0 .3 2 18.48 17.5
5 a i 11 .72 15 .58 14 .10 13 .8
6a^ 11 .17 14 .83 13 .30 13 .0
l b 2 2 7 .28 2 7 .6 4 . . . .
2b2 19 .65 22 .1 0 2 0 .17 19 .5
3b2 12.92 16 .55 15 .17 15 .1
4b 2 11 .80 16 .07 14.69 14 .4
l b j  (tt) 15.26 17 .37 15.47 15 .6
2bx (Tr) 9 .9 4 11.11 10 .36 10.31
1^2 (it) 8 .3 8 9 .1 5 8 .8 7 8 .8 8
a von N ie s s e n ,  Kraemer and Cederbaum (1976) 
b D e r r i c k  and o t h e r s  (1971a)
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TABLE 3-6. Comparison of MINDO/3 ionization potentials 
(eV) with ab initio and experimental values 
for thiophene
Orbital MINDO/3
ab initioa
Hartree-Fock Many-Body
Jj
Experimental
u i 37.30 32.09 • • • • • • • •
2 a i 23.99 26.99 • • • • . .
3 a i 18.04 20.49 18.79 18.3
4 a i 15.71 19.20 17.50 16.6
5 a i
11.50 14.34 13.44 13.9
6 a i 9.61 13.08 12.01 12.1
lb2 27.96 26.75 .. ..
2b2 18.17 20.76 18.70 17.6
3b2 12.32 14.90 14.52 14.3
4b2 10.43 14.43 13.29 13.3
l b^TT) 13.11 15.97 12.88 12.7
2 b 1 (TT) 9.09 9.45 8.98 9.52
la2 (it) 8.92 9.23 8.77 8.87
a von Niessen, Kraemer and Cederbaum (1976) 
b Derrick and others (1971b)
PY
R
R
O
LE
 
FU
R
A
N
 
TH
IO
P
H
E
N
E
92
rrr
o
II /
/ If 
! : ) !  
I l l  U  
I lU
i lit»
ii / / I nuii lit
«
/ / / /
/*7
• 11 I
• ii i 
I U I 
I u i
/ • (
//
I I
j I I I I Ii i
k
.7 >7 // (/ 
///7
ii //i ii /, i 
ii « I I i / / 1 
ii a  I
I I I I I  I I  I T I I I  I I  I I  I I  I I I I I I I I l I I I  I I I I  I I 11
KO o «o o—  CN •O OCN CO •O OCO ^
(A3) ! V U N 3 i O d  NOI1VZINOI
Fi
gu
re
 3
—3
 
En
er
gy
 l
ev
el
 d
ia
gr
am
 f
or
 t
he
 h
et
er
oc
yc
le
s.
 
Fo
r 
ea
ch
 m
ol
ec
ul
e 
MI
ND
O/
3 
en
er
gi
es
 
ar
e 
on
 t
he
 l
ef
t 
an
d 
ex
pe
ri
me
nt
al
 e
ne
rg
ie
s 
(D
er
ri
ck
 a
nd
 o
th
er
s,
 
19
71
a,
 1
97
1b
, 
19
71
c)
 a
re
 o
n 
th
e 
ri
gh
t.
93
RESULTS AND DISCUSSION FOR AMIDE AND UREA SERIES
The amides and ureas shown in Figure 3-4 were chosen because 
they allow the study of nitrogen lone-pair delocalization into an 
adjacent carbonyl TT-system. Table 3-7 shows that the geometries of 
the amides are predicted satisfactorily by MINDO/3. Comparison is 
made with experimental gas-phase electron diffraction data (Kitano and 
Kuchitsu, 1973, 1974a, 1974b). Bond lengths are estimated to within
o O0.04 A, and bond angles to within 3 of experimental values for all but 
the C2-N1-C4 bond angle in N-methylformamide, which is significantly 
overestimated.
The experimental conformation of formamide has not been clearly 
resolved in the past, but more recent evidence from both microwave 
spectroscopy (Hirota and others, 1974) and low-temperature X-ray 
crystallography (Stevens, 1978) indicates that it has a preferred planar 
conformation. This is in agreement with MINDO/3, which predicts 
planar conformations for all the molecules in this series. In the 
only nonsymmetrically substituted member of the series, N-methylform­
amide, MINDO/3 favours the Z-conformation, again in agreement with 
experimental evidence (Kitano and Kuchitsu, 1974b) . The results 
reported for this molecule all refer to the Z-conformation.
Dipole moments and atomic charges for the amides are listed in 
Tables 3-8 and 3-9, where MINDO/3 calculations are compared to 
experimental (Kurland and Wilson, 1957; Meighan and Cole, 1964) and 
ab initio (Ottersen, 1975) results. Similar dipole moments are pre­
dicted by MINDO/3 and ab initio calculations. There is also a basic 
agreement between the atomic charges. In the MINDO/3 calculations 
N1 and C4 electron densities are apparently underestimated, this being 
reflected in lower polarities for N-H and methyl C-H bonds. It is useful to 
also compare the direction of the MINDO/3 dipole moment vector for 
formamide with estimates from microwave spectroscopy (Kurland and
94
Figure 3-4 Chemical structures for the amide and urea series.
From left to right: formamide and acetamide (top);
N-methylformamide and N ,N-dimethylformamide (centre); 
urea and tetramethylurea (bottom). Numbering of 
amides is shown in formamide. The Nl-H positions are 
defined as (z) and (e) for ois and trans orientations 
with respect to 03. In acetamide and N-methylformamide 
the carbon of the methyl group is numbered C4. 
N-methylformamide is shown in the Z-conformation, where 
C4 and 03 have a e-is orientation.
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Wilson, 1957) and ab initio calculations (Robb and Csizmadia, 1968; 
Stenkamp and Davidson, 1977) . Figure 3-5 shows that both methods 
accurately predict the experimental direction of the dipole moment 
vector. The MINDO/3 and ab initio errors in the direction of the vector 
are only 3.7° and 1.6° (Stenkamp and Davidson, 1977) or 5.9° (Robb 
and Csizmadia, 1968) respectively. On the basis of this evidence it 
cannot be said which of the MINDO/3 or ab initio methods gives a better 
picture of the electron distribution of formamide.
Figure 3-5 Dipole moment vectors for formamide: MINDO/3 (M),
ab initio {Ag^, Stenkamp and Davidson (1977); Arc, 
Robb and Csizmadia (1968)} and experimental 
{E, Kurland and Wilson (1957)}. The M, Ag^, Ar ,^ 
and E vectors have magnitudes of 3.86, 4.1, 4.15 
and 3.71 Debye, and directions of 35.9°, 38° 45.5° 
and 39.6° from the N1-C2 axis.
It can be seen from Table 3-10 that in comparison to experimental 
(Siegbahn and others, 1974) and ab initio (Christensen and others,
1970) values, MINDO/3 provides an accurate estimate of the energy 
levels of formamide, although two of the upper a-orbitals (5a" and 6a') 
have lower ionization potentials than experiment. The same frontier 
orbital configuration for formamide is predicted by both MINDO/3 and 
the ab initio methods. Both methods place the 2a^ (tt) orbital as the
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first ionization, and the 7a" orbital as the second ionization. More 
rigorous db initio calculations, which estimate the energies of both 
neutral and ionized states of formamide and also take electron correl­
ation into account, have been applied to the upper two ionizations of 
formamide (Brundle and others, 1969). They predict that the 2a" (it) 
and la' orbitals have ionization potentials of 11.25 and 10.26 eV 
respectively, in better qualitative, although not quantitative, 
agreement with the experimental results. Recent configuration inter­
action db initio calculations on formamide also predict the correct 
ordering of the uppermost ionizations (Oliveros and others, 1978).
Table 3-11 shows that MINDO/3 generally predicts frontier ion­
ization potentials of the amides and ureas to within 0.5 eV of observed 
experimental values (Brundle and others, 1969; Mines and Thompson,
1975; Siegbahn and others, 1974; Sweigart and Turner, 1972). There 
is a discrepancy of 0.87 eV between MINDO/3 and experimental ionization 
potentials for the tt^ CNjN) orbital in urea. However the experimental 
ordering of the frontier orbitals in urea has been confirmed by db 
initio calculations (Elbert and Davidson, 1974).
TABLE 3-10. Comparison of MINDO/3 ionization potentials 
(eV) for formamide with db initio and 
experimental values
Orbital MINDO/3 Ab initioa Experimental^
la" 32.58 38.36 33.1
2a" 27.71 33.08 29.2
3a" 21.23 23.05 20.5
4a" 17.19 20.45 18.8
5a" 14.91 18.37 16.30
6 a " 12.62 16.78 14.75
la' 10.49 12.01 10.42
la""(7r) 14.41 15.74 14.03
2a"" (tt) 10.40 11.57 10.70
a Christensen and others (1970) 
b Siegbahn and others (1974)
TA
BL
E 
3-
11
. 
Co
mp
ar
is
on
 o
f 
MI
ND
O/
3 
fr
on
ti
er
 i
on
iz
at
io
n 
po
te
nt
ia
ls
 (
eV
) 
wi
th
 e
xp
er
im
en
ta
l 
va
lu
es
 f
or
 t
he
 
am
id
e 
an
d 
ur
ea
 s
er
ie
s
100
<3 rQ
Si
eg
ba
hn
 a
nd
 o
th
er
s 
(1
97
4)
 
o 
Sw
ei
ga
rt
 a
nd
 T
ur
ne
r 
(1
97
2)
Br
un
dl
e 
an
d 
ot
he
rs
 (
19
69
) 
d 
Mi
ne
s 
an
d 
Th
om
ps
on
 (
19
75
)
101
Due to orbital mixing effects of methyl substituents, methylation 
of both formamide and urea results in a decrease in the experimental 
binding energies of the ir-orbitals, and to a lesser extent the non­
bonding a-orbital centered on oxygen. MINDO/3 correctly predicts 
this trend.
3-2 MOLECULAR ELECTROSTATIC POTENTIALS
THEORETICAL PROCEDURE
Molecular electrostatic potential represents the energy of 
interaction resulting from the approach of a unitary positive charge 
towards a molecule. The reliability of semi-empirical methods as the 
basis for the calculation of electrostatic potential is not clearly 
established. Nevertheless semi-empirical methods have proved useful 
within homogenous series of molecules. In order to evaluate the present 
theoretical approach to electrostatic potentials, calculations have 
been performed on a series of model compounds. Formaldehyde, formamide, 
urea, thymine and cytosine have been chosen for this purpose. As one 
of the common structural features of anticonvulsant drugs is a nitrogen 
heteroatomic system containing one or more carbonyl groups, these 
compounds serve as useful model structures. In addition electrostatic 
potentials have also been calculated for these compounds by other workers 
using ab initio methods. Initial geometries were obtained using idealized 
values. Subsequent optimization of bond lengths and bond angles was 
carried out for all compounds using the MINDO/3 programme. Calculated 
wave functions have been used to supply electron densities for the 
estimation of electrostatic potentials.
The molecular electrostatic potential for the interaction of a 
molecule with a unitary positive charge at point P is given by the 
expression (Giessner-Prettre and Pullman, 1972):
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VP = z
ij
P. . I ij J
The first term represents repulsion between the positive charge and
the nucleii of the molecule, and the second term is the sum of nuclear
attraction integrals between the molecular wavefunction and the positive
charge. R ^  is the distance between the positive charge and the atomic
centre A, with nuclear charge Z . P .. is the bond order betweenA 1J
atomic orbitals d). and d)..i J
Electrostatic potentials have been calculated using the averaged 
spherioal atomio orbital approximation with complete neglect of diff­
erential overlap. Application of these approximations to semi- 
empirical wavefunctions has been shown to reproduce important features 
of ab initio calculations (Giessner-Prettre and Pullman, 1972). Using 
these approximations for the calculation of the following expression 
is derived.
- Z
where Z' is the effective valence nuclear charge on atomic centre A
A ( Z 7 « Z. - 2 for second row atoms), and q. and d) are the total A A A sA
valence electron density and an averaged spherical atomic orbital on 
centre A respectively. Values for the two-centre nuclear attraction 
integrals are calculated using Roothaan's formulae (Roothaan, 1951b) and 
Slater's effective nuclear charges (Slater, 1930b).
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RESULTS AND DISCUSSION
The compounds studied in the evaluation of electrostatic 
potentials are shown in Table 3-12. All compounds have at least one 
carbonyl group, with thymine containing two carbonyl groups and 
cytosine containing both a carbonyl group and a pyridine type nitrogen. 
Figures 3-6 to 3-10 show the results of the calculations. Electro­
static potentials and electron densities are listed in Table 3-13, 
where they are compared with results from db initio calculations 
(Bonaccorsi and others, 1972; Clementi and others, 1969; Dreyfus,
Maigret and Pullman, 1970; Giessner-Prettre and Pullman, 1972; Orita 
and Pullman, 1977; Perahia and Pullman, 1978; Scrocco and Tomasi, 1973).
There is a good agreement between the relative values of MINDO/3 
and db initio electrostatic potentials. In formaldehyde the potential 
is least negative. More negative potentials occur in formamide and urea, 
where nitrogen atoms can release electron density to the neighbouring 
carbonyl group. Electrostatic potentials for the two carbonyl groups 
in thymine are ordered in agreement with both db initio calculations 
(Perahia and Pullman, 1978) and experimental protonation evidence for 
the related compound uracil (Poulter and Frederick, 1975) . As seen in 
Figure 3-10 the calculations do not predict a separate negative potential 
region near the pyridine-type nitrogen in cytosine. This is in contrast 
to db initio calculations, which indicate that pyridine-type nitrogen 
atoms do create regions of high negative potential (Giessner-Prettre 
and Pullman, 1974,1975).
The data in Table 3-13 shows that electron density on a carbonyl 
oxygen atom offers only an approximate guide to the electrostatic 
potential surrounding the carbonyl group. This is because electron 
density does not accurately reflect the overall molecular environment 
surrounding the carbonyl group. Compare for example the carbonyl 
groups of thymine and cytosine, where there is no significant difference
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between oxygen electron densities in either compound. In cytosine the 
influence of a neighbouring pyridine-type nitrogen results in a highly 
negative electrostatic potential being associated with the carbonyl group. 
This shows how molecular electrostatic potential takes the complete 
molecule into account, and therefore gives a better estimate of chemical 
reactivity.
TABLE 3-12. Carbonyl-containing model compounds for 
evaluation of molecular electrostatic 
potentials
1C
;^ R2
id)
Compound Ri R2
Formaldehyde H H
Formamide n h2 H
Urea n h2 NH
Thymine
Cytosine
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I I I I I I I I I I I 
0 1  2 3 4 5 6 7 8 9  10
DISTANCE IN ANGSTROMS
(NUMBER OF CONTOURS 20 CONTOUR INTERVAL 2 . 0 0  KCAL/MOLE)
F i g u r e  3 -6  E l e c t r o s t a t i c  p o t e n t i a l  c o n to u r  map i n  t h e  m o le c u la r  
p l a n e  o f  fo rm a ld e h y d e .  T here  i s  a  n e g a t i v e  p o t e n t i a l  
w e l l  ( - 1 4 .3  k c a l  mol 2) s u r r o u n d in g  t h e  c a r b o n y l  oxygen 
atom (shown i n  l i g h t  s h a d i n g ) . The r e g i o n  s u r r o u n d in g  
th e  h y d ro g en  atom s i s  a  p o s i t i v e  p o t e n t i a l  a r e a .
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0 1  2 3 4 5 6 7 8 9 1 0
D I S T A N C E  IN ANGSTROMS
(NUMBER OF CONTOURS 2 0  CONTOUR IN T E R V A L  2 . 0 0  K C A L / M O L E )
Figure 3-7 Electrostatic potential map of formamide. The oxygen 
and nitrogen atoms are shown in light and dark shading 
respectively. There is a negative potential well 
(-24.3 kcal mol x) associated with the oxygen atom.
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I I I I I I I I I I 1
0 1  2 3 4 5 6 7 8 9  10
DISTANCE IN ANGSTROMS
(NUMBER OF CONTOURS 20  CONTOUR INTERVAL 2 . 0 0  KCAL/MOLE)
Figure' 3-8 Electrostatic potential map of urea. The negative 
potential well associated with the oxygen atom is 
-29.7 kcal mol 1.
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9 10
DISTANCE IN ANGSTROMS
(NUMBER OF CONTOURS 20 CONTOUR INTERVAL 2 . 0 0  KCAL/MOLE)
Figure 3-9 Electrostatic potential map of thymine. Negative
potential wells surround each of the carbonyl oxygens 
0(1)_ (-20.7kcal mol 1 , lower) and 0(2) (-22.7 kcal 
mol 1t upper right).
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D I S T A N C E  IN A N G S T R O M S
(NUMBER OF C O N T O U R S  20 C O N T O U R  INTERVAL 2.00 KCAL /MOLE)
Figure 3-10 Electrostatic potential map of cytosine. An
extended negative potential region (-32.1 kcal mol 1) 
surrounds the carbonyl oxygen in this compound, due 
to the presence of a neighbouring pyridine-type 
nitrogen atom.
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3-3 RESULTS OF MINDO/3 CALCULATIONS 
IN OTHER C H E MICA L SYSTEMS
The MINDO/3 method was originally developed to predict fundamental 
ground-state molecular properties such as heats of formation, molecular 
geometries, dipole moments and ionization potentials. In these areas 
of application the method has had considerable success (Bingham, Dewar 
and Lo, 1975a, 1975b, 1975c, 1975d; Dewar, Lo and Ramsden, 1975). It 
has also been successfully applied to activation energies for a number 
of hydrocarbon reactions (Dewar, 1975a). Subsequent studies in specialist 
areas have illustrated both inadequacies and virtues of the method. In 
particular, the following results may be noted.
HEATS OF FORMATION
Heats of reaction for several hydrocarbon reactions are estimated 
poorly as compared to db initio and experimental values (Pople, 1975).
Due to the nature of the INDO approximation, calculated heats of 
formation for heteroatomic molecules with adjacent lone-pair heteroatoms 
are too low (Dewar, 1975b).
GEOMETRY AND CONFORMATION
Bond angles in some molecules are significantly overestimated 
(Hehre, 1975), conformational equilibria should be viewed with caution 
where rotation occurs about an essential single bond which connects 
two TT-electronic systems (Bally and others, 1976), and ring puckering 
in strained-ring compounds is underestimated (Combs and Rossie, 1976).
The method successfully accounts for conformational trends in p- 
substituted anilines (Parr and Wasylishen, 1977) and benzyl halides 
(Schaefer and others, 1976; Schaefer, Kruczynski and Parr, 1976).
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PHYSICAL PROPERTIES
ESCA chemical shifts (Dewar and Lo, 1975), molecular vibration 
frequencies (Dewar and Ford, 1977) and NMR coupling constants (Dewar 
and others, 1977; Schulman, 1977) are estimated fairly by the method. 
Hydrogen-bonding is unsatisfactorily treated. The method severely 
underestimates the stability of hydrogen-bonded species (Klopman and 
others, 1978; Zielinski, Breen and Rein, 1978).
Ionization potentials are generally calculated satisfactorily.
This is also observed in earlier versions of MINDO (Worley, 1971).
There is a tendency to underestimate the binding energy of upper level 
Q-orbitals to some degree (Haselbach and Heilbronner, 1970; Krause,
Taylor and Fenske, 1977). The method has been successfully applied to 
ionization potentials in both 1,3-dipole (Caramella and others, 1977) 
and a-dicarbonyl (Gleiter, Schang and Seitz, 1978; Gleiter and others,
1977) molecular systems.
3-4 CONCLUSION
MINDO/3 calculations have been applied to a collection of model 
compounds which are related to the structures of anticonvulsant drugs 
as well as several important biological systems. The calculations 
have been used to study ground-state molecular properties in a series 
of five-membered heterocycles, amides and ureas, and also molecular 
electrostatic potentials in a further series of heteroatomic compounds.
The results show that calculated geometries for the molecules 
studied are generally good. Bond lengths are accurate to within 0.04 
and most bond angles to within 3° of experimental values. The deficiencies 
which occur in some bond angles are acceptable for the purpose of cal­
culating electronic structure. Calculated atomic charges are generally 
in agreement with ab initio results, and dipole moments are estimated
J>
o
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satisfactorily. MINDO/3 predicts less polarization away from hydrogen 
atoms than is suggested by db initio calculations, however comparison 
with experimental dipole moments indicates that MINDO/3 may not be giving 
an inferior description of the electron distribution. Ionization 
potentials are generally estimated to within 0.5 eV of experimental 
values. Orbital sequencing and energy level differences are estimated 
accurately, although the binding energy of some upper level a-orbitals 
is underestimated by about 2eV. MINDO/3 provides a reliable estimate of 
the energies of frontier orbitals, and therefore gives a useful indic­
ation of molecular reactivity. The method also accounts satisfactorily 
for the influence of electronegativity on energy levels.
The results also show that MINDO/3 charge distributions, in 
conjunction with the averaged spherical atomic orbital approximation, 
provide a useful estimate of molecular electrostatic potentials.
Although care should be exercised where pyridine-type nitrogens are 
present, the averaged spherical atomic orbital approximation, restricted 
to complete neglect of differential overlap, is suitable for the cal­
culation of electrostatic potentials.
The overall evaluation shows that MINDO/3 provides a good 
description of the geometries and electronic properties of the hetero- 
atomic molecules studied. Subject to the cautions outlined, the method 
should be well suited to a study of anticonvulsant drugs, and also 
appears to have a wide applicability to molecules of biological interest.
CHAPTER 4
DEVELOPMENT AND USE OF
COMPUTER SOFTWARE
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This chapter describes the use of computer software for the 
calculation of conformation and electronic structure. Two types of 
software are involved; programmes for numerical calculation of con­
formational energy and electronic structure, and plotting programmes 
for interactive graphics at a computer terminal or hard copy plotting 
on a paper plotter. Use has been made of several available software 
packages for both numerical and graphical processing. Some programmes 
have also been written as part of the present work, and flow-charts 
for these programmes are included here. All programmes used in this 
work have been written in the FORTRAN computer language. This chapter 
also describes the use of a molecular structure data base which has been 
developed as part of the present work. The computer techniques des­
cribed in this chapter provide a useful and convenient presentation of 
three-dimensional information. Both molecular conformation and energy 
surfaces can be readily appreciated through the use of computer graphics.
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4-1 NUMERICAL SOF TWAR E FOR THE CALCULATION 
OF CONFORMATION AND ELECTRONIC STR UCTU RE
MOLECULAR STRUCTURE DATA BASE
A molecular structure data base has been established for the 
purpose of constructing anticonvulsant drugs from component fragments. 
Each molecular fragment is stored as a data file. BASE files contain 
data for the principal molecular fragments. Information on heteroatomic 
systems for use in the BASE files has been collected from molecular 
structure reports on barbiturates (Craven, Vizzini and Rodrigues, 1969), 
hydantoins (Koch and others, 1975; Mootz, 1965), oxazolidinediones 
(Kistenmacher and Stucky, 1970), succinimides (Brown, 1961; King, 1966), 
glutarimides (Koch and Dideberg, 1973; Petersen, 1971), benzodiazepines 
and triazolobenzodiazepines (Camerman and Camerman, 1972a; Kamiya, Wada 
and Nishikawa, 1973),amid es (Kitano and Kuckitsu, 1973, 1974a, 1974b), 
azetidinone analogues (Berman and others, 1969; Fujiwara, Varley and 
Van der Veen, 1977; Pitt, 1952; Vigevani and Gallo, 1967) and urea 
(Caron and Donohue, 1969). There are also the substituent files SUB1, 
SUB2 and SUB3, which contain data for substituent molecular fragments. 
Standard geometries have been used for phenyl, ethyl and methyl sub­
stituents (Pople and Gordon, 1967). One or more substituent fragments 
can be joined onto a base fragment in order to make up a complete 
anticonvulsant drug. Figure 4-1 outlines the procedure for constructing 
diphenylhydantoin (phenytoin).
Information in the data base files is in the format for input to 
the C0M0L empirical potential energy programme (Koch, 1973). Each base 
and substituent fragment contains a set number of atoms. In most cases 
the BASE file will contain 23 atoms. With the hydantoin base fragment 
there are 11 real atoms, which requires the addition of extra dummy 
atoms to make up the standard base data file. In the case of diphenyl-
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add BASE . HYDANTOINI
delete unwanted atomsI
add SUB 1 . PHENYLI
specify position of phenyl substituentI
add SUB2. PHENYLi
specify position of phenyl substituentI
input t i t l e  and control parameters
I
checkI
submit d a ta f i le  PPH for execution 
with programme f i l e  COMOL
Figure 4-1 Construction of phenytoin (diphenylhydantoin, PPH) 
with the molecular structure data base.
hydantoin there are two hydrogen atoms in the base fragment which are 
replaced with phenyl substituents. The procedure adopted here is to 
delete the two hydrogen atoms as well as one dummy atom, making the 
total number of atoms in the base fragment equal to 20. After this 
modification to the data file has been carried out the two phenyl
substituents can be added on. With the addition of each substituent
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it is necessary to specify the position of substitution on the hydantoin 
base fragment and the associated bond length, bond angle and torsion 
angle. All torsion angles have been set equal to zero for convenience. 
Each substituent file SUB1 and SUB2 contains fifteen atoms, some of 
which are dummy atoms, and so the total number of atoms in the complete 
molecule is equal to 50. In diphenylhydantoin there are 33 real atoms 
and 17 dummy atoms. In the case of benzodiazepines there are more than 
20 real atoms in the base fragment. Here the base fragment is made up 
to 35 atoms, and the substituent files SUB2 and SUB3 are used to add on 
substituents. After the molecular structure has been built up it is then 
necessary to input title and control parameters to make a complete data 
file for execution with the programme COMOL.
C0M0L
The first stage of computer processing has utilized the COMOL 
programme to carry out conformational analysis. Calculations have been 
performed on the UNIVAC 1100/42 mainframe computer at the Australian 
National University. The COMOL programme allows for two torsion angles 
to be varied at a time. Conformational energy is calculated for all 
combinations of each torsion angle. The number of combinations will 
depend on the increments chosen for the torsion angles. If increments 
for each 360° rotation of a substituent are taken at 30° intervals then 
12 values of the torsion angle T will be considered, starting with t = 0° 
and finishing with T = 360°. If two torsion angles are being studied 
then a 12 x 12 matrix of energy values will be generated.
After performing the empirical potential energy calculations, the 
COMOL programme then outputs information relating to conformational energy 
and molecular structure. The two-dimensional matrix of energy values is 
output to a file which can be used by the graphical contouring programme 
ENMAP. The COMOL programme also establishes a molecular structure data
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file for entry to the interactive plotting programme MOLMOD.
MINDO/3
Once conformational analysis has been carried out electronic 
structure calculations can be performed using the MINDO/3 programme 
(Dewar and others, 1976), data for which is generated by MOLMOD. The 
MINDO/3 programme uses a self-consistent field method to determine the 
total energy. Iteration is continued until the programme achieves 
consistence with the previous cycle to within acceptable limits of 
accuracy. The programme also makes use of a set of efficient geometry 
optimization subroutines. This capability allows the total energy to be 
minimized with respect to the molecular geometry, with the resulting 
end-point geometry corresponding to a local minimum on the multi-dimensional 
energy surface. For calculations on a particular conformation torsion 
angles can be kept constant, maintaining the desired conformation, while 
all bond lengths and bond angles are optimized until the energy minimum 
is reached. The programme concludes by outputting the complete wave 
function for the molecule, orbital energy values, electron densities 
and also the optimized geometry which has been obtained. The results of 
MINDO/3 calculations can then be used for further analysis of electronic 
structure using the programmes REACTIVITY and ELPOT.
REACTIVITY
The REACTIVITY programme has been written as part of the present 
work. It uses the complete wave function for a molecule and the set 
of orbital energies to calculate several reactivity indexes. The 
programme has been designed so that any wave function can be used.
Although in the present work only MINDO/3 wave functions are calculated, 
the REACTIVITY programme should be suitable for use with most other 
semi-empirical molecular orbital methods. The programme outputs
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Read in data (OIN):
number of atoms and
number of orbitals (m)
atomic numbers
wave function matrix (eigenvectors)
orbital, energies
▼
Calculate number of occupied orbitals (n)
f
Calculate for each atom A, summing over 
all orbitals:t
Is orbital number > n?
I--------------------------------------------- -^----------------------------------------------------[
NoICalculate increments to electron 
density and electrophilic super- 
delocalizability for atom A:
Yes
Calculate increment to nucleo­
philic superdelocalizability 
for atom A:
n C
i=n+l1 i
Calculate net atomic charge
Write results
Figure 4-2 Flow-chart for the REACTIVITY programme which
calculates indexes related to chemical reactivity 
using the OIN file as input. The programme 
calculates electron densities and net charges to 
. compare with MINDO/3 results for checking purposes,
as well as supplying superdelocalizabilities for 
a further indication of chemical reactivity.
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information relating to electron density, net charge and both electro­
philic and nucleophilic superdelocalizabilities. Figure 4-2 shows a 
flow-chart of the REACTIVITY programme.
4-2 COMPUTER GRAPHICS
ENMAP AND ENSUR
The conformational energy matrix serves as input to the contouring 
programme ENMAP. This programme utilizes the KONTOR subroutine (Palmer, 
1970) for producing a contour map of energy as a function of two torsion 
angles. Points on the conformational grid are joined by lines connecting 
points of equal energy, at specified intervals of energy between each 
line. In this work the interval between contour lines has been set at 
2.5 kcal mol 1. There are up to 20 lines drawn, with the contours being 
cut off when the energy reaches 50 kcal mol 1 above the global minimum. 
ENMAP also generates an energy matrix suitable as input to the three- 
dimensional plotting programme ENSUR. This programme has been written 
as part of the present work to give a three-dimensional perspective view 
of the energy surface. A flow-chart for the programme is shown in 
Figure 4-3. ENSUR utilizes the PL0T3D subroutine (Watkins, 1974) to 
provide three views of the energy surface. The first view is at an 
angle of 45° to the viewer, and the other two views show the surface 
at different angles. This assists in viewing behind high energy hills, 
which may obscure the background surface. The three-dimensional plots 
produced by ENSUR are used to help interpret the contour maps from ENMAP. 
Figure 4-4 shows the contour map and associated energy surface which 
result from calculations on phenytoin. For convenience in the present­
ation of results only the principal energy surfaces at the 45° viewing 
angle are shown for the compounds studied.
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Read in data:
angle of rotation for viewing 
energy surface
labels for torsion angles and 
size of energy matrix
matrix of energy values (POTSUR)
t
Cut off energy at 100 kcal mol 1: 
if ENERGY > 100, 
then ENERGY =100
7
Plot energy surface (CSUR):
go to each value along energy 
axis, then -
1. read line of energy matrix into one­
dimensional array
2. CALL PL0T3D subroutine
t
Cross-hatch by plotting in perpendicular 
direction.
7
Draw frame around bottom of surface:
CALL FRAMERlLabel axes:
calculate angles of axes 
calculate positions for labels 
CALL PLOT, SYMBOLIRepeat for 2nd and 3rd views of energy 
surface
Figure 4-3 Flow-chart for the plotting of a conformational 
energy surface using the ENSUR programme. The 
matrix of conformational energies is supplied in the 
the input file POTSUR. Plotting information is 
contained in the plot file CSUR. The programme 
utilizes the PL0T3D and FRAMER subroutines (Watkins, 
1974), as well as the UNIVAC systems routines PLOT 
and SYMBOL.
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MOLMOD AND PLUTO
Data is also prepared by COMOL for entry into the MOLMOD 
programme (Andrews, unpublished documentation). This interactive 
programme has been used for viewing the molecular conformation of anti­
convulsant drugs. MOLMOD has been executed at a Tektronix 4014-1 terminal 
which is interfaced with the mainframe UNIVAC computer via a PDP 11/50 
computer. Using the MOLMOD programme geometrical transformations 
(translations, rotations) can be applied to a drug molecule at the 
computer terminal. Superimpositions of two or more drugs then allow 
for the comparison of structural features among a series of drugs.
MOLMOD outputs data suitable for use as input to the MINDO/3 programme. 
MOLMOD has also been used to prepare data for the PLUTO programme 
(Motherwell, 1975). PLUTO generates hardcopy plot files of molecular 
structures for later batch processing on a Calcomp 960 vertical plotter. 
The programme has been modified slightly so that Van der Waal’s radii 
of atoms are scaled to correspond to the values given by Bondi (1964).
Figure 4-5 Ball-and-stick (left) and space-filling (right) 
diagrams of phenytoin produced using the PLUTO 
programme. For reasons of clarity in comparing 
different conformations throughout a series of 
molecules, ball-and-stick diagrams have been used 
in the present work.
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Figure 4-6 Molecular structures of phenytoin (upper left) and
the dechlorinated derivative of diazepam (upper right) 
drawn with PLUTO programme. The lower superimposition 
is a hardcopy print of both structures which have been 
superimposed on the Tektronix 4014-1 terminal using the 
MOLMOD programme. Superimpositions of this type are 
useful for interactively comparing the conformations of 
different molecules.
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Figure 4-5 shows ball-and-stick and space-filling plots of phenytoin 
generated using the PLUTO programme. Throughout the present work ball- 
and stick drawings have been used, as they more clearly show the 
similarities in conformation from one drug to another. Figure 4-6 
shows the conformations of phenytoin and the dechlorinated derivative of 
diazepam, illustrating the PLUTO diagrams for each molecule and the MOLMOD 
superimposition of the structures. The MOLMOD superimposition is also 
available as a hardcopy print through the use of a hardcopy unit 
adjacent to the graphics terminal.
ELPOT
ELPOT is another programme which has been written in the present 
work. This programme performs numerical calculations of molecular 
electrostatic potential and then presents the results graphically. The 
programme has been written as a main programme which incorporates PLUTO, 
KONTOR, and PL0T3D as subroutines. The output consists of numerical 
results of electrostatic potential and a plot of the molecular structure 
of the drug, with surrounding contour lines joining points of equal 
electrostatic potential, as well as a three-dimensional presentation of 
the potential surface. For convenience the three-dimensional potential 
surfaces are not shown in the results, as electrostatic potentials are 
presented with sufficient clarity through the use of contour maps only. 
Figure 4-7 shows a flow-chart for the programme.
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Draw molecular structure:
CALL PLUTO -
read in data (PIN):
co-ordinates and atom types 
draw molecular structure
return scaling parameters to main programmeJ
Rescale co-ordinates to units in Al
Read in data:
electron densities 
atomic numbers
reference atom for choosing electrostatic 
potential plane parallel to X,Y plane
distance above or below reference atom (R)
Calculate reference plane:
Z = Z (reference atom) + Rt
Calculate for each point on potential plane (at 
0.25 A spacing between points), summing over all 
atoms A in the molecule:
Calculate distance from positive charge to atom Al
Is atom A a hydrogen atom?
No YesI ICalculate nuclear attraction Calculate nuclear attraction 
integral with a 2s average integral with a l s  average
orbital, 0, orbital, (f).
/ dv
I
Calculate increment to diectrostatic potential at point P
7/  ,2
ELCPOT = Z - Z q f ^  dv
A KAP A A KAP
129
v
Write matrix of ELCPOT values for all points on 
potential plane
▼Rescale atomic co-ordinates to size of PLUTO drawing
Plot electrostatic potential contour map:
CALL ELCMAP -
read in data:
number of contours and size of contour 
intervals
make potential values relative to global 
minimum
plot contour lines:
CALL KONTOR 
plot labels on axes1Plot electrostatic potential surface:
CALL ELCSUR
read in data:
angle of rotation for viewing potential surface
cut off potential at 20 kcal mol 1:
if ELCPOT > 20, 
then ELCPOT = 2 0
plot energy surface:
CALL PLOT3D
cross-hatch by plotting in perpendicular direction
Figure 4-7 Flow-chart for calculating molecular electrostatic
potentials using the ELPOT programme. The programme 
utilizes PLUTO (Motherwell, 1975) as a subroutine, 
and starts by reading from input file PIN in order 
to draw the molecular structure. The programme 
then determines the plane in which electrostatic 
potential is to be calculated. Nuclear attraction 
integrals and electron densities are then used to 
calculate the potential at all points in the plane. 
An electrostatic potential contour map and potential 
surface are then drawn using the KONTOR (Palmer, 
1970) and PL0T3D (Watkins, 1974) subroutines.
4 - 3  INTEGRATION OF COMPUTER SOFTWARE
Once anticonvulsant drugs were constructed using the molecular 
structure data base, the first stage of computer processing has 
involved calculations with the COMOL programme. Using this programme 
data has been prepared for the plotting programmes ENMAP and ENSUR, 
which produce conformational energy contour maps and three-dimensional 
surfaces respectively. Analysis of energy maps has then enabled the 
preferred conformations of anticonvulsants to be determined. Higher 
energy conformations which are still accessible to the molecules have 
also been determined at this stage. Molecular structures output from 
the COMOL programme have then been used as input for the interactive 
programme MOLMOD. This programme has been used to view the alternative 
conformations of molecules, and to generate input for the PLUTO programme 
which has then been used to draw diagrams of drugs in their preferred 
or other conformations. The PLUTO programme also generates input 
for MINDO/3, which is the beginning of calculations on the electronic 
structure of anticonvulsants in their preferred conformations. The 
MINDO/3 programme provides printed output, as well as generating input 
for the REACTIVITY programme, which carries out further analysis of the 
chemical reactivity of anticonvulsants. MINDO/3 electron densities were 
finally used, in conjunction with the input PLUTO file, to provide input 
for the calculation of molecular electrostatic potentials with the ELPOT 
programme. Figure 4-8 shows a flow-chart of the computer processing 
carried out, and Table 4-1 gives a brief description of each of the data 
and plot files and computer programmes used.
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CHAPTER 5
CONFORMATIONAL ANALYSIS OF
ANTICONVULSANT DRUGS
134
5-1 SELECTION OF COMPOUNDS 
FOR STUDY
In selecting compounds for study it has been necessary to con­
sider several factors relating to drug activity. While emphasis is placed 
on clinically active anticonvulsants, other types of compounds have also 
been included to make the study more comprehensive. 5,5-Diphenylbarbituric 
acid and other derivatives have been studied to allow for greater com­
parison among diphenyl-substituted anticonvulsants. Some smaller molecules 
have also been studied in an effort to determine the minimal structural 
features associated with activity. Most compounds studied here have 
activity against experimentally induced electroshock seizures, which are 
a useful model for tonic-clonic (grand mal) epilepsy (Close and 
Spielman, 1961; Maffii, 1959; Nakajima, Hattori and Nagawa, 1971;
Sternbach, Sancilio and Blount, 1974). A small number of compounds have 
also been studied which show activity against chemically induced seizures 
(Close and Spielman, 1961). These experimental seizures are a useful 
model for absence (petit mal) epilepsy. Other forms of epilepsy do not 
have a well defined range of compounds which are used in the clinical 
management of seizures. Therefore compounds in the study have been 
restricted to those showing activity against electroshock or chemically 
induced seizures.
Drug metabolism is another factor to consider. One of the major 
routes of metabolism of anticonvulsant drugs is p-hydroxylation of 
aromatic rings (Alvin and Bush, 1977). The resulting metabolites are 
inactive (Leal and Troupin, 1977). Dihydroxy metabolites can also be 
formed. Another minor route of metabolism of some anticonvulsants 
produces open-chain compounds. However the activity of these minor 
open-chain metabolites has not been established. Therefore it is most 
likely that anticonvulsant activity is associated with the fundamental
135
anticonvulsant structures. For this reason parent compounds have usually 
been considered for study. With some clinically used anticonvulsants 
the N-desmethyl metabolites account for a significant amount or most of 
the anticonvulsant activity (Eadie, 1976) . Parent drugs of this type 
can be considered as pro-drugs which release an active constituent 
within the body itself. In the present study one drug in this category 
is mephenytoin, which has been investigated as the demethylated metabolite 
5-phenyl-5-ethylhydantoin (Nirvanol). Table 5-1 shows the chemical 
structures of the anticonvulsants which have been used for conformational 
analysis.
The physical properties of anticonvulsant drugs also have to be 
taken into account. Compounds having the imide nitrogen system -CO-NH-CO- 
are weak acids. The acid strength of individual compounds depends to 
a large extent on the type of neighbouring atoms which are adjacent to 
the carbonyl groups of the imide system. Where there are neighbouring 
hydrocarbon units, as in glutarimides and succinimides, the acid strength 
is relatively weak. The pK^ of succinimides usually has a value of about 
9 (Robin, 1965). In hydantoins although there is an adjacent nitrogen 
there is little increase in acidity. The pK value for phenytoin hascL
been determined by several different methods to be in the range 8-9 
(Schwartz, Rhodes and Cooper, 1977). Acidity is stronger in barbiturates 
where there are two fused imide systems in the -CO-NH-CO-NH-CO- structure 
of the barbiturate ring. In unsubstituted barbituric acid the aliphatic 
carbon (C5) of the barbiturate ring is even more acidic than the imide 
system. The first pK corresponding to C5 of barbituric acid itself has
ct
a value of 4.1 (Vida and Gerry, 1977). In 5,5-disubstituted barbiturates, 
as in phenobarbitone, there are no hydrogens on atom C5 for acid ionization. 
In these compounds the acidic nitrogen (N1) of the imide system has a pK
cL
value of 7-9. A second pK corresponding to subsequent ionization of the3.
remaining nitrogen has a value of about 12 (Sitsen and Fresen, 1973; Vida
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and Gerry, 1977). In oxazolidinediones there is an oxygen atom adjacent 
to the imide system. In these compounds the pK^ value of the imide 
nitrogen is about 6 (Clark-Lewis, 1958). At physiological pH of 7.4, 
with the exception of oxazolidinediones, anticonvulsants will exist most 
significantly in the unionized form. Tautomerism can also occur in 
compounds containing the imide system:
OH
-CO-NH-CO- «■ - - -CO-N=C-
Evidence on barbiturates and hydantoins indicates that the imide system 
with protonated nitrogen is the preferred form (Goenechea, 1972a; Vida 
and Gerry, 1977). In acylurea derivatives the imide tautomeric form 
has again been observed (Goenechea, 1972b; Uno and others, 1969). 
Ionization will not be significant in the other anticonvulsants studied, 
including benzodiazepines and amides. In the present work anticonvulsants 
have been studied in the form predominantly found at physiological pH : 
the unionized form, and in the imide tautomeric structure where this is 
present in the molecule.
5 - 2  THEORETICAL PROCEDURE
Anticonvulsant drugs have been constructed using the molecular 
structure data base described in Chapter 4. Molecules have then been 
submitted for calculations on conformational energy using the COMOL 
programme. As described in Chapter 2 the total energy is given by the 
non-bonded potential component. For most compounds there are two 
degrees of conformational freedom corresponding to the rotation of 
hydrocarbon substituents. A thorough search for low energy conformations 
has been made, using increments of 5° to perform complete rotations of 
substituents. This represents 5, 184 values of the conformational 
energy for each compound. For the open-chain acetylurea compounds there 
are further degrees of conformational freedom. Torsion angle 3 in these
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compounds corresponds to rotation about the C-CO bond in the acetyl 
fragment. In addition to rotation of the hydrocarbon substituents, 
x3 has also been rotated at 30° increments through a complete 360°
rotation. At each of the 12 values of x3 (0°, 30°, 60°.....) a complete
analysis of xl and l2 for the hydrocarbon substituents has been carried 
out at 5° increments for each torsion angle. For 5-phenyl-5-ethylacetyl- 
urea (pheneturide) this analysis of xl, x2 and x3 has been made for each 
of the four possible conformations of the acetylurea side-chain. If 
COMOL calculations show that a side-chain conformation is stable on steric 
grounds, for a combination of xl, x2 and x3 values, then the minimum 
energy orientation of xl, x2 and x3 for that conformation of the side- 
chain has been further submitted for MINDO/3 calculations. The MINDO/3 
programme has then been used to allow geometry optimization of the 
acetylurea side-chain and to take electrostatic interactions of the side- 
chain into account. Using this approach the global minimum energy 
conformation of pheneturide has been determied. For 5,5-diphenylacetylurea 
the side-chain has been placed in one of the preferred conformations as 
determined from calculations on pheneturide. Subsequent analysis has 
then been carried out for xl and x2 (at 5° increments) for each of 12 
values of x3 (at 30° increments).
The computer software described in Chapter 4 has then been used 
to prepare conformational energy contour maps and energy surfaces. Low 
energy conformations have also been compared throughout the set of anti­
convulsants, using both the MOLMOD and PLUTO graphics programmes.
5-3 RESULTS AND DIS CU S S I O N  FOR DRUGS 
ACTIVE A G A INST T O N I C - C L O N I C  SEIZURES
This section presents the results for the conformational analysis 
of drugs showing activity against experimentally induced electroshock 
seizures. Some of the compounds are used clinically for the treatment
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of tonic-clonic (grand mal) and other types of epileptic seizures.
Several series of compounds have been investigated. Phenyl, ethyl and 
diphenyl derivatives of five- and six-membered heterocycles have been 
used to provide an initial assessment of anticonvulsant conformation.
Some larger benzodiazepines and smaller partial structures have also 
been studied. The partial structures represent minimal structural 
requirements for activity. Open-chain acetylurea derivatives have also 
been used to compare with their cyclic hydantoin analogues.
PHENYL, ETHYL DERIVATIVES
Definitions and values of torsion angles in preferred conformations 
of phenyl, ethyl derivatives are shown in Table 5-2. Preferred conformat­
ions for the series of derivatives are shown in Figure 5-1. Conformational 
energy contour maps and energy surfaces are presented in Figures 5-2 to 
5-7. Throughout the series of phenyl, ethyl derivatives there are two 
conformations which are common to all compounds. They are illustrated in 
the left and centre columns of Figure 5-1, and are referred to as con­
formations 1 and 2 respectively. In each of these two types of con­
formation the phenyl substituent is approximately eclipsed with 
respect to the bond between the substituted carbon atom and one of the 
adjacent atoms in the heteroatomic ring. In conformation 1 the phenyl 
substituent is aligned towards the front carbonyl group. In conformation 
2 the phenyl substituent is aligned towards the atom at the back of the 
ring, adjacent to the substituted carbon atom. It is apparent that 
although ethyl substituents may adopt different torsion angles throughout 
the series, torsion angles for phenyl substituents are similar for all 
type 1 conformations (15°-35°) and for all type 2 conformations (100°- 
135°) illustrated in Figure 5-1. Within each type of conformation (1 or 2) 
the central oxygen atoms, adjacent nitrogen atoms, and upper phenyl 
substituents have the same orientation for all derivatives. It should 
be noted that mirror image conformations of optically active derivatives
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TABLE 5-2. Torsion angles and relative energies for
conformationsrof phenyl,ethyl and diphenyl 
derivatives^
Compound
Type 1 Conformation Type 2 Conformation
T 1° t 2° AE
(kcal 
mol 1 )
i o Tl t 2° AE
(kcal 
mol 1 )
PEB 25 300 0* 100 295 0*
15 78 7 105 160 7
PEH 23 310 1* 118 298 0*
10 75 4 118 183 0
PEO 15 313 2* 123 300 0*
5 70 5 123 ’ 188 0 *
PES 30 305 0* 135 305 9
18 75 4 133 173 7*
80 183 2
PEGC(equatorial 40 335 6 115 338 10
phenyl) 35 60 0* 115 168 0*
PEG^(axial 30 303 1* 130 178 0*
phenyl) 38 208 2
5 85 1
PPB 25 80 0* 100 155 0*
PPH 25 68 0* 113 155 0*
PPO 38 68 0* 113 143 0*
PPS 5 100 0* 78 178 0*
a Torsion angles are taken as positive for clockwise rotation of 
far bond from near bond. For phenyl, ethyl and diphenyl deriv­
atives Tl = x(C -C.-C-CO) and t2 = l(C-C-C-CO); In the con­
formation shown^Tl - 60° and T2 = 300°.
b Conformations marked with an asterisk in this and following 
tables are shown in the figures.
o Global minima for both glutarimide ring conformations are equal 
in energy.
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represent alternative structures for interaction at the biological 
receptor. The mirror images of conformation 1 are shown in the right 
hand column of Figure 5-1. Mirror images for conformation 2 are not 
shown. Because of a vertical plane of symmetry of the barbituric acid 
ring, the mirror image of conformation 1 in 5-phenyl-5-ethylbarbituric 
acid (phenobarbitone) is the same as conformation 2.
In 3-phenyl-3-ethylsuccinimide the methylene group adjacent to 
the substituted carbon atom contains two out-of-plane hydrogen atoms.
The presence of these hydrogens causes the type 2 conformations of this 
compound to be relatively high in energy. This is due to a steric 
interaction between the hydrogens and the phenyl substituent. The nearest 
conformation to a type 2 orientation is 2 kcal mol 1 above the global 
minimum at Tl = 80° and x2 = 183°. In 3-phenyl-3-ethylsuccinimide the 
more usual type 2 conformation (xl = 133°) is 7 kcal mol 1 higher in 
energy than the type 1 conformation. Therefore it is most likely that 
the conformations responsible for therapeutic activity are conformation 
1 and its mirror-image, as these conformations are accessible to all 
compounds.
Because of ring inversion in 3-phenyl-3-ethylglutarimide there are 
two possible conformations of the glutarimide ring. One ring conformation 
has the phenyl substituent approximately equatorial, and the other has the 
phenyl substituent approximately axial. Calculations show that the two 
alternative ring conformations are equal in energy. Each of the ring 
conformations of 3-phenyl-3-ethylglutarimide results in similar overall 
molecular shape in type 1 and 2 conformations to the other derivatives 
in the series. It is likely that 3-phenyl-3-ethylglutarimide is active 
in either or both of the equatorial and axial type 1 conformations, or 
their mirror images.
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DIPHENYL DERIVATIVES
Torsion angles in preferred conformations of diphenyl derivatives 
are also listed in Table 5-2. Preferred conformations for the series of 
derivatives are illustrated in Figure 5-8. Conformational energy contour 
maps and energy surfaces are shown in Figures 5-9 to 5-12. There are 
again two preferred conformations for each compound in the diphenyl 
series of derivatives. Conformation 1 represents one likely bioactive 
conformation, as outlined for the phenyl, ethyl series. Because of the 
lack of an asymmetric centre in the diphenyl derivatives, conformations 1 
and 2 are mirror images. Therefore conformation 2 (as the mirror image 
of conformation 1) can also be considered a likely bioactive conformation. 
In Figure 5-8 the type 2 conformations of diphenyl derivatives are 
oriented in a way which also illustrates their similarity to the mirror 
images of type 1 conformations shown for the phenyl, ethyl derivatives.
BENZODIAZEPINES AND PARTIAL STRUCTURES
Torsion angles in preferred conformations of benzodiazepines and 
partial structures are listed in Table 5-3. Preferred conformations 
are illustrated in Figure 5-13, and conformational energy contour maps 
and energy surfaces are shown in Figures 5-14 to 5-17. Each benzo­
diazepine can undergo ring inversion to the opposite boat form of the 
diazepine ring. NMR studies (Linscheid and Lehn, 1967; Raban and 
others, 1975; Sarrazin and others, 1975) show that the free energy 
barrier to ring inversion of diazepam and related benzodiazepines is 
about 17 kcal mol 1 . Demethylation of diazepam reduces the barrier to 
about 12 kcal mol 1. In one boat form of the diazepine ring the result­
ing conformation is similar to conformation 1 as shown for the phenyl, 
ethyl and diphenyl derivatives. The other boat form produces a type 2 
conformation, and in the benzodiazepines, as in the diphenyl derivatives, 
this conformation is a mirror image of conformation 1. Consequently for 
each benzodiazepine the type 2 conformation is also oriented to illustrate
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Figure 5-8 Preferred conformations for diphenyl derivatives: 
conformation 1 (left), conformation 2 (centre) and 
the mirror image of conformation 1 (right). From 
top to bottom: PPB, PPH, PPO and PPS.
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Figure 5-13 Preferred conformations for benzodiazepines
and partial structures: conformation 1 (left),
conformation 2 (centre) and the mirror image of 
conformation 1 (right). From top to bottom: 
DcD, DcA, PMMAc and PMAz.
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its similarity to the mirror images of type 1 conformations shown 
previously.
Further similarities are evident between the benzodiazepines and 
the phenyl, ethyl and diphenyl derivatives. In the benzodiazepines the 
pyridine type nitrogen of the diazepine ring (N4) occupies the position 
of the central oxygen atom of diphenylhydantoin (04). There is no 
corresponding atom in the benzodiazepines for the adjacent nitrogen atom 
of diphenylhydantoin (N3). However the second oxygen atom of diphenyl­
hydantoin (02) does have a corresponding atom. It is matched by the 
carbonyl oxygen in dechlorodiazepam (02), and by a pyridine-type nitrogen 
of the triazole ring of dechloroalprazolam (N10).
There are also similarities between the acetamide and azetidinone 
partial structures and the phenyl, ethyl and diphenyl derivatives.
In 3-phenyl-3,3-dimethylacetamide two degrees of conformational freedom 
have been considered. Torsion angle 1 is associated with rotation of 
the phenyl substituent. Torsion angle 2 refers to rotation about the 
C-CO bond joining the substituted carbon and the carbon of the carbonyl 
group. Table 5-3 shows that the lowest energy conformations of 3-phenyl-
3.3- dimethylacetamide have x2 in the range 70-300°. These conformations 
do not closely correspond to the preferred conformations of the phenyl, 
ethyl and diphenyl derivatives. There are however two further conform­
ations at 5 kcal mol 1 above the global energy minimum for the compound. 
These two conformations correspond to type 1 and type 2 conformations 
shown for previous derivatives. The central oxygen atoms, adjacent 
nitrogen atoms, and upper phenyl substituents occupy similar positions
in all compounds. It is likely that the type 1 conformation of 3-phenyl-
3.3- dimethylacetamide is responsible for the observed activity of this 
compound. In the other partial structure, 3-phenyl-3-methylazetidin-2- 
one, there are also type 1 and 2 conformations which are observed. Both 
partial structures indicate that the second oxygen atoms present in other
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anticonvulsants may be omitted provided the other structural features 
associated with activity are present.
OPEN-CHAIN ACETYLUREAS
Two open-chain acetylurea derivatives have also been studied.
These compounds are open-chain analogues of cyclic hydantoin anticon­
vulsants. 5-Phenyl-5-ethylacetylurea (pheneturide) is the analogue of 
5-phenyl-5-ethylhydantoin and is used clinically. 5,5-Diphenylacetylurea 
is the analogue of 5,5-diphenylhydantoin (phenytoin). This diphenyl 
open-chain analogue is interesting to examine as it is inactive as an 
anticonvulsant. Table 5-4 gives the definitions of torsion angles and 
the nomenclature of backbone conformations of the acetylurea fragment for 
the two compounds. The acetylurea backbone is defined by the torsion 
angles t4 and x5. Because of planarity, due to electron delocalization 
in the backbone fragment, each of these two torsion angles has a value 
of either 0° (Z conformation) or 180° (E conformation). Taking the two 
values for each of the torsion angles t 4 and X5 in combination means 
that four backbone conformations are possible: Z,E; Z,Z; E,E; and
E,Z. Results for the two acetylurea derivatives are discussed 
separately.
5 -PH E N Y L - 5-ETHYLACETYLUREA (PHENETJJRIDE)
Conformational calculations have been performed on the torsion 
angles Tl, t2 and x3 for each of the four backbone conformations of this 
compound. Increments of x3 have been made every 30°. At each of the 12 
values of x3 the torsion angles xl and x2 have been examined at increments 
of 5°. Results of COMOL calculations of conformational energy as a function 
of x3 are presented in Table 5-5. Results are reported for the Z,E and 
ZyZ low energy conformations of the acetylurea backbone. E,E and E,Z 
backbone forms produce unfavourable conformations. At each value of x3 
in the Table the energy is minimized with respect to both xl and x2.
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TABLE 5-4. Definition of backbone conformations in 
acetylurea derivatives 3 3
Conformation Torsion Angle (degrees)
x4 x5
Z,E 0 180
Z,Z 0 0
E,E 180 180
E,Z 180 0
a Tl and t 2 are as defined in Table 5-2.
b Other torsion angles are defined as :
t 3 = x(H-C5-C4-N3) 
x4 = T(0(4)-C4-N3-C2) 
x5 = T(C4-N3-C2-0(2))
o The acetylurea backbone is defined bg x4 and x5, and is drawn 
in the Z,E conformation, with x4 = 0 (Z) and x5 = 180°(E).
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TABLE 5-5. COMOL conformational energies of 5-phenyl- 
5-ethylacetylurea (PEAu) as a function of 
t3 (kcal mol 1)a
x3
(degrees)
Backbone Conformation
Z,E^ Z,Z°
0 1.4 1.4
30 0.3 0.4
60 0.0 0.0
90 5.5 5.4
120 17.0 16.8
150 8.6 8.5
180 4.6 4.6
210 10.0 10.0
240 21.8 21.8
270 10.5 10.5
300 2.1 2.2
330 1.2 1.2
a For each value of t3 the conformational energy is minimized 
with respect to Tl and t2.
b Energies relative to Tl, t2, t3 minimum for Z,E conformation 
(at t3 = 60°).
c Energies relative to xl, x2, x3 minimum for Z,Z conformation 
(at x3 = 60°).
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It can be seen that in both Z,E and Z,Z backbone conformations the energy 
is lowest for T3 in the range 30-60°. Contour maps of conformational 
energy as a function of both Tl and x2, for each of the 12 values of 
x3, are presented for both backbone conformations in Figures 5-18 and 
5-19.
When x3 = 30°, which is in the low energy range for x3, conformations 
are found which correspond to the type 1 and 2 conformations shown for 
previous derivatives. Table 5-6 shows preferred values of xl and x2 for 
each of the Z,E and Z,Z backbone conformations where x3 = 30°. In the 
Z,E form there are three type 1 and one type 2 conformations observed.
It can be seen that values of xl which define type 1 and 2 conformations 
of 5-phenyl-5-ethylacetylurea are not the same as those for the previous 
phenyl,ethyl derivatives. This is because of the different internal 
orientation of the acetylurea fragment when compared to the cyclic imide 
system of the phenyl, ethyl derivatives. Nevertheless the Z,E form of 
5-phenyl-5-ethylacetylurea does display type 1 and 2 conformations which 
are similar to those of previous derivatives considered. These low 
energy conformations are illustrated in Figure 5-20. The other low energy 
backbone conformation is the Z,Z form. Preferred values of xl and x2 
for the Z,Z form are similar to those for the Z,E form as indicated in 
Table 5-6. Conformations of the Z,Z form are not classified as type 1 
and 2 however, because the Z,Z backbone conformation is not comparable 
to previous anticonvulsants. Figure 5-21 illustrates the different 
backbone conformation of the Z,Z form.
In order to evaluate electrostatic interactions within the 
acetylurea backbone MINDO/3 calculations have also been performed on 
Z,E and Z,Z conformations. Calculations have been carried out on low 
energy conformations found on the basis of C0M0L results described 
in Table 5-6. The Z,E conformation is for xl = 135°, x2 = 290° and 
x3 = 30°. The Z,Z conformation is for xl = 125°, x2 = 290° and x3 = 30°.
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Molecular geometries have been optimized for all bond lengths and bond 
angles. Results for the MINDO/3 calculations are presented in Table 5-7. 
The Z,E conformation is found to be preferred to the Z,Z form by 2.3 kcal 
mol 1. The reason for the lower stability of the Z,Z form is the 
repulsive interaction between the two neighbouring carbonyl groups.
The data in the table shows that to partly compensate for the repulsive 
interaction, oxygen electron density is lower in the Z,Z form. The closer 
vicinity of two negative charges is also reflected in the dipole moment 
for the Z,Z form, which is considerably larger than the Z,E dipole moment.
COMOL conformational energy contour maps are not given for the E,E 
and E,Z forms of the compound. The E,Z form is high in energy for any 
value of xl and t2, for all values of T3 except x3 = 60°. The E,E form 
is high in energy for all values of xl, x2 and x3. The reason for the 
unfavourable energies of the E,E and E,Z forms is the steric repulsion 
which results when x4 = 180° (E,... conformation). Figure 5-22 shows how 
steric interaction occurs in the E,E conformation of the backbone. Neither 
E,E nor E,Z conformations are likely to be responsible for anticonvulsant 
activity. They are both high in energy and do not show the same similarity 
to previous anticonvulsants as that shown by the Z,E form of the compound.
5 j 5 - DIPHENYLA CETYL UREA
COMOL calculations have also been performed on 5,5-diphenylacetyl- 
urea. Because of a greater similarity to other anticonvulsants, the 
Z,E form of the compound has been chosen for calculation. Calculations 
on 5-phenyl-5-ethylacetylurea also indicate that this is a low energy 
conformation of the backbone fragment. Table 5-8 presents conformational 
energy as a function of x3. Again the low energy range fori 3 is 30°-60°. 
Contour maps of conformational energy as a function of both xl and x2, 
for each of the 12 selected values of x3, are presented in Figure 5-23. 
Preferred values of xl and x2 for x3 = 30° are listed in Table 5-9.
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Figure 5-21 Low energy conformation for Z,Z backbone form 
of PEAu (t 1 = 125°, t 2 = 290°, x3 = 30°).
Figure 5-22 High energy conformation for E,E backbone form
of PEAu Cxi, x2 and x3 same as for Z,Z conformation 
shown in Figure 5-21). Energy is high in E,E form 
due to steric interaction between terminal nitrogen 
(Nl) and substituted carbon atom (C5).
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TABLE 5-8. COMOL conformational energies of 5,5-
diphenylacetylurea (PPAu) as a function 
of t3 (kcal mol l)a
t3
(degrees)
Backbone conformation 
Z,E^
0 1.5
30 1.0
60 0.0
90 6.0
120 15.6
150 7.6
180 4.5
210 7.6
240 15.6
270 6.0
300 0.0
330 1.0
a For each value of t3 the conformational energy is minimized with 
respect to xl and x2.
b Energies relative to xl, t2, t3 minimum for Z,E conformation 
(at t3 = 60°).
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Unlike previous diphenyl derivatives, the type 2 conformation listed is 
not an exact mirror image of a type 1 conformation. Although a high 
degree of symmetry is observed in the energy values of Table 5-8, when 
t 3 = 30° the molecule no longer contains a plane of symmetry passing 
through the heteroatomic system. This is because of the out-of-plane 
hydrogen attached to C5. Consequently the mirror image of a type 1 con­
formation will be distinct from a type 2 conformation. The compound 
is illustrated in a low energy type 1 conformation in Figure 5-24.
As shown in Figure 5-24, 5,5-diphenylacetylurea can assume a type 
1 conformation which is similar to 5-phenyl-5-ethylacetylurea and cyclic 
hydantoin anticonvulsants. In both acetylurea and hydantoin compounds 
there is a similar orientation of upper phenyl substituents, central 
oxygens and adjacent nitrogen atoms, and also secondary oxygen atoms.
It is therefore interesting to note that 5,5-diphenylacetylurea is 
inactive as an anticonvulsant. Table 5-10 shows the anticonvulsant 
activities of the phenyl, ethyl and diphenyl derivatives of acetylurea 
and hydantoin, as well as their solubility in Sorensen’s buffer at pH 
7.4 (Swinyard and Toman, 1950). In both the phenyl, ethyl and diphenyl
TABLE 5-10. Solubilities and anticonvulsant activities 
of phenyl, ethjl and diphenyl acetylureas 
and hydantoins
Compound Solubility
(mM)
Anticonvulsant 
Activity^ 
(mmole kg :)
PEH 5.36 0.05
PEAu 1.83 0.09
PPH 0.17 0.12
PPAu 0.06 >6.3 d
a Data derived from Swinyard and Toman (1950) 
b In Sorensen's buffer at pH 7.4
o Activity against electroshock induced seizures as ED,-q 
d No activity observed up to this dose
185
cases, the acetylurea derivative is approximately one-third as soluble 
as its corresponding hydantoin analogue. It can be seen from the Table 
that only 5,5-diphenylacetylurea is inactive. Therefore the reduced 
solubility of this compound compared to 5,5-diphenylhydantoin cannot 
be used to explain its significant loss of activity. A more likely ex­
planation can be found by looking at the orientation of the lower phenyl 
substituent in both acetylureas and hydantoins. Figure 5-25 shows the 
front views of type 1 conformations of the phenyl, ethyl and diphenyl 
derivatives of acetylurea, as well as for 5,5-diphenylhydantoin. It can 
be seen that in each of the two active compounds the lower substituent 
is oriented directly underneath the heteroatomic system of the molecule.
In 5-phenyl-5-ethylacetylurea the ethyl substituent occupies the same 
position as the left-hand side of the lower phenyl substituent in 
5,5-diphenylhydantoin. However in 5,5-diphenylacetylurea the lower 
phenyl substituent is positioned well outside the vertical plane of the 
molecule. Because of the lack of activity of this compound it may be that 
the lower phenyl substituent prevents the molecule from effectively 
interacting with the drug receptor.
5-4 RESULTS AND DISCUSSION FOR DRUGS 
ACTIVE AGAINST ABSENCE SEIZURES
This section presents the results for drugs showing activity 
against chemically induced (pentylenetetrazole) experimental seizures.
All three compounds studied here are related to drugs used clinically 
for the treatment of absence seizures. 3-Ethyl-3-methylsuccinimide 
(ethosuximide) is used itself in the treatment of absence seizures.
Two demethylated derivatives of clinical anticonvulsants have also been 
studied. 5,5-Diethylbarbituric acid and 5-ethyl-5-methyloxazolidine-2, 
4-dione are the N-demethylated derivatives of metharbitone and para- 
methadione respectively.
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Figure 5-24 Low energy type 1 conformation for Z,E backbone form 
of PPAu (Tl = 155°, T2 = 255°, T3 = 30°), left, and 
mirror image conformation, right.
Figure 5-25 Front views of type 1 conformations (mirror image 
forms) for PEAu, PPAu and PPH.
187
Values of torsion angles in preferred conformations of the compounds 
are shown in Table 5-11. Definitions of the torsion angles for upper and 
lower substituents are as follows:
T1 = t (C-C-C-CO)
t2 = t (C or H-C-C-CO)
Preferred conformations for the three compounds are illustrated in 
Figure 5-26, and conformational energy contour maps and energy surfaces 
are presented in Figures 5-27 to 5-29. As can be seen from Table 5-11 
and Figure 5-26, in each of the compounds the upper ethyl substituent 
can adopt three different orientations. Each of these orientations is 
staggered about the bond joining the methylene carbon atom of the ethyl 
substituent to the substituted carbon atom of the heteroatomic ring. In 
both 5,5-diethylbarbituric acid and 5-ethyl-5-methyloxazolidine-2,4-dione 
the most preferred staggered orientation is where the ethyl substituent 
is pointing directly above the ring, in a plane perpendicular to that 
which contains the ring system. In 3-ethyl-3-methylsuccinimide this type 
of conformation is also low in energy, being only 1 kcal mol 1 higher in 
energy than the global minimum. The most preferred orientation of the 
ethyl substituent in this compound is for Tl = 185°. As shown in Figure 
5-26, in this conformation the ethyl group is oriented away from the 
heteroatomic system. This conformation is preferred here due to inter­
action of the ethyl substituent with the out-of-plane hydrogens of the 
succinimide ring.
There are two main similarities observed in the compounds studied 
in this section. Each compound possesses the imide -CO-NH-CO- heteroatomic 
system. Also each compound has small alkyl substituents attached to the 
heteroatomic ring. Although there is some degree of flexibility in upper 
ethyl substituents, all compounds have a low energy conformation in which 
the ethyl substituent is pointing directly upwards. As with compounds 
active against tonic-clonic seizures, it is also useful to examine the
188
Figure 5-26 Preferred conformations, from top to bottom, 
for EEB, EMO and EMS.
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TABLE 5-11. Torsion angles and relative energies 
of compounds showing activity against 
chemically induced seizures
Compound i 0Tl x2° AE
(kcal mol )
EEB 63 298 0*
208 305 5
275 290 5
55 153 5
70 85 5
EMO 58 300 0*
- 163 315 1
290 280 4
EMS 55 303 1
185 313 0*
- 278 290 3
a Torsion angles Tl and t2 are defined in text
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anticonvulsant activities of open-chain analogues of the compounds 
studied in this section. On the basis of calculations on phenyl sub­
stituted acetylureas, acetylurea derivatives with small alkyl substituents 
should show similar conformational properties to the cyclic compounds 
studied here. It is therefore interesting to note that 5,5-diethylacetyl- 
urea and related derivatives do show activity against chemically induced 
seizures (Close and Spielman, 1961). This comparison is complicated 
however, by the observed clinical activity of phenyl substituted compounds, 
including methsuximide, phensuximide and diazepam. Although these 
compounds also possess heteroatomic systems, the relationship of their 
larger hydrocarbon groups to the small alkyl substituents seen in the 
compounds in this section is not clear. It appears that conformational 
requirements for activity against absence seizures may not be too strict.
5 -5  COMPARISON OF THEORETICAL AND 
EXPERIMENTAL CONFORMATIONS
The preferred conformations of anticonvulstants obtained in the 
present work are supported by previous theoretical and experimental 
studies. Several crystal structure determinations of 5-phenyl-5-ethyl- 
barbituric acid (Kim and Rich, 1968; Williams, 1973, 1974) have led to 
the same conformation described here, where the phenyl substituent is 
aligned towards the carbonyl group adjacent to the substituted carbon 
atom of the barbituric acid ring. In this conformation the plane of the 
phenyl substituent is approximately eclipsed with respect to the C5-C0 
bond of the barbituric acid ring. In two of these structures (Williams, 
1973, 1974) the ethyl substituent is in a staggered orientation and 
pointing directly below the barbituric acid ring. This is the conformation 
found in the present work and illustrated in Figure 5-1. COMOL calculations 
show that a higher energy conformation of 5-phenyl-5-ethylbarbituric acid 
has the ethyl substituent pointing more away from the barbituric acid ring.
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This higher energy conformation has been observed in the other crystal 
structure of this compound (Kim and Rich, 1968). Theoretical calculations 
on the compound using the EHT (Holtje, 1977; Laprade and others, 1976) 
and PCILO (Pullman, Coubeils and Courriere, 1972) methods also support 
the results of the present work. For 5,5-diethylbarbituric acid both 
the solid state (Craven, Vizzini and Rodrigues, 1969) and theoretical 
(Laprade and others, 1976; Pullman, Coubeils and Courriere, 1972) conformations 
also agree with the results found here, where the two ethyl substituents 
are oriented directly above and below the barbituric acid ring.
The crystal structure of morsuximide, a 3-phenylsuccinimide 
derivative (Argay and Seres, 1973), also supports the results of the 
present work, in which the phenyl substituent is again aligned towards 
the neighbouring carbonyl group of the heteroatomic ring. Crystallographic 
studies of 3-phenyl-3-ethylglutarimide have also been performed (Bonamico, 
Coppola and Giacomello, 1960, 1961; Bonamico and others, 1962). These 
studies suggest that both conformations of the glutarimide ring are 
stable. This is in agreement with the present calculations which show 
that both equatorial and axial orientations of the phenyl substituent 
are equally preferred. It is interesting to note that a crystal structure 
determination of thalidomide, a glutarimide containing a 3-(N-phthalimido) 
substituent, shows that the larger bicyclic substituent prefers the 
equatorial position (Allen and Trotter, 1971).
Crystallographic studies on 5,5-diphenylhydantoin (Camerman and 
Camerman, 1971a), benzodiazepines (Bandoli and Clemente, 1976; Camerman 
and Camerman, 1972a; Gilli and others, 1977) and triazolobenzodiazepines 
(Hester, Duchamp and Chidester, 1971; Kamiya, Wada and Nishikawa, 1973) 
are also in agreement with the conformations found in the present work. 
Experimental evidence is also available to support the results which 
have been obtained for the acetylurea compounds. NMR studies of open- 
chain imide systems (Noe and Raban, 1975) indicate that the Z,E backbone
195
conformation is the predominant form of these compounds. These authors 
suggest that carbonyl dipole interactions destabilize the Z,Z conformation. 
This observation supports the present MINDO/3 calculations, which also 
show that the Z,E form of the imide system in acetylurea is the preferred 
orientation.
CHAPTER 6
ELECTRONIC STRUCTURE OF
ANTICONVULSANTS
197
This chapter discusses the results of calculations on the electronic 
structure of anticonvulsant drugs. Having determined the conformational 
behaviour of a range of anticonvulsants using COMOL calculations, as 
discussed in Chapter 5, the MINDO/3 programme has been used here to 
study the electronic structure of drugs in their low energy conformations. 
Representative compounds have been chosen from the drugs active against 
tonic-clonic seizures (phenyl,ethyl derivatives, benzodiazepines, partial 
structures, and open-chain acetylureas) and also from the drugs active 
against absence seizures. MINDO/3 calculations have been used to provide 
indexes of chemical reactivity and molecular electrostatic potentials.
13C-NMR spectroscopy has also been used to correlate experimental chemical 
shifts with calculated values of electron densities. This provides 
further information on the electronic structure of carbonyl groups in 
anticonvulsant drugs.
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6-1 THEORETICAL AND EXPERIMENTAL 
PROCEDURE
Calculations using the MINDO/3 programme were carried out on the 
UNIVAC 1100/42 computer at the Australian National University. Con­
vergence parameters were set at the values recommended in the programme 
documentation. The MINDO/3 programme has been used to provide molecular 
wavefunctions, electron densities, net atomic charges and dipole moments, 
optimizing all bond lengths and bond angles throughout the series of 
compounds. MINDO/3 calculations have been applied to each of the phenyl, 
ethyl derivatives of five- and six-membered heterocycles. Diphenyl 
derivatives have not been studied because of the similarity to their 
phenyl,ethyl analogues, and because some of the diphenyl compounds are 
too large for use with the MINDO/3 programme. Of the benzodiazepines, 
dechloroalprazolam has not been studied because it is also too large 
for the programme. One of the partial structures and one of the open- 
chain acetylureas have been studied to represent these classes of 
compounds. MINDO/3 calculations have also been applied to each of the 
compounds active against chemically induced seizures. Of the series of 
compounds studied in this Chapter it should be noted, that in particular, 
5-phenyl-5-ethylglutarimide has been studied in the conformation of the 
glutarimide ring where the phenyl substituent is in an axial position, 
as illustrated in Figure 5-1. Also 5-phenyl-5-ethylacetylurea has been 
studied in the Z,E backbone conformation, with Tl = 135°, T2 = 290° and 
t 3 = 30°, as illustrated in Figure 5-20. This is the conformation which 
corresponds to the proposed bioactive conformations of other anticon­
vulsants. Dechlorodiazepam has been studied here as the demethylated 
derivative. This has been done in order to restrict the molecule to a 
size suitable for use with the MINDO/3 programme. Abbreviations for 
compounds are those used in Chapter 5. MINDO/3 calculations have been
199
applied to the compounds in the following type 1 conformations:
PEB (Tl = 25°, t2 = 300°)
PEH (Tl = 23°, t2 = 310°)
PEO (Tl = 15°, t2 = 313°)
PES (t1 = 30°, t2 = 305°)
PEG (axial phenyl substituent; ll = 30°, t2 = 303°)
DcD (as demethylated derivative; Tl = 130°)
PMAz (Tl =* 0°, t2 = 93°)
PEAu (Z,E backbone conformation; xl = 135°, t2 = 290°, t3 = 30°)
EEB (Tl = 63°, t2 = 298°)
EMO (Tl = 58°, t2 = 300°)
EMS H H—* II 185°, t2 = 313°)
The MINDO/3 programme has also been used to provide data for two 
further programmes which have been described in Chapter 4. The REACTIVITY 
programme uses the molecular wavefunctions of anticonvulsants to cal-
Eculate electrophilic and nucleophilic superdelocalizabilities and
NS . The ELPOT programme gives a further estimate of reactivity, by
Ü
providing molecular electrostatic potentials surrounding anticonvulsant 
drugs. Electrostatic potentials have been calculated in the plane of 
the heteroatomic system of anticonvulsants, in accordance with the 
theoretical procedure described in Chapter 3.
13C-NMR spectra have been obtained using a Joel 90 MHz multinuclear 
fourier transform (FT) spectrometer at the Australian National University. 
Individual spectra were obtained by accumulating a number of pulse FT 
scans. For most molecules the spectra were derived from accumulating 
2,000 - 3,000 scans per compound. Spectra were recorded using a 
spinning 10mm wide sample tube at a temperature of 30°C. Samples have 
not been degassed to remove dissolved oxygen. All chemical shifts are 
given in the 6 scale relative to tetramethylsilane (TMS) as internal 
reference (6 TMS = 0). Deuterated chloroform (CDCI3) has been used as
200
the solvent, and for obtaining an internal lock for the spectrometer. 
Solutions have been prepared at a concentration of 0.0625 M. This low 
concentration should minimize the effect on chemical shifts of inter- 
molecular hydrogen bonding between solute molecules. FT scans have been 
accumulated and processed using the computer software supplied with the 
spectrometer. Where available, 13C spectra have been recorded for each 
anticonvulsant drug Cor its close analogue) for which MINDO/3 calcul­
ations have been carried out. The phenyl,ethyl derivatives of oxazolidine- 
2,4-dione and succinimide, and the phenyl,methyl derivative of azetidin-2- 
one were not available. The following compounds have been studied: 
5-phenyl-5-ethylbarbituric acid (phenobarbitone), 3-methyl-5-phenyl-5- 
ethylhydantoin (mephenytoin), 3-phenyl-3-ethylglutarimide (glutethimide), 
diazepam, 5-phenyl-5-ethylacetylurea (pheneturide), 5,5-diethylbarbituric 
acid Cbarbitone), 5,5-dimethyloxazolidine-2,4-dione, and 3-ethyl-3- 
methylsuccinimide (ethosuximide).
6-2 INDEXES OF C H E M I C A L  R E A C T I V I T Y
ATOMIC CHARGES AND DIPOLE MOMENTS
Electron density can be used as a guide to the hydrogen bonding
potential of a molecule. This is most important for the heteroatoms 
in a molecule. In the anticonvulsants studied here the heteroatoms 
occur in imide or equivalent systems:
—  CO --- NH --- CO —
Previous studies have examined the electron densities of each of the 
carbonyl oxygens and the imide hydrogen atom (Andrews, 1969; Laprade 
and others, 1976). In the present work these three atoms are also 
examined, as well as the imide nitrogen atom itself, and other atoms 
which are equivalent in hydrogen bonding potential to the imide system. 
For benzodiazepines the pyridine-type nitrogen is equivalent to the 
central carbonyl oxygen of other anticonvulsants. Tables 6-1 and 6-2
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show MINDO/3 electron densities and associated net atomic charges 
for the anticonvulsants studied. The net atomic charges of the central 
and secondary oxygen atoms are mostly within the ranges -0.51 to -0.53 and 
-0.52 to -0.56 e.u. (.electron units) respectively. In 5^phenyl-5- 
ethylacetylurea these charges are a little higher, at values of -0.564 
and -0.596 e.u. In the demethylated derivative of dechlorodiazepam the 
net atomic charge of the pyridine-type nitrogen is -0.203 e.u. Net 
atomic charges for imide—type nitrogens and their attached hydrogens are 
in the ranges -0.24 to -0.32 and +0.08 to +0.14 e.u. respectively.
Dipole moments are listed in Table 6-3. MINDO/3 values are 
usually to within 1.5 Debye of experimental values listed. The largest 
deviation occurs for dechlorodiazepam, where the MINDO/3 and experimental 
values for the dipole moment are 4.64 and 2.65 Debye respectively.
This larger difference may be due to the fact that calculations have 
been performed on the demethylated derivative of dechlorodiazepam, which 
possesses the N-H group in place of the N-CH3 group. The more polar 
N-H group may account for the larger value of the theoretical dipole 
moment.
Despite the deviations observed in benzodiazepines, net atomic 
charges and dipole moments are within fairly narrow ranges throughout 
the series of anticonvulsants. The net atomic charges for the oxygen, 
nitrogen and hydrogen atoms listed are approximately -0.5, -0.3 and 
+0.1 e.u. respectively. While both oxygens have net atomic charges of 
approximately -0.5 e.u., the central oxygen, 0^, has slightly less net 
charge than the secondary oxygen, 0g, in most compounds studied. These 
results suggest that the 0^, 0g, N and H atoms listed may be important 
for activity in most anticonvulsants. The hydrogen bonding potential 
is fairly constant for the range of compounds studied here. This is 
supported by experimental evidence on the enthalpies of hydrogen bonding 
of anticonvulsants (Patrick and Bresee, 1976). The enthalpies of hydrogen
205
TABLE 6-3. MINDO/3 dipole moments of anticonvulsants
Compound
Dipole Moment, |y| (Debye)
MINDO/3 aExperimental
PEB 1.70 0.87
PEH 3.21 1.74
PEO 2.45 1.69
PES 2.90 1.47
PEG 4.07 2.83
DcD 4.64 2.65
PMAz 3.28 -
PEAu 2.40 2.06
EEB 1.31 1.13
EMO 1.97 1.69
EMS 2.58 1.47
a Taken from Andrews (1969) and Lien, Liao and Shinouda (1979) 
for listed compounds or their analogues.
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bonding between phenol and a series of anticonvulsants have all been 
found to be about -4 to -5 kcal mol 1.
SUPERDELOCALIZABILITIES
EElectrophilic superdelocalizability, S is a measure of theA>
ability of atom A to attract an electrophilic, or electron-seeking
Eagent. The value of is therefore most significant for the electron-
Erich atoms in a molecule. For anticonvulsants the highest values 
occur for the negatively charged carbonyl oxygen atoms. The values found 
are about 0.44 for both central and secondary oxygen atoms. Values 
greater than about 0.3 represent significant superdelocalizability.
Results for several anticonvulsants are presented in Table 6-4. The
E •range of S for carbonyl oxygens of compounds listed is 0.43 to 0.46.
ri.
Nucleophilic superdelocalizability is also listed for several atomic
positions, representing the ability of atoms to attract a nucleophilic,
Nor electron-donating agent. Values of are given for several atoms,
including the positively charged carbons of carbonyl groups, for which
N NS is in the range 2 to 3.5. Values of S. are also given for theA  A
nitrogen capable of hydrogen bonding, because of the possibility of
Nincoming negative charge through a hydrogen bond. is relatively
low for this atomic position, indicating that little charge is likely
to be transferred from a drug receptor to the imide-type nitrogen of
Nanticonvulsants during hydrogen-bonding. Values of are also given 
for C^, the substituted carbon atom of the phenyl substituent in phenyl 
substituted anticonvulsants. It can be seen from the Table that C, is 
a likely centre for receiving negative charge from a drug receptor. 
Although is not a centre of high positive charge, it is nevertheless 
an attractive centre for incoming negative charge. This is a result of 
significant values for the wavefunction coefficients, C^, for atom
over the unoccupied molecular orbitals. Other carbon atoms in phenyl
Nsubstituents also have significant values. As a result the whole
E
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phenyl ring may act to receive incoming negative charge. However, in
each case the substituted carbon atom of the phenyl substituent has the 
Nhighest value. Therefore this atomic position is the most reactive 
centre in each phenyl substituent.
6-3 CORRELATION OF M1ND0/3 ELECTRON 
DENSITIES WITH CHEMICAL SHIFTS FROM
13c -n m r  s p e c t r o s c o p y
13C-NMR spectra for the compounds studied are presented in 
Figures 6-1 to 6-8. Chemical shifts of carbonyl carbon atoms occur in 
the range 148 to 183 ppm, with aromatic carbons of phenyl substituents 
occurring at about 130 ppm. The substituted carbon of the phenyl 
substituent gives rise to a characteristically small signal several ppm 
above the other atoms of the phenyl substituent. The substituted carbon 
atom in the heteroatomic system of anticonvulsants also produces a small 
signal, at about 46 to 85 ppm. Signals occurring in the approximate 
range 10 to 40 ppm correspond to ethyl and methyl substituents, or to 
saturated carbon atoms in heteroatomic rings. Assignments of chemical 
shifts have been made by reference to spectra of barbiturates (Fratiello, 
Mardirossian and Chavez, 1973; Long and Goldstein, 1974; Okada and Esaki, 
1974), hydantoins (Colebrook, Icli and Hund, 1975; Long and Goldstein, 
1974) , glutarimides CHirsch and Havinga, 1976) , succinimides (Levy and 
Nelson, 1972) and isocyanides and other model compounds (Levy and Nelson, 
1972; Maciel and Beatty, 1965). The TMS reference signal occurs at 0 ppm, 
and the large triplet at about 77 ppm is due to the deuterated chloroform 
used as a solvent.
MINDO/3 electron densities have been compared with the chemical 
shifts of several carbon atoms. Table 6-5 presents electron densities 
and chemical shifts of carbon atoms in the central and secondary carbonyl
209
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groups of anticonvulsants. Table 6-6 presents results for the substit­
uted carbon atom in the heteroatomic system of the anticonvulsants.
Results for the three types of carbon atoms are shown graphically in 
Figure 6-9. As shown in the Figure, electron densities cannot be used 
to correlate with chemical shifts of carbonyl carbons within a series
of atoms of the same type (i.e. either C or C ). Nevertheless chemicalc s
shifts cluster into two separate regions having approximate ranges of 
150-160ppm and 170-180ppm respectively. This effect is 
the result of the paramagnetic contribution to the shielding parameter 
for carbonyl carbon atoms (De Jeu, 1970). For a positively charged 
carbonyl carbon a greater electron density (reduced net positive charge) 
is associated with a greater paramagnetic effect, and consequently a 
greater 6 value of the chemical shift. The region at 170-180ppm corr­
esponds to a carbonyl group which is located at the end of a heteroatomic 
system. This applies to all carbonyl carbon atoms. The region at 
150-160ppm corresponds to a carbonyl group which is flanked by two 
electronegative atoms in the heteroatomic system. Most Cg carbonyl 
carbon atoms fall within this region. Exceptions occur with 3-phenyl-3- 
ethylglutarimide, diazepam and 3-ethyl-3-methylsuccinimide. In these 
compounds each carbonyl group in the molecule is in a similar molecular
environment with chemical shifts for both C and C atoms falling withinc s
the 170-180ppm region.
Although paramagnetic effects may also be significant with some 
sp3 (tetrahedrally) hybridized carbon atoms (Emsley, Feeney and Sutcliffe, 
1966), this is not the case for the substituted carbon atom in anti­
convulsants. Figure 6-9 shows that as electron density decreases the 
substituted carbon is deshielded, resulting in higher values of the 
chemical shift. Table 6-6 shows that in the oxazolidine-
2,4-dione ring the substituted carbon atom is highly deshielded due to its 
low electron density.
229
The experimental results obtained in this section add further 
support to the evaluation of the MINDO/3 method in Chapter 3. It has 
been shown in this section that MINDO/3 provides a useful description of 
electron density in carbonyl and other molecular groupings. Even though 
differences in electron density between different carbon atoms are fairly 
small, the electron densities are ordered correctly and can be correlated 
with observed differences in 13C chemical shifts.
6-4 MOLECULAR ELECTROSTATIC POTENTIALS
In Chapter 3 an evaluation has been carried out on the calculation 
of molecular electrostatic potentials for a series of model compounds.
The series comprised formaldehyde, formamide, urea, thymine and cytosine. 
These compounds are useful model structures for anticonvulsant drugs, 
and in addition, electrostatic potentials have been calculated for these 
compounds by other workers using ab ini,tio procedures. The evaluation 
has shown the usefulness of electrostatic potentials calculated using 
MINDO/3 electron densities and the average spherical atomic orbital 
approximation, restricted to complete neglect of differential overlap. 
There was a good agreement between MINDO/3 electrostatic potentials and 
published results of ab 'in'it'Lo calculations. Caution was indicated 
however where a pyridine-type nitrogen atom is present. On the basis 
of this evaluation electrostatic potentials have been calculated for a 
series of anticonvulsant drugs.
Electrostatic potentials have been calculated for most of the 
compounds described in section 6-1. An electrostatic potential has not 
been calculated for dechlorodiazepam because of the pyridine-type nitrogen 
present in this compound. Based on the evaluation of Chapter 3 it was 
felt that the method used here for electrostatic potentials is not 
appropriate for molecules of this type. Also potentials have not been
230
calculated for compounds active against chemically induced seizures.
These compounds possess the same heterocyclic systems, and therefore should 
possess similar potential fields, as the phenyl,ethyl derivatives for 
which electrostatic potentials have been estimated. Compounds have been 
studied in the mirror images of type 1 conformations. The compounds 
studied and their low energy conformations are illustrated in Figure 
6-10. All the anticonvulsants possess carbonyl oxygens as electronegative 
centres, and nitrogens in either imide— or amide-type systems. Results 
for the calculation of electrostatic potentials are presented in Figures 
6-11 to 6-17.
A common electrostatic potential field is shown throughout the 
series of anticonvulsants. A region of positive potential surrounds the 
hydrocarbon substituents, and is seen at the left hand side of each 
electrostatic potential contour map. Important regions of negative 
potential are situated close to carbonyl oxygen atoms. The first 
negative potential is associated with the central carbonyl group adjacent 
to the hydrocarbon substituents, and is seen at the top of the potential 
maps. A second region of negative potential is associated with the 
secondary carbonyl group, and is located towards the right hand side of 
the potential field. Between the two negative regions is a smaller area 
of positive potential, associated with the imide-type nitrogen. The 
electrostatic potential field of 5-phenyl-5-ethylacetylurea is very 
similar to the field shown for its cyclic analogue, 5-phenyl-5-ethyl- 
hydantoin. In the acetylurea derivative the positive potential region 
associated with the terminal nitrogen atom is a little larger relative to 
the hydantoin analogue, due to the presence of two attached hydrogen 
atoms instead of one.
The electrostatic potentials calculated for anticonvulsants support 
the findings based on net atomic charges, showing that carbonyl groups 
are regions of high reactivity towards an approaching electrophilic
231
Figure 6-10 Anticonvulsants (type 1 mirror image conformations) 
used for electrostatic potential calculations.
Left hand column top-to-bottom: PEH, PEO, PES and 
PEG (axial phenyl substituent). Right hand column: 
PEAu (Z,E backbone conformation), PMAz and PEB.
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Figure 6-11 Electrostatic potential map of PEH in the plane 
of the hydantoin ring. Regions of positive 
potential surround the hydrocarbon substituents 
and the imide nitrogen. Negative potential wells 
are associated with 0(4) (-19.0 kcal mol 1, top) 
and 0(2) (-22.4 kcal mol 1, lower right).
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Figure 6-12 Electrostatic potential map of PEO in the plane
of oxazolidine-2,4-dione ring. Negative potentials 
are associated with 0(4) (-16.7 kcal mol 1, top) 
and 0(2) (-20.7 kcal mol 1, lower right). The 
lower negative potential region is widened by the 
presence of the neighbouring oxygen 0(1) in the 
ring.
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Figure 6-13 Electrostatic potential map of PES in the plane
of the succinimide ring. Negative potentials are 
associated with 0(2)_(-19.4 kcal mol 1, top) and 
0(5) (-20.3 kcal mol 1, lower right).
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Figure 6-14 Electrostatic potential map of PEG in the plane
of the glutarimide ring. Negative potentials are 
associated with 0(2) (-20.7 kcal mol 1, top) and 
0(6) (-21.6 kcal mol 1, lower right).
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Figure 6-15 Electrostatic potential map of the open-chain
anticonvulsant PEAu in the plane of the acetyl- 
urea side-chain. Negative potentials are associated 
with 0(4) (-16.6 kcal mol 1, top) and 0(2) (-26.0 
kcal mol 1, lower right). The potential field of 
this open-chain compound is very similar to that of 
its cyclic analogue PEH.
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Figure 6-16 Electrostatic potential map of PMAz in the plane 
of azetidin-2-one ring. The carbonyl oxygen 0(2) 
is associated with a negative potential of -23.9 
kcal mol 1. In this compound there is no negative 
region in the lower right of the potential field.
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Figure 6-17 Electrostatic potential map of PEB in the plane
of the barbituric acid ring. Negative potentials 
are associated with both 0(4)_(—16.6 kcal mol 1, 
top) and 0(2) (-19.1 kcal mol 1, right). An 
additional region of negative potential is associated 
with the third oxygen of the barbituric acid ring, 
0(6) (-16.0 kcal mol 1, bottom).
239
agent, and are therefore suitable for hydrogen bonding interactions.
This predicted reactivity is also in agreement with experimental pro­
tonation studies on barbituric acid, succinimide and glutarimide 
systems, which show that carbonyl oxygens are the preferred sites of 
protonation (Olah and Schlosberg, 1968). Figure 6-16 shows that in 
3-phenyl-3-methylazetidin-2-one there is a wide spread region of positive 
potential surrounding the hydrocarbon substituents, suggesting that the 
secondary negative potential region shown for other compounds may not be 
essential for activity. As shown in Figure 6-17 the hydrocarbon region 
of positive potential in 5-phenyl-5-ethylbarbituric acid is relatively 
narrow, due to the presence of a third carbonyl group. It is apparent 
that the region of negative potential associated with this third carbonyl 
group is tolerated at the biological receptor site. In addition to 
hydrogen bonding through carbonyl groups, the anticonvulsants can also 
participate in hydrogen bonding through the imide-type nitrogen. In this 
case the nitrogen atom, with its attached hydrogen (or hydrogens as in 
acetylurea derivatives) may bind to an electronegative centre in the
receptor site.
CHAPTER 7
STRUCTURE-ACTIVITY RELATIONSHIPS 
OF ANTICONVULSANT DRUGS
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Most a n t i c o n v u l s a n t  d r u g s  p o s s e s s  one  o r  more h y d r o c a r b o n  su b ­
s t i t u e n t s  a t t a c h e d  to  a  h e t e r o a t o m i c  s y s te m .  I m p o r ta n t  c l a s s e s  o f  
d r u g s  w h ic h  c o n t a i n  t h e  im id e  g roup  i n  t h e i r  s t r u c t u r e  i n c l u d e  b a r b i t ­
u r a t e s ,  h y d a n t o i n s ,  o x a z o l i d i n e d i o n e s ,  s u c c i n i m i d e s  and g l u t a r i m i d e s . 
A l l  o f  t h e s e  d rug  c l a s s e s  p o s s e s s  c y c l i c  h e t e r o a t o m i c  s y s te m s .  The 
a c e t y l u r e a s  a r e  a n o th e r  c l a s s  o f  a n t i c o n v u l s a n t  c o n t a i n i n g  t h e  im id e  
g r o u p .  However th e y  c o n t a i n  t h e  g ro u p  w i t h i n  an o p e n - c h a in  s t r u c t u r e .  
I n  b o t h  c y c l i c  and o p e n - c h a in  a n t i c o n v u l s a n t s  t h e  f o l l o w i n g  s t r u c t u r e  
i s  commonly fo u n d .
R2 0 H 0
I I I I
Ri ------ C ------ C ------ N ------ C ------
I
I n  some c a s e s  t h e  i m i d e - t y p e  n i t r o g e n  h a s  a  s m a l l  a l k y l  s u b s t i t u e n t
a t t a c h e d ,  a s  i n  m e p h e n y to in  w h ic h  c o n t a i n s  an  N -m eth y l  s u b s t i t u e n t .
Compounds h a v in g  t h e  s u b s t i t u t i o n
R
<j) ------ C ------
commonly have  e x p e r i m e n t a l  a c t i v i t y  a g a i n s t  e l e c t r o s h o c k  s e i z u r e s ,  
and c l i n i c a l  u s e  i n  t h e  t r e a t m e n t  o f  t o n i c - c l o n i c  (g ra n d  m al)  e p i l e p s y .  
The f o l l o w i n g  a r e  exam ples  o f  a n t i c o n v u l s a n t s  c o n t a i n i n g  t h i s  ty p e  o f  
s u b s t i t u t i o n .
H
4> -----  C ------ 5 - p h e n y l a c e t y l u r e a
(p h en acem id e )
E t
4> -----  C ------ 5 - p h e n y l - 5 - e t h y l b a r b i t u r i c  a c i d
( p h e n o b a r b i t o n e )
I
4) -----  C ------ 5 ,5 - d ip h .e n y lh y d a n to in
( p h e n y to in )
P h e n o b a r b i to n e  and p h e n y to in  a r e  u se d  c l i n i c a l l y .  Phenacem ide  h a s  now 
b e e n  r e p l a c e d  i n  t h e  c l i n i c a l  t r e a t m e n t  o f  s e i z u r e s  by i t s  a n a lo g u e
5-phenyl-5-ethylacetylurea Cpheneturide). Compounds bearing the 
substitution
R2
R i --- C ---
where Rj and R2 are small alkyl substituents, are more commonly associated 
with activity against chemically induced (pentylenetetrazole) experimental 
seizures and clinical use in the treatment of absence (petit mal) epilepsy. 
An example of an anticonvulsant of this type is 3-ethyl-3-methylsuccinimide 
(ethosuximide), which has the substitution
Me
Et --- C ---
and provides effective control of absence seizures. Benzodiazepines are 
another class of anticonvulsants, which possess experimental activity 
against both electroshock and chemically induced seizures. In clinical 
practice they are used more commonly to treat absence rather than tonic- 
clonic epilepsy. Their clinical usefulness is limited however by a 
decreasing effect with time, possibly due to tolerance which may develop 
during drug therapy.
This Chapter reviews the structural requirements which have been 
determined in the present work for experimental and therapeutic anti­
convulsant activity. Both conformational and electronic features of anti­
convulsant drugs are reviewed. A comparison is made between these 
structural features and previous investigations, and the influence of the 
physical properties of anticonvulsant drugs is also examined. The results 
of the present work are used to suggest possible modes of interaction of 
anticonvulsants with drug receptors, and to obtain some understanding 
of the stereospecificity of anticonvulsant action. The relationship of 
molecular structure to the mechanism of action of anticonvulsant drugs is
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also discussed.
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7-1 S T R U C T U R A L  R E Q U I R E M E N T S  FOR 
A N T I C O N V U L S A N T  A C T IVIT Y
DRUG CONFORMATION
Several series of anticonvulsants have been studied in the present 
work. Compounds active against electroshock type seizures comprise 
phenyl, ethyl and diphenyl derivatives of five- and six-membered hetero­
cycles, benzodiazepines and partial structures, and open-chain acetylurea 
derivatives. In relation to activity against chemically induced seizures 
a series of heterocycles bearing small alkyl substituents has also been 
studied. In compounds active against experimental electroshock seizures, 
some of which are used clinically in the treatment of tonic-clonic 
epilepsy, four main structural features are usually present :
(1) A phenyl ring or equivalent hydrocarbon substituent;
(2) A carbonyl or other electronegative group adjacent to 
the phenyl substituent;
(3) A nitrogen able to participate in hydrogen-bonding on the 
opposite side of the first electronegative group;
(4) A second electronegative group diagonally opposite the first 
electronegative region.
Groups (2), (3) and (4) are conveniently placed in their correct 
position when contained within an imide system. This results in the 
type of substitution mentioned in the introduction to this Chapter :
R 0 R 0 
C c N C
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Empirical potential energy calculations using the COMOL programme have 
indicated that there are two main orientations of the phenyl substituent. 
These have been labelled type 1 and type 2 conformations. Anticonvulsant 
activity is more likely to be associated with the type 1 conformation, as 
this is accessible to all compounds. In this conformation the phenyl 
substituent is aligned so that its own plane is pointing towards the 
first electronegative region. The value for the torsion angle of the 
phenyl substituent, Tl = T (C^ - - C - CO), is usually in the range
15-35°. Figure 7-1 illustrates the type 1 conformation and its mirror 
image for 5,5-diphenylhydantoin Cphenytoin). COMOL and MINDO/3 calcul­
ations also indicate that 5-phenyl-5-ethylacetylurea (pheneturide) can 
assume a type 1 conformation similar to the cyclic hydantoin anticonvulsants. 
The lack of activity of 5,5-diphenylacetylurea has been explained on the 
basis of steric interference of the lower phenyl substituent with the 
drug receptor.
Conformational analysis on benzodiazepines and partial structures 
provides further information on the structural requirements for activity. 
Studies on these compounds help to define which of the four main structural 
features of anticonvulsants are most essential for activity. Figure 7-2 
illustrates the low energy conformations of dechlorodiazepam and 3-phenyl- 
3-methylazetidin-2-one, both of which have activity against electroshock 
type seizures. The diazepam analogue contains the upper phenyl substituent, 
and the two electronegative regions as the pyridine-type nitrogen and the 
carbonyl oxygen. It is missing the imide-type nitrogen shown in the 
hydantoin ring, indicating that this atom, with its attached hydrogen for 
hydrogen bonding, can be absent for anticonvulsant activity. The 
azetidinone analogue contains the phenyl substituent, the central electro­
negative group as the carbonyl oxygen, and the nitrogen for hydrogen 
bonding. This compound indicates that the secondary electronegative group 
may also be absent. This is supported by pharmacological evidence, based
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Figure 7-1 Type 1 conformation (left) and its mirror image 
(right) for PPH.
V
Figure 7-2 Conformations of DcD (left) and PMAz (right) 
corresponding to the mirror image type 1 con­
formation of PPH shown in Figure 7-1.
r ')  O
Figure 7-3 Crystal structure conformation of procyclidine
(Camerman and Camerman, 1971b) . It is seen that 
PPH (Figure 7-1) and procyclidine have similar 
conformations.
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on the activity of de-oxygenated analogues of 5 -^phenyl^5-ethylbarbituric 
acid (primidone; Baumel and others, 1973) and 5,5-diphenylhydantoin 
(Goodman and others, 1954), which suggests that the secondary electro­
negative group is not essential for activity.
Looking at previous studies it is seen that the stereochemical 
hypothesis of Camerman and Camerman (1970, 1971a, 1971b, 1972a, 1972b,
1974, 1975, 1977) and Fawcett, Camerman and Camerman (1977) is a particular 
case of the structure-activity relationship outlined here. These authors 
investigated a series of anticonvulsants containing primarily diphenyl or 
phenyl,cyclohexyl substitution. Emphasis in the Camerman and Camerman 
hypothesis is placed on the orientation of the following groups:
(1) Two hydrocarbon rings.
(2) Two electronegative groups.
The structure-activity relationship outlined in the present work covers 
a wider range of compounds, and shows that only one phenyl substituent 
is necessary for activity against electroshock seizures, and that in 
addition to the two electronegative groups, a nitrogen appears to be 
required for hydrogen bonding. It should be noted that in respect of 
this nitrogen the theory of Camerman and Camerman appears inconsistent.
For two of the compounds studied in their series of reports, procyclidine 
and trihexyphenidyl, ammonium type nitrogens are described as electro­
negative groups. However at physiological pH these nitrogens will exist 
predominantly in the cationic form. In fact both procyclidine and 
trihexyphenidyl show the importance of a nitrogen which is able to 
participate in hydrogen bonding, as outlined in the present structure- 
activity relationship. The oxygen-to-nitrogen distance in procyclidine 
(3.6 X) and trihexyphenidyl (2.8 X) has been criticized elsewhere because 
it is shorter than the distance between the two electronegative centres 
in most of the compounds studied by Camerman and Camerman (Jones and
247
Kennard, 1978). Considering the nitrogen in procyclidine and trihexy­
phenidyl to be in its cationic form, then the oxygen-to-nitrogen distance 
in these compounds is comparable to the distance between the central 
electronegative group and imide-type nitrogen in the present series of 
compounds. The crystal structure conformation of cationic procyclidine 
(Camerman and Camerman, 1971b) is shown in Figure 7-3, where it is shown 
to be similar to the preferred conformation of 5,5-diphenylhydantoin, 
as determined in the present work.
Another previous study (Weintraub, 1977) also supports the results 
of the present work. Calculations of the preferred conformations of 
succinimides and other anticonvulsants indicate that highest activity 
is obtained where both electronegative groups in the imide system 
—  CO -- NH --- CO —
are sterically unhindered. Calculations on N-substituted succinimides 
show that activity is reduced where the substituents fold back and 
sterically hinder the carbonyl groups. An N-isopropyl substituent in 
l-isopropyl-3-phenylsuccinimide causes a threefold decrease in activity 
relative to the sterically unhindered compound l-methyl-3-phenylsuccinimide 
(phensuximide). This evidence supports the present structure-activity 
relationship, in which the secondary electronegative group, although 
possibly not essential for activity, is seen in most of the anticonvulsants, 
including those used clinically for the treatment of tonic-clonic 
epilepsy.
In the anticonvulsants active against chemically induced seizures, 
and used clinically in the treatment of absence epilepsy, there are small 
alkyl substituents present. As a result there is not much conformational 
variability. These drugs also contain the imide system, so that the main 
structural features associated with activity can be summarized as follows :
(1) One or more small alkyl substituents, for example ethyl and methyl;
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(2) A carbonyl electronegative group adjacent to the substituted 
carbon atom ;
(3) A nitrogen able to participate in hydrogen bonding on the opposite 
side of the first electronegative group;
(4) A second electronegative group diagonally opposite the first 
electronegative region.
Although the conformation of the upper ethyl substituent in ethyl 
substituted compounds may not be too critical, it appears that anti­
convulsant activity possibly results from the ethyl substituent pointing 
directly above the heteroatomic system. This is the conformation shown 
to be preferred for 5,5-diethylbarbituric acid (barbitone). The structural 
requirements for activity against chemically induced seizures are com­
plicated by the benzodiazepines. These anticonvulsants are active against 
chemically induced seizures and are also used clinically in the treatment 
of absence epilepsy. Because their structural relationship to the anti­
convulsants bearing small alkyl substituents is not clear, it may be that 
benzodiazepines are acting on different receptors to drugs like 5,5- 
die thy lbarbituric acid and 3^thyl-3-methylsuccinimide.
ELECTRONIC STRUCTURE
MINDO/3 calculations have been used in the present work to describe 
the electronic structure of anticonvulsants from the following series 
active against electroshock seizures : phenyl, ethyl derivatives of five- 
and six-membered heterocycles, benzodiazepines and partial structures, 
and open-chain acetylureas. Calculations have also been performed on 
several compounds active against chemically induced seizures. Calculated 
values of MINDO/3 electron densities are supported by the results of
1 3C-NMR spectroscopy which has also been carried out. Net atomic charges 
have been reported in this work for the following atomic positions :
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(1) First or central electronegative group. This is usually a 
carbonyl oxygen atom, 0^, with net charge of -0.51 to -0.53 e.u.
(2) Secondary electronegative group, 0^, with net charge of -0.52 
to -0.56 e.u.
(.3) Imide-type nitrogen, N, with net charge -0.24 to -0.32 e.u.
(4) Hydrogen atom attached to the imide-type nitrogen, H(N), with net 
charge +0.08 to +0.14 e.u.
In benzodiazepines there is a pyridine-type nitrogen atom which is 
equivalent to 0^, and the positions N and H(N) are not present. In 
acetylureas the terminal nitrogen of the acetylurea fragment, with its 
two attached hydrogens, is equivalent to the imide-type nitrogen, N, of 
other anticonvulsants. Calculated dipole moments for the anticonvulsants 
are in the range 1.31-4.64 Debye. This compares with experimental values 
in the range 0.87 to 2.83 Debye. Relatively narrow ranges for net atomic 
charges and dipole moments in the imide system of anticonvulsants have also 
been found in a previous study using the EHT and CNDO/2 methods (Andrews, 
1969) .
It appears that each of the atomic positions 0^, 0^ and H(N) may 
contribute towards anticonvulsant activity. Because of the narrow ranges 
of net atomic charges and dipole moments found, each of these three atomic 
positions is likely to participate in similar interactions with a drug 
receptor throughout the range of anticonvulsants studied. This is 
supported by experimental evidence which shows that the enthalpies of 
hydrogen bonding between phenol and a series of anticonvulsants are all 
in the range of about -4 to -5 kcal mol 1. Calculations on molecular 
electrostatic potentials in the present work have also shown the exist­
ence of a common electrostatic potential field surrounding anticonvulsant
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drugs. This applies to both cyclic and open-chain compounds. The 
principal features of the potential field are a positive potential 
region surrounding hydrocarbon substituents, negative potentials 
associated with carbonyl groups, and a positive potential about the 
imide-type nitrogen. As outlined here electronic features appear to 
play an important role in determining anticonvulsant activity against 
electroshock seizures, and clinical use in the treatment of tonic-clonic 
epilepsy. Based on the net atomic charges and electrostatic potentials 
found for anticonvulsants, the following types of electrostatic or 
hydrogen bonding interactions are likely to occur with a drug receptor :
(1) Interaction between electronegative carbonyl groups and positively 
charged regions of a drug receptor :
(2) Hydrogen bonding of the imide or equivalent system with a donor 
atom in the receptor. For example:
Drug --- N --- H ...... 0 ---- Receptor
Calculations of superdelocalizability in the present work show that 
carbonyl oxygens of anticonvulsants have high electrophilic super- 
delocalizabilities. This means that during interactions of type (1) 
the carbonyl oxygens may be involved in transferring electron density 
to the drug receptor. Atoms possessing high nucleophilic superdelocal- 
izabilities are the carbon atoms of carbonyl groups and the substituted 
carbon atom of phenyl substituents. Therefore donation of electron 
density from the receptor back to the anticonvulsant drug is also possible,
as indicated in the further interactions :
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(3) Donation of electron density from receptor to carbonyl group. 
For example charge transfer involving lone pair electrons :
Receptor
(4) Donation of electron density from receptor to phenyl substituent. 
For example charge transfer of tt electrons from aromatic region 
of receptor :
Drug --- (tt)
</> (tt) --- Receptor
For drugs active against chemically induced seizures, and used 
clinically in the treatment of absence epilepsy, similar drug-receptor 
interactions are possible. With compounds possessing small alkyl sub­
stituents interactions of type Cl)» (2) and (3) could occur. With 
benzodiazepines, where there are aromatic regions in the molecule, but 
no imide-type nitrogen, interactions of type (1), (3) and (4) are possible. 
In the case of benzodiazepines there are two different type (1) inter­
actions, involving the central electronegative region (pyridine-type 
nitrogen) and secondary electronegative region (carbonyl oxygen) :
(la)
(lb)
V-
/
\
/c=
,6+
.6- .6+
Receptor
Receptor
There is experimental evidence to suggest that interaction of the
secondary electronegative region Ccarbonyl oxygen) of benzodiazepines 
may be important for anticonvulsant activity (Ramanujam and Trieff,
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1978) . A correlation has been shown between activity against chemically 
induced seizures and the rate of borohydride reduction of the carbonyl 
group in benzodiazepines :
\ \c —/ —  0 + BHi+ ---►  / C  —V
H
—  0\ _
b h 3
There was no correlation for activity against electroshock type seizures. 
This means that the carbonyl group is possibly participating in different 
types of interactions at different receptors. An interaction of type 
(lb) might be involved at receptors for activity against electroshock 
seizures, whereas an interaction of the borohydride type, possibly 
involving charge transfer, could conceivably be involved at the receptor 
for activity against chemically induced seizures.
PHYSICAL PROPERTIES AND STEREOSPECIFICITY
The results of the present work can also be compared to previous 
studies on anticonvulsants using the Hansch type of approach to free 
energy relationships. Lapsewicz and others (1978) have derived the 
following relationship for activity against electroshock seizures in a 
series of phenyl substituted succinimides :
log =r^- = 0.3857T + 3.249ED5 o
where ED50 is the effective dose in 50% of animals, and tt is a measure 
of the lipophilicity of a compound. The definition of tt is based on the 
partition coefficient P :
"s = 108 Ps " 1 0 8 Po
where P is the partition coefficient of a compound bearing substituent
u
S, and Pq is the partition coefficient of the parent compound. This 
relationship indicates that anticonvulsant activity increases with 
increasing lipophilicity of compounds. A similar relationship has been
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derived by Lien, Liao and Shinouda Q-979) for a range of anticonvulsants, 
including barbiturates, hydantoins, oxazolidinediones, succinimides, 
acetylureas and benzodiazepines :
log — —  = 0.647 log P - 0.133b + 2.785ED 5 o
This relationship again shows the importance of lipophilicity, as 
expressed by the octanol-water partition coefficient, P. The dipole 
moment, b> has also been taken into account, although the small coefficient 
of -0.133 shows that there is not much variation of activity with dipole 
moment. For example 5,5-diphenylhydantoin (phenytoin) and 5-phenyl- 
acetylurea (phenacemide) have similar dipole moments, 1.74 and 2.06 
respectively. The greater activity of phenytoin is correlated with a 
significantly higher log P value (.2.47) compared to the log P value of 
phenacemide (0.57).
Because of the influence of lipophilicity on anticonvulsant activity, 
it is important to understand how this particular physical property might 
affect drug action. The biological parameter ED50 represents the activity 
of a drug in the whole animal. It therefore reflects the entire process 
of drug action : absorption into the bloodstream from the site of admin­
istration, distribution to the site of action, interaction with the drug 
receptor, and metabolism to inactive species and excretion from the body. 
The conformational and electronic similarities for anticonvulsant drugs 
found in the present work indicate that the drug receptor stage is likely 
to be similar for most anticonvulsants. Lipophilicity is more likely to 
be associated with the other stages of drug action, and in particular 
with the distribution of anticonvulsants to the site of action. This is 
because of the structural requirements of drugs in crossing the blood- 
brain barrier. Ionized and highly polar compounds have difficulty in 
penetrating from the bloodstream into brain tissue. The more lipophilic 
a compound is, the more rapidly it will be transferred across the blood- 
brain barrier. Because anticonvulsants act on the central nervous system,
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it is likely that their increase in activity with increase in lipo- 
philicity is due to a more rapid distribution to the site of action.
The stereospecificity of anticonvulsant action has also been 
investigated with some compounds. Each optical isomer of both 5-phenyl, 
5-ethylhydantoin and its N-methylated derivative (mephenytoin) display 
activity against electroshock seizures (Pfeiffer and Jenney, 1967; Swinyard 
and others, 1950). In the open-chain analogue of these compounds, 5- 
phenyl-5-ethylacetylurea (pheneturide), again both optical isomers have 
been shown to have activity against electroshock seizures (Frommel, Gold- 
Aubert and Fleury, 1959). An explanation for these observed activities 
can be found by examining the imide system of anticonvulsants in their 
most probable bioactive type 1 conformation. Figure 7-4 shows that 
because the two electronegative carbonyl groups are located diagonally 
opposite each other, rotation of molecules about a vertical axis results 
in a conformation which is very similar to the mirror image of the original 
type 1 conformation. Due to this similarity between a type 1 conformation 
and its mirror image, both isomers of an optically active compound may 
interact in the same way with a drug receptor. Therefore in anticonvul­
sants possessing both central and secondary electronegative groups, 
individual isomers of optically active compounds can display similar 
anticonvulsant activities.
7-2  RELATIONSHIP OF CHEMICAL 
STRUCTURE TO MECHANISM OF ACTION
In Chapter 1 the possible mechanisms of action of anticonvulsant 
drugs were reviewed. The various mechanisms discussed included biochemical 
effects on enzymes and metal ions, interference with the regulatory role 
of cyclic nucleotides, and actions on neurotransmission involving acetyl­
choline, gamma-aminobutyric acid and the monoamines. Also some specific
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Figure 7-4 Stereochemical relationship between a type 1 
conformation (left and lower right) and its 
mirror image (upper right). After rotation 
about a vertical axis conformation 1 is shown 
to have a similar conformation to its mirror 
image. In each of the right hand structures 
there is a similar orientation of phenyl and 
imide components of the molecule.
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mechanisms of action were seen. For example methazolamide, acetazolamide 
and sulthiame are inhibitors of the enzyme carbonic anhydrase. Another 
specific mechanism is where anticholinergic drugs can be used to suppress 
seizures induced by acetylcholine. These drugs are used in treating 
insecticidal poisoning, where levels of acetylcholine are elevated due 
to inhibition of the degradative enzyme cholinesterase. Subsequent 
Chapters have examined the conformational behaviour and electronic structure 
of anticonvulsant drugs. It has been shown in this work that there are 
distinct similarities in the preferred conformations and electronic 
structures of a range of anticonvulsants. This is most evident for drugs 
active against experimental electroshock seizures, some of which are used 
clinically to treat tonic-clonic (grand mal) epilepsy. Therefore although 
each drug may have more than one action contributing to its anticonvulsant 
effect, it is likely that all these drugs act at a common site to bring 
about a part of their activity. It is this possible common site that is 
of particular interest. Of the different mechanisms of action described 
in Chapter 1, this section discusses those which are most likely to 
involve anticonvulsants sharing the same site of action.
GAMMA-AMINOBUTYRIC ACID (GABA)
There is some evidence to suggest that anticonvulsants may act in 
part through an effect on the neuroinhibitory transmitter GABA. Facil­
itation of GABA synthesis is one effect which may be involved. When 
isoniazid is used to deplete stores of GABA, the anticonvulsants 
phenytoin, phenobarbitone, primidone and diazepam have the ability to 
increase GABA levels. This is possibly achieved by increasing the rate 
of synthesis, in which glutamine is converted to glutamate, which is 
then decarboxylated to give GABA. However the site of action is not 
clear, since diazepam has been shown not to increase the activity of the 
biosynthetic enzyme GAD, glutamic acid decarboxylase (Tong and Edmonds,
1976) .
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In the GABA receptor complex there are also sites at which anti­
convulsants may act. Phenytoin, phenobarbitone and diazepam have been 
shown not to interact with the receptor site itself (Olsen and others,
1978). But neighbouring ionophore and modulator sites have been proposed 
as possible regions where some drugs may interact. The ionophore site 
appears to be linked to GABA function, as the administration of GABA leads 
to an increase in chloride permeability. A binding site, possibly near 
the chloride channel, has been shown for a-dihydropicrotoxinin (a-DHP), 
which blocks the GABA-mediated increase in permeability (Olsen, Ticku 
and Miller, 1978; Olsen and others, 1978; Ticku, Ban and Olsen, 1978;
Ticku and Olsen, 1978). Several anticonvulsants, including phenytoin, 
phenobarbitone and primidone, have been shown to inhibit a-DHP binding. 
Diazepam does not influence a-DHP binding. It has been suggested that 
anticonvulsants like phenytoin and phenobarbitone might bind to the site 
in a different way to a-DHP, and have the opposite pharmacological effect 
(Olsen and others, 1978; Ticku and Olsen, 1978). While the stereochemical 
similarities of phenytoin and phenobarbitone would permit action at a 
common site, there is no pharmacological evidence that these anticonvulsants 
directly antagonize the effects of a-DHP on chloride permeability.
It has also been suggested that there is a natural modulator 
which inhibits the binding of GABA to the receptor (Guidotti and others, 
1978; Johnston and Kennedy, 1978). Because diazepam and other benzo­
diazepines appear to compete with the modulator it has been suggested 
that these drugs could increase GABA binding to the receptor, and thereby 
facilitate the neuroinhibitory action of GABA. However it has been observed 
that during chronic in vivo administration diazepam results in a reduction 
of GABA binding (Möhler, Okada and Enna, 1978).
The most important effects of anticonvulsant drugs on GABA neuro­
transmission can be summarized as follows :
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1. Increase in GABA synthesis.
2. Binding to a-DHP site near chloride ionophore.
3. Binding of benzodiazepines to natural modulator site.
While the pharmacological significance of these effects is not clear, 
the effect on GABA synthesis represents one action which benzodiazepines 
and other anticonvulsants have in common. The stereochemical similarities 
found for the range of anticonvulsants in the present work suggest that 
there may be a common receptor somewhere in the biosynthetic sequence for 
GABA. Although a specific location cannot be postulated at this stage, 
a receptor which accommodates the main structural features required for 
anticonvulsant activity may be responsible for the observed increase in 
GABA levels.
MONOAMINES : SEROTONIN, DOPAMINE AND NORADRENALINE
There is evidence to suggest that the monoamines, in particular 
noradrenaline, may also be involved in the action of anticonvulsant drugs.
A range of compounds acting at various sites in the monoamine synapse, 
including anticonvulsants, have an effect on experimental seizures. The 
important effects of drugs on monoamines and electroshock type seizures 
can be summarized as follows :
STORAGE A W  RELEASE
Reserpine depletes all three monoamines and antagonizes the action 
of phenytoin and phenobarbitone. Amphetamine causes the release of 
catecholamines (dopamine and noradrenaline) and is an anticonvulsant.
It also potentiates the action of phenytoin and phenobarbitone.
UPTAKE
The uptake of noradrenaline is inhibited by a range of drugs showing 
anticonvulsant activity : phenytoin, diazepam, procyclidine, trihexyphenidyl 
and imipramine. Phenobarbitone however does not appear to be a good
inhibitor of the uptake process.
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METABOLISM
Compounds increasing monoamine synthesis have an anticonvulsant 
action, whereas compounds decreasing synthesis result in enhanced 
susceptibility to seizures. Inhibitors of the degradative enzyme 
monoamine oxidase also have an anticonvulsant action.
Of the catecholamines, noradrenaline appears to have more import­
ance for anticonvulsant action than dopamine. Selective depletion with 
6-hydroxydopamine (6-OHDA) of forebrain stores of noradrenaline and 
dopamine indicates that noradrenaline is involved in the suppression of 
electroshock seizures (Mason and Corcoran, 1979). Evidence from metabolic 
studies also supports the greater involvement of noradrenaline. In the 
final stage of noradrenaline synthesis dopamine is converted by the 
enzyme dopamine ^-hydroxylase into noradrenaline. Disulfiram and FLA-63 
are two inhibitors of dopamine ß-hydroxylase. Administration of these 
drugs lowers noradrenaline levels while leaving dopamine levels normal or 
elevated, and results in an increase in the susceptibility to seizures 
(Kilian and Frey, 1973). The monoamine serotonin may also be involved 
to some extent in the action of anticonvulsant drugs. Administration of 
the biosynthetic precursor to serotonin decreases susceptibility to 
electroshock seizures, whereas p-chlorophenylalanine, which inhibits the 
biosynthesis of serotonin, causes an increase in the susceptibility to 
seizures.
Examining the noradrenaline synapse it appears that uptake is the 
process most likely to be involved as a common site of action of anti­
convulsant drugs. A range of anticonvulsants, including phenytoin and 
diazepam, as well as several other drugs, are able to inhibit the uptake 
of noradrenaline into presynaptic terminals. This is the process called 
neuronal uptake (uptake 1). Hadfield and Weber (1975) have shown that
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phenytoin inhibition of neuronal uptake is non-competitive, suggesting 
that phenytoin may not be interacting at the uptake site itself, but at 
some neighbouring site on the neuronal membrane. It is therefore 
interesting to note that phenytoin and diazepam have been shown to inhibit 
Na+ , K+-ATPase in brain synaptosomes. As neuronal uptake appears to 
depend on Na+ , K^-ATPase, this represents a way by which phenytoin and 
diazepam could inhibit neuronal uptake.
It is still interesting to structurally compare phenytoin with some 
of the other compounds which are able to inhibit neuronal uptake. Fro- 
cyclidine and imipramine both possess activity against electroshock 
seizures and are inhibitors of neuronal uptake. Each compound contains an 
ammonium type nitrogen as seen in noradrenaline, and it has been shown 
that imipramine is able to inhibit uptake competitively (Horn, Coyle and 
Snyder, 1971). Figure 7-5 compares the preferred type 1 conformation 
(mirror image form) of phenytoin from the present work to the crystal 
structure conformations of procyclidine (.Camerman and Camerman, 1971b), 
imipramine (Post, Kennard and Horn, 1975) and noradrenaline (Carlström and 
Bergin, 1967). Noradrenaline is shown in the cationic form, which is the 
ionic species determined for the crystal structure, and also the species 
preferred in aqueous solution at the physiological pH of 7.4 (Kappe and 
Armstrong, 1965). The crystal structure shows noradrenaline in the trans 
conformation, which is also the preferred conformation as determined by 
both INDO (Pedersen, Hoskins and Cable, 1971) and PCILO (Pullman and others, 
1972) theoretical calculations, and also in aqueous solution by NMR 
spectroscopy (Ison, Partington and Roberts, 1973). The conformations of 
all compounds in Figure 7-5 correspond to the naturally occurring R(-) 
isomer of noradrenaline.
The principal structural features of noradrenaline are the aromatic 
catechol ring, the aminoethyl side-chain as the protonated cation, and a 
hydroxy group at the B position in the side-chain. The R(-) isomer of
261
Figure 7-5 Preferred conformations of drugs corresponding 
to the naturally occurring R(-) isomer of nor­
adrenaline. Left column top-to-bottom : 
phenytoin (PPH; this work), procyclidine 
(Camerman and Camerman, 1971b), and imipramine 
(Post, Kennard and Horn, 1975). Right column : 
noradrenaline (Carlström and Bergin, 1967).
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noradrenaline has the hydroxy group pointing towards the back of the 
molecule. The catechol ring in the preferred conformation shown is 
approximately perpendicular to the aminoethyl side-chain. Both pro- 
cyclidine and imipramine have upper aromatic rings and ammonium type 
nitrogens in similar positions to noradrenaline. Procyclidine also has 
a hydroxy which corresponds to the 3-hydroxy group of noradrenaline. The 
compounds also possess a lower hydrocarbon ring. In compounds possessing 
both upper and lower hydrocarbon rings it has been suggested that the 
upper ring binds to the same region of the uptake site as the catechol 
nucleus of noradrenaline, and the lower ring binds to an accessory region 
of the uptake site (Maxwell and others, 1970; Tuomisto, 1979).
In Figure 7-5 it is seen that phenytoin possesses similar structural 
features to those shown for noradrenaline. Corresponding to the catechol, 
ammonium nitrogen and hydroxy groups of noradrenaline are the phenyl, imide 
nitrogen and carbonyl oxygen groups of phenytoin. The most important 
difference between the two molecules is that noradrenaline contains the 
cationic ammonium group, whereas phenytoin is a neutral molecule and does 
not contain a positively charged nitrogen. To determine the effect of the 
ammonium nitrogen on the electrostatic potential field of noradrenaline, 
MINDO/3 and electrostatic potential calculations have also been carried out. 
Calculations have been performed on the crystal structure conformation of 
noradrenaline, as well as two further conformations showing different 
orientations of the 3-hydroxyl hydrogen. The conformations studied are 
illustrated in Figure 7-6. Electrostatic potential maps are not shown, as 
no local minimum was detected near the 3-hydroxy group, the potential field 
being positive at all locations around the molecule, decreasing in value 
as distance from the molecule increases. Similar results on electrostatic 
potential have also been obtained using CNDO/2 calculations on other 
adrenergic drugs (Petrongolo and others, 1974). The lack of a cationic 
centre in phenytoin may explain the non—competitive nature of this drug's
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Figure 7-6 Conformations of R(.-)-noradrenaline used for electro­
static potential calculations, at different values of 
the torsion angle x(H-Og-Cg-Ca). Potential planes 
are perpendicular to page and contain horizontal lines 
shown in the left hand column: upper (j= 180 , plane 
contains Og);Qcentre (t= 135 , plane 1A above 0^); 
lower (t- 315 , plane lX below Og). Top side views of 
each of the three conformations are shown in the right 
hand column.
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inhibition of the neuronal uptake of noradrenaline. The Na , K -ATPase 
required for the uptake process represents a likely site of action for 
phenytoin. Procyclidine has a cationic centre in common with imipramine 
and noradrenaline. Because of its stereochemical similarity to phenytoin, 
it also has the potential to act at the same site as phenytoin and other 
anticonvulsants.
There are several uptake processes occurring within the noradrenaline 
synapse. After release noradrenaline can be taken back up into the pre- 
synaptic nerve terminal through neuronal uptake (uptake 1) or taken up 
into extraneuronal tissue (uptake 2). In addition to neuronal uptake, 
noradrenaline is also taken up into storage vesicles (vesicular uptake) 
once inside the presynaptic terminal. Anticonvulsant drugs also have the
I [
potential to inhibit vesicular uptake. This process is dependent on Mg 
ATPase, which has been shown to be inhibited by a range of anticonvulsants, 
including phenytoin, phenobarbitone and diazepam (Gilbert and Wyllie, 1976) .
I IMg -ATPase therefore represents another possible common site of action 
of anticonvulsant drugs. It is also interesting to note that phenytoin has 
been shown to inhibit the activity of the degradative enzyme MAO, monoamine 
oxidase (Azzaro, Gutrecht and Smith, 1973). This means that if phenytoin 
prevents noradrenaline from entering storage vesicles, it also has the 
potential to prevent the subsequent breakdown of noradrenaline within the 
presynaptic terminal. Effects of drugs on other ATPases have also been 
observed. Willow and Johnston (1979) have shown that anaesthetic barb-
f Iiturates are able to stimulate Ca -ATPase in brain synaptosomes, having
I Ithe potential to decrease intracellular Ca and inhibit the release of
++neurotransmitters in Ca -dependent processes. However this type of effect
would reduce rather than facilitate the action of noradrenaline. The 
[ -[activation of Ca -ATPase by barbiturates may be more related to other, 
possibly excitatory neurotransmitters in the central nervous system.
CHAPTER 8
CONCLUSIONS
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Epilepsy occurs in about 1 out of every 200 to 400 people.
There are numerous types of epileptic seizures. There are partial or 
focal seizures, which may involve both elementary and complex symptom­
atology. There are also generalized seizures, including the absence 
(petit mal) type, which are characterized by brief and abrupt losses of 
consciousness, and the tonic-clonic (.grand mal) type, which involve major 
convulsions where there is usually tonic spasm of body muscles, followed 
by clonic jerking and prolonged depression of the central nervous system. 
The annual rates of incidence per 100 000 of the population for absence 
and tonic-clonic forms of epilepsy are 3.4 and 12.5 people respectively. 
Where remission is defined as being seizure free for 5 or more years it 
has been reported that there is a 46% remission rate for absence seizures. 
The rate for tonic-clonic seizures is somewhat lower at 29% remission.
Previous structure-activity studies on anticonvulsant drugs have 
suggested the importance of molecular conformation and physico-chemical 
properties including the partition coefficient and dipole moment. In a 
series of papers Camerman and Camerman have observed similarities in the 
crystal structures of several anticonvulsant drugs, some of which are 
used clinically for the treatment of epilepsy including phenytoin and 
diazepam. The present work has been designed to examine these similarities 
and extend the study of conformation by applying theoretical calculations 
to a range of anticonvulsants. Unlike crystallography, theoretical cal­
culations allow for the determination of alternative low energy confor­
mations of a molecule and their relative energies. Empirical potential 
energy calculations using the C0M0L method have been applied to this 
conformational analysis. Empirical calculations are suitable for the 
anticonvulsants studied, because the main variable in conformation here 
is the rotation of hydrocarbon substituents, for which steric interactions 
are the principal determinant of conformational energy. After having 
applied conformational analysis to a range of anticonvulsants, MINDO/3
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calculations have been used to study the electronic structure of drugs in 
their preferred conformations. The MINDO/3 method has been evaluated in 
this work for its ability to estimate ground-state properties and molecular 
electrostatic potentials. By comparison to published ab initio calculations 
and experimental results the method has been found to provide a good des­
cription of electronic structure in a series of model compounds.
The basic structural feature of anticonvulsant drugs is a hetero- 
atomic system to which is attached one or more hydrocarbon substituents. 
Commonly the heteroatomic system is a cyclic or open-chain imide having 
the following structure.
R2 0 H 0 
Ri --- C --- C --- N --- C ---
Compounds active against chemically induced seizures, or used clinically 
in the treatment of absence (petit mal) epilepsy, usually have small alkyl 
substituents attached to the substituted carbon atom. For activity against 
experimental electroshock seizures, or clinical use in the treatment of 
tonic-clonic (grand mal) epilepsy, at least one phenyl substituent is 
required. A common low energy conformation has been found in the present 
work for a range of compounds possessing this type of activity. The con­
formation is shared by phenyl, ethyl and diphenyl derivatives of a range 
of five- and six-membered heterocycles, as well as by the open chain phenyl, 
ethyl derivative of acetylurea. The main features of this proposed bioactive 
conformation are:
(1) A phenyl ring or equivalent hydrocarbon substituent;
(2) A central carbonyl or other electronegative group adjacent to the
phenyl substituent \
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(3) A nitrogen able to participate in hydrogen bonding on the opposite
side of the first electronegative group;
(A) A secondary electronegative group diagonally opposite the first
electronegative region.
The phenyl substituent is aligned so that it is pointing towards the 
first, or central electronegative region. In this conformation the 
torsion angle defining the phenyl substituent (xl) is usually in the 
range 15-35°. The preferred conformations of benzodiazepines and amide- 
type partial structures indicate that the hydrogen bonding nitrogen and 
the secondary electronegative region may be less important for receptor 
binding than the phenyl substituent and the central electronegative region.
Calculations of the electronic structure of anticonvulsants indicate 
that different drugs have a similar potential for interaction with a drug 
receptor. MINDO/3 electron densities calculated for the anticonvulsants 
are supported by the results of 13C-NMR spectroscopy. The most reactive 
centres for electrostatic and hydrogen bonding interactions are the 
carbonyl or other electronegative regions and the imide-type nitrogen 
with its attached hydrogen atom. Calculations on superdelocalizability 
indicate that carbonyl oxygens may also be involved in donation of electron 
density to the drug receptor. If transfer of electron density from the 
receptor to the anticonvulsant drug also takes place, then this is most 
likely to occur at the carbon atom of carbonyl groups or at the phenyl 
substituent. In benzodiazepines the central electronegative region is a 
pyridine-type nitrogen, while the secondary electronegative region is a 
carbonyl oxygen. It appears that the carbonyl group may be important 
for activity against chemically induced seizures, possibly involving 
charge transfer to the drug receptor.
Other factors also need to be taken Into account when assessing 
anticonvulsant activity. Increased activity against electroshock type
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seizures is associated with a greater degree of lipophilicity in anti­
convulsants. The importance of lipophilic character is most probably 
related to the distribution of drugs to the site of action. The more 
lipophilic a drug, the more rapidly it penetrates the blood-brain barrier 
and reaches its site of action in the central nervous system. After 
having arrived at the site of action, an anticonvulsant drug may be inter­
acting with a stereospecific receptor. However the degree of specificity 
of the drug receptor is not clearly defined. This is because of the 
stereochemical properties of the imide system in optically active anti­
convulsants. Each of the two isomers is able to adopt a similar conformation 
with respect to a stereospecific receptor, accounting for the similar 
activities of individual isomers which are observed with these compounds.
A number of mechanisms of action have previously been suggested for 
anticonvulsant drugs. Most information is available for activity against 
experimental electroshock seizures, and associated clinical use in the 
treatment of tonic-clonic epilepsy. While some drugs may have more than 
one site of action, the similarity in conformation and electronic structure 
found in the present work for a range of drugs suggests that a common site 
of action may also be involved. Interaction of anticonvulsant drugs at 
the common site could be responsible for a part of the activity of each 
compound. Of the various proposed mechanisms of anticonvulsant activity, 
those most likely to involve a common site of action relate to the neuro­
transmitters gamma-aminobutyric acid (GABA) and noradrenaline. A number 
of anticonvulsants appear to increase the rate of GABA synthesis, although 
the specific site of action in the biosynthetic pathway has not as yet 
been determined. Anticonvulsants also have effects at the noradrenaline 
synapse. A number of drugs have the potential for facilitating the action 
of noradrenaline by interfering with the processes of neuronal and vesicular 
uptake. While phenytoin and other anticonvulsants show some structural 
similarity to noradrenaline itself, these effects are more likely to be
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mediated through receptors located at or near the ATPase enzyme systems 
of neuronal membranes.
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